KR20140091487A - Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same - Google Patents

Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same Download PDF

Info

Publication number
KR20140091487A
KR20140091487A KR1020140003500A KR20140003500A KR20140091487A KR 20140091487 A KR20140091487 A KR 20140091487A KR 1020140003500 A KR1020140003500 A KR 1020140003500A KR 20140003500 A KR20140003500 A KR 20140003500A KR 20140091487 A KR20140091487 A KR 20140091487A
Authority
KR
South Korea
Prior art keywords
unsubstituted
substituted
group
compound
mol
Prior art date
Application number
KR1020140003500A
Other languages
Korean (ko)
Inventor
현서용
윤용호
송정한
Original Assignee
(주)피엔에이치테크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)피엔에이치테크 filed Critical (주)피엔에이치테크
Publication of KR20140091487A publication Critical patent/KR20140091487A/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76Dibenzothiophenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices

Abstract

Disclosed are a compound for an organic electroluminescent device and an organic electroluminescent device including the same. Accordingly, provided are a compound for an organic electroluminescent device and an organic electroluminescent device, the compound having excellent electric stability and electron- and hole-transporting capabilities and being usable as a host which is capable of enhancing the luminous efficiency of phosphorescent and luminescent materials due to its high triplet-state energy and as an electron transporting material.

Description

새로운 유기전계발광소자용 화합물 및 그를 포함하는 유기전계발광소자{NOVEL COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME}TECHNICAL FIELD [0001] The present invention relates to a compound for a novel organic electroluminescent device and an organic electroluminescent device including the same. BACKGROUND OF THE INVENTION [0002]

본 발명은 유기전계발광소자용 화합물 및 그를 포함하는 유기전계발광소자에 관한 것으로, 보다 상세하게는 유기전계발광소자의 발광효율을 향상시킬 수 있는 유기전계발광소자용 화합물 및 그를 포함하는 유기전계발광소자에 관한 것이다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a compound for an organic electroluminescent device and an organic electroluminescent device including the same, and more particularly to a compound for an organic electroluminescent device capable of improving the luminous efficiency of the organic electroluminescent device, Device.

정보화 사회로의 움직임이 가속화되면서 평판 디스플레이의 비중이 점차 증가하고 있다. 그 중 LCD(liquid crystal display)가 현재 가장 많이 쓰이고 있지만 액정에 전압을 가해 백라이트로부터의 빛을 컬러필터로 통과시켜 삼원색을 얻음으로써 화면을 만드는 방식이며, 유기EL(OLED; Organic Light Emitting Diodes)은 자체발광 소자로써 시야각 및 대조비 등이 우수하고, 경량 및 박형이 가능하며 휘는 성질의 기판에도 사용할 수 있어, 투명, 플렉서블 디스플레이가 가능하여 차세대 표시소자로서 주목을 받고 있다.As the move to the information society accelerates, the proportion of flat panel displays is gradually increasing. LCD (liquid crystal display) is the most widely used method, but it is a method to make a screen by applying voltage to liquid crystal and passing light from backlight through color filter to obtain three primary colors. Organic light emitting diodes (OLED) As a self-luminous element, it has excellent viewing angle and contrast ratio, is lightweight and thin, can be used for a substrate having a bending property, and is capable of transparent and flexible display, and has attracted attention as a next generation display element.

유기EL은 유기물 박막에 음극과 양극을 통하여 주입된 전자와 정공이 재결합을 통해 여기자를 형성하고, 형성된 그 여기자로부터 특정한 파장의 빛이 발생하는 현상으로 1963년 Pope 등에 의해 안트라센(anthracene)의 단결정으로부터 처음으로 발견되었고 이후 이스트만 코닥사의 탕(C.W Tang)등에 의해 적층형의 유기EL 소자의 보고(C.W Tang, S.A Vanslyke, Applied physics Letters. 51권 913p, 1987) 된 이후 활발히 연구 되고 있다.Organic EL is a phenomenon in which excitons are formed by recombination of electrons and holes injected through a cathode and an anode into an organic thin film, and light of a specific wavelength is generated from the excitons formed. In 1963, Pope et al. Reported that an anthracene single crystal (CW Tang, SA Vanslyke, Applied Physics Letters, Vol. 51, No. 913p, 1987) by Eastman Kodak Co., Ltd. (CW Tang) et al.

유기전계발광소자에 사용되는 유기물질은 크게 고분자와 저분자 형태로 나누어 지며 저분자는 순 유기물질과 메탈과 킬레이트를 형성한 메탈 콤플렉스로 나뉘어 질 수 있다.Organic materials used in organic electroluminescent devices are classified into polymer and small molecule, and small molecules can be divided into pure organic material and metal complex which forms metal and chelate.

고분자 물질은 다양한 기능의 유닛을 고분자 체인에 결합하여 다 기능의 물질을 만들어 낼 수 있으나, 합성물 정제시나 소자 형성 시 어려움이 있고, 저분자 물질은 각 특성의 물질을 합성 할 수 있으나 다 기능의 특성을 나타내는 물질 합성에는 한계가 있다 하겠다. Polymers can combine diverse functional units into polymer chains to produce multifunctional materials. However, it is difficult to purify compounds or to form devices, while low-molecular materials can synthesize materials of various properties. There is a limit to the synthesis of the substances.

유기전계발광소자를 적층구조로 형성할 수 있다. 적층구조의 장점으로는 각 기능에 맞게끔 물질을 선택하여 사용 할 수 있는 것인데, 일반적으로 소자구조는 양극과 음극 사이에 정공주입층, 정공수송층, 발광층, 전자수송층, 전자주입층을 형성하여 발광층에서 여기자 형성을 쉽게 하게 하고, 발광 효율을 높일 수 있다.The organic electroluminescent device can be formed in a laminated structure. In general, the device structure is formed by forming a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and an electron injecting layer between an anode and a cathode to form a light emitting layer It is possible to facilitate the formation of excitons and increase the luminous efficiency.

발광물질은 호스트물질과 발광물질(도판트)물질로 크게 나눌 수 있고, 발광물질은 발광 기작에 따라 형광과 인광으로 구별된다. The luminescent material can be roughly divided into a host material and a luminescent material (dopant) material, and the luminescent material is distinguished by fluorescence and phosphorescence depending on the luminescence mechanism.

화합물 내 전자의 여기 상태는 일중항 대 삼중항의 비율이 1:3으로 삼중항 상태가 3배 정도 더 생성된다. 따라서, 일중항 상태에서 기저상태로 떨어지는 형광의 내부양자효율이 25%에 그치는 반면 삼중항 상태에서 기저상태로 떨어지는 인광의 내부양자효율은 75%이다. 또한 일중항 상태에서 삼중항 상태로 계간전이가 일어날 경우 내부양자효율의 이론적 한계치는 100%에 달한다. 이러한 점을 이용해 발광효율을 개선한 발광재료가 인광 발광재료이다.The excited state of the electrons in the compound is 1: 3 ratio of singlet to triplet, and triplet state is generated about 3 times more. Thus, the internal quantum efficiency of phosphorescence falling from the triplet state to the base state is 75% while the internal quantum efficiency of the fluorescence falling from the singlet state to the ground state is only 25%. In addition, the theoretical limit of internal quantum efficiency reaches 100% when the interplanar transition from singlet state to triplet state occurs. A light emitting material that improves the light emitting efficiency by using this point is a phosphorescent material.

유기물의 특성상 인광 발광은 어려움이 있어, 인광 발광재료로는 전이금속(이리듐)을 이용환 유기금속화합물이 개발되고 있으며, 이를 보조하는 호스트 물질로 유기물질이 이용되고 있다. 인광발광물질을 보조하는 물질(호스트)는 밴드갭이 넓고 상중항 상태 에너지가 높아야 한다. 전류효율과 발광효율이 우수한 인광물질이 각광을 받고 있으나 전자 수송능력과 홀 수송능력, 열적, 전기적으로 안정한 호스트 물질과 정공이 여기자를 형성할 때까지 유지되고, 전자 수송능력이 뛰어난 유기전계발광소자용 화합물의 개발이 필요한 실정이다.Due to the nature of organic materials, it is difficult to emit phosphorescence. As a phosphorescent material, transition metal (iridium) is utilized as an organometallic compound, and an organic material is used as a host material to assist it. The material that assists the phosphorescent material (host) should have a wide bandgap and a high half-energy state energy. A phosphorescent material having excellent current efficiency and luminous efficiency is received in the spotlight, but the electron transporting ability, the hole transporting ability, the host material which is thermally and electrically stable, and the organic electroluminescent device It is necessary to develop a compound for use.

본 발명은 전기적 안정성 및 전자와 정공 수송능력이 우수하며, 삼중항 상태 에너지가 높아 인광발광재료의 발광효율을 향상 시킬 수 있는 호스트로서 발광층에 사용될 수 있는 유기발광소자용 화합물 및 이를 포함하는 유기전계발광소자를 제공할 수 있다.The present invention relates to a compound capable of being used for a light emitting layer as a host which is excellent in electrical stability, electron and hole transporting ability, and has high triplet state energy and can improve the luminous efficiency of a phosphorescent light emitting material, A light emitting element can be provided.

또한 본 발명은 유기전계발광소자의 전자수송재료나, 정공수송재료에 사용될 수 있는 유기발광소자용 화합물 및 이를 포함하는 유기전기 발광소자를 제공할 수 있다.In addition, the present invention can provide an organic electroluminescent compound that can be used for an electron transporting material and a hole transporting material of an organic electroluminescent device, and an organic electroluminescent device including the same.

그러나, 본원이 해결하고자 하는 과제는 이상에서 언급한 과제로 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the problems to be solved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned can be clearly understood by those skilled in the art from the following description.

본 발명의 일 측면에 따르면, 하기 구조식 1로 표시되는 유기전계발광소자용 화합물이 제공될 수 있다.According to an aspect of the present invention, a compound for an organic electroluminescence device represented by the following structural formula 1 may be provided.

[구조식 1][Structural formula 1]

Figure pat00001
Figure pat00001

상기 구조식 1에서,In the above formula 1,

X1은 산소원자, 황원자,

Figure pat00002
,
Figure pat00003
,
Figure pat00004
, 또는
Figure pat00005
이고,X 1 represents an oxygen atom, a sulfur atom,
Figure pat00002
,
Figure pat00003
,
Figure pat00004
, or
Figure pat00005
ego,

Ar1은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 1 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

R7 내지 R11은 서로 같거나 다를 수 있고, R7 내지 R11은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 7 to R 11 may be the same or different from each other, and R 7 to R 11 each independently represent a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

Y1 및 Y2는 서로 같거나 다를 수 있고, Y1 및 Y2는 각각 독립적으로 질소원자, 또는

Figure pat00006
이고,Y 1 And Y 2 may be the same or different from each other, and Y 1 And Y < 2 > are each independently a nitrogen atom, or
Figure pat00006
ego,

R12는 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 12 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,

R1 내지 R6은 서로 같거나 다를 수 있고, R1 내지 R6은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이다.R 1 to R 6 may be the same or different from each other and each of R 1 to R 6 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.

본 발명의 일 실시예에 따르면, 바람직하게는,According to an embodiment of the present invention, preferably,

상기 유기전계발광소자용 화합물은 하기 구조식 2 내지 4 중 어느 하나로 표시되고,The organic electroluminescent device compound is represented by any one of the following structural formulas 2 to 4,

Figure pat00007
Figure pat00007

상기 구조식 2 내지 4에서,In the above Structural Formulas 2 to 4,

Ar1은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 1 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

Y1 및 Y2는 서로 같거나 다를 수 있고, Y1 및 Y2는 각각 독립적으로 질소원자, 또는

Figure pat00008
이고,Y 1 And Y 2 may be the same or different from each other, and Y 1 And Y < 2 > are each independently a nitrogen atom, or
Figure pat00008
ego,

R12는 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 12 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,

R1 내지 R6은 서로 같거나 다를 수 있고, R1 내지 R6은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 1 to R 6 may be the same or different from each other and each of R 1 to R 6 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Substituted C1 to C30 heterocycloalkyl groups, substituted or unsubstituted C6 to C30 aryl groups, or substituted or unsubstituted C1 to C30 heteroaryl groups.

본 발명의 다른 하나의 실시예에 따르면, 바람직하게는,According to another embodiment of the present invention, preferably,

R1 내지 R4, 및 R12는 서로 같거나 다를 수 있고, R1 내지 R4, 및 R12는 각각 독립적으로 수소원자,

Figure pat00009
,
Figure pat00010
,
Figure pat00011
,
Figure pat00012
,
Figure pat00013
,
Figure pat00014
,
Figure pat00015
,
Figure pat00016
,
Figure pat00017
,
Figure pat00018
,
Figure pat00019
,
Figure pat00020
,
Figure pat00021
,
Figure pat00022
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,R 1 to R 4 , and R 12 may be the same or different from each other, and R 1 to R 4 and R 12 are each independently a hydrogen atom,
Figure pat00009
,
Figure pat00010
,
Figure pat00011
,
Figure pat00012
,
Figure pat00013
,
Figure pat00014
,
Figure pat00015
,
Figure pat00016
,
Figure pat00017
,
Figure pat00018
,
Figure pat00019
,
Figure pat00020
,
Figure pat00021
,
Figure pat00022
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,

X2 내지 X9는 서로 같거나 다를 수 있고, X2 내지 X9는 각각 독립적으로 산소원자, 황원자,

Figure pat00023
, 또는
Figure pat00024
이고,X 2 to X 9 may be the same or different from each other, and each of X 2 to X 9 independently represents an oxygen atom, a sulfur atom,
Figure pat00023
, or
Figure pat00024
ego,

Ar2는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 2 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

R57 및 R58은 서로 같거나 다를 수 있고, R57 및 R58은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 57 and R 58 may be the same or different from each other, and R 57 and R 58 are each independently a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

Y3 내지 Y16은 서로 같거나 다를 수 있고, Y3 내지 Y16은 각각 독립적으로 질소원자, 또는

Figure pat00025
이고,Y 3 To Y 16 may be the same or different from each other, and Y 3 To Y 16 each independently represents a nitrogen atom, or
Figure pat00025
ego,

R59는 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 59 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,

R13 내지 R56은 서로 같거나 다를 수 있고, R13 내지 R56은 각각 독립적으로 수소원자, 실릴기, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 13 to R 56 may be the same or different from each other, and each of R 13 to R 56 independently represents a hydrogen atom, a silyl group, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Or an unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.

본 발명의 다른 또 하나의 실시예에 따르면, 바람직하게는,According to another embodiment of the present invention, preferably,

R13 내지 R56은 서로 같거나 다를 수 있고, R13 내지 R56은 각각 독립적으로 수소원자,

Figure pat00026
,
Figure pat00027
,
Figure pat00028
,
Figure pat00029
,
Figure pat00030
,
Figure pat00031
,
Figure pat00032
,
Figure pat00033
,
Figure pat00034
,
Figure pat00035
,
Figure pat00036
,
Figure pat00037
,
Figure pat00038
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,R 13 to R 56 may be the same or different from each other, and R 13 to R 56 each independently represent a hydrogen atom,
Figure pat00026
,
Figure pat00027
,
Figure pat00028
,
Figure pat00029
,
Figure pat00030
,
Figure pat00031
,
Figure pat00032
,
Figure pat00033
,
Figure pat00034
,
Figure pat00035
,
Figure pat00036
,
Figure pat00037
,
Figure pat00038
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,

Ar3은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 3 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

X10 내지 X14는 서로 같거나 다를 수 있고, X10 내지 X14는 각각 독립적으로 산소원자, 황원자,

Figure pat00039
, 또는
Figure pat00040
이고,X 10 to X 14 may be the same or different from each other, and X 10 to X 14 each independently represent an oxygen atom, a sulfur atom,
Figure pat00039
, or
Figure pat00040
ego,

Ar4는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 4 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

R105 및 R106은 서로 같거나 다를 수 있고, R105 및 R106은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 105 and R 106 may be the same or different from each other, and each of R 105 and R 106 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

Y17 및 Y18은 서로 같거나 다를 수 있고, Y17 및 Y18은 각각 독립적으로 탄소원자, 또는 규소원자이고,Y 17 And Y 18 may be the same or different from each other, and Y 17 And Y 18 are each independently a carbon atom or a silicon atom,

Y19 내지 Y23은 서로 같거나 다를 수 있고, Y19 내지 Y23은 각각 독립적으로 질소원자, 또는

Figure pat00041
이고,Y 19 to Y 23 may be the same or different from each other, Y 19 to Y 23 each independently represent a nitrogen atom, or
Figure pat00041
ego,

R107은 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 107 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,

R60 내지 R104는 서로 같거나 다를 수 있고, R60 내지 R104는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 60 to R 104 may be the same or different from each other, and each of R 60 to R 104 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Substituted C1 to C30 heterocycloalkyl groups, substituted or unsubstituted C6 to C30 aryl groups, or substituted or unsubstituted C1 to C30 heteroaryl groups.

본 발명의 다른 또 하나의 실시예에 따르면, 바람직하게는,According to another embodiment of the present invention, preferably,

Ar1

Figure pat00042
,
Figure pat00043
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,Ar 1 is
Figure pat00042
,
Figure pat00043
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,

X15는 산소원자, 황원자,

Figure pat00044
, 또는
Figure pat00045
이고,X 15 represents an oxygen atom, a sulfur atom,
Figure pat00044
, or
Figure pat00045
ego,

Ar5는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 5 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

R113 및 R114는 서로 같거나 다를 수 있고, R113 및 R114는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 113 and R 114 may be the same or different from each other, and each of R 113 and R 114 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

R108 내지 R112는 서로 같거나 다를 수 있고, R108 내지 R112는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 108 to R 112 may be the same or different from each other, and each of R 108 to R 112 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Substituted C1 to C30 heterocycloalkyl groups, substituted or unsubstituted C6 to C30 aryl groups, or substituted or unsubstituted C1 to C30 heteroaryl groups.

본 발명의 다른 또 하나의 실시예에 따르면, 바람직하게는,According to another embodiment of the present invention, preferably,

R5 및 R6은 서로 같거나 다를 수 있고, R5 및 R6은 각각 독립적으로 수소원자,

Figure pat00046
,
Figure pat00047
,
Figure pat00048
,
Figure pat00049
,
Figure pat00050
,
Figure pat00051
,
Figure pat00052
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,R 5 and R 6 may be the same or different from each other, and R 5 and R 6 are each independently a hydrogen atom,
Figure pat00046
,
Figure pat00047
,
Figure pat00048
,
Figure pat00049
,
Figure pat00050
,
Figure pat00051
,
Figure pat00052
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,

Ar6 및 Ar7은 서로 같거나 다를 수 있고, Ar6 및 Ar7은 각각 독립적으로 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 6 and Ar 7 may be the same or different from each other, Ar 6 and Ar 7 each independently represent a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

X16은 산소원자, 황원자,

Figure pat00053
, 또는
Figure pat00054
이고,X 16 represents an oxygen atom, a sulfur atom,
Figure pat00053
, or
Figure pat00054
ego,

Ar8은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 8 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

R141 및 R142는 서로 같거나 다를 수 있고, R141 및 R142는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 141 and R 142 may be the same or different from each other, and R 141 and R 142 are each independently a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

R115 내지 R140은 서로 같거나 다를 수 있고, R115 내지 R140은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 115 to R 140 may be the same or different from each other, and each of R 115 to R 140 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Substituted C1 to C30 heterocycloalkyl groups, substituted or unsubstituted C6 to C30 aryl groups, or substituted or unsubstituted C1 to C30 heteroaryl groups.

본 발명의 다른 또 하나의 실시예에 따르면, 바람직하게는,According to another embodiment of the present invention, preferably,

Ar6 및 Ar7은 서로 같거나 다를 수 있고, Ar6 및 Ar7은 각각 독립적으로

Figure pat00055
,
Figure pat00056
,
Figure pat00057
,
Figure pat00058
,
Figure pat00059
,
Figure pat00060
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,Ar 6 and Ar 7 may be the same or different from each other, Ar 6 and Ar 7 are each independently
Figure pat00055
,
Figure pat00056
,
Figure pat00057
,
Figure pat00058
,
Figure pat00059
,
Figure pat00060
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,

Ar9는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 9 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

X17 및 X18은 서로 같거나 다를 수 있고, X17 및 X18은 각각 독립적으로 산소원자, 황원자,

Figure pat00061
, 또는
Figure pat00062
이고,X 17 and X 18 may be the same or different from each other, and X 17 and X 18 are each independently an oxygen atom, a sulfur atom,
Figure pat00061
, or
Figure pat00062
ego,

Ar10은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,Ar 10 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,

R161 및 R162는 서로 같거나 다를 수 있고, R161 및 R162는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 161 and R 162 may be the same or different from each other, and R 161 and R 162 are each independently a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,

Y24 내지 Y26은 서로 같거나 다를 수 있고, Y24 내지 Y26은 각각 독립적으로 질소원자, 또는

Figure pat00063
이고,Y 24 To Y 26 may be the same or different from each other, and Y 24 To Y < 26 > each independently represent a nitrogen atom, or
Figure pat00063
ego,

R163은 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 163 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,

R143 내지 R160은 서로 같거나 다를 수 있고, R143 내지 R160은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 143 to R 160 may be the same or different from each other, and each of R 143 to R 160 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Substituted C1 to C30 heterocycloalkyl groups, substituted or unsubstituted C6 to C30 aryl groups, or substituted or unsubstituted C1 to C30 heteroaryl groups.

본 발명의 다른 또 하나의 실시예에 따르면, 바람직하게는,According to another embodiment of the present invention, preferably,

R115 내지 R140은 서로 같거나 다를 수 있고, R115 내지 R140은 각각 독립적으로 수소원자,

Figure pat00064
,
Figure pat00065
,
Figure pat00066
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,R 115 to R 140 may be the same or different from each other, and R 115 to R 140 each independently represent a hydrogen atom,
Figure pat00064
,
Figure pat00065
,
Figure pat00066
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,

Y27 내지 Y29는 서로 같거나 다를 수 있고, Y27 내지 Y29는 각각 독립적으로 질소원자, 또는

Figure pat00067
이고,Y 27 To Y 29 may be the same or different from each other, and Y 27 To Y 29 each independently represent a nitrogen atom, or
Figure pat00067
ego,

R173은 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,R 173 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,

R164 내지 R172는 서로 같거나 다를 수 있고, R164 내지 R172는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기일 수 있다.R 164 to R 172 may be the same or different from each other and each of R 164 to R 172 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Substituted C1 to C30 heterocycloalkyl groups, substituted or unsubstituted C6 to C30 aryl groups, or substituted or unsubstituted C1 to C30 heteroaryl groups.

상기 치환 또는 비치환된 C6 내지 C30 아릴기의 예는 치환 또는 비치환된 페닐기, 치환 또는 비치환된 바이페닐기, 치환 또는 비치환된 터페닐기, 치환 또는 비치환된 나프탈레닐기, 치환 또는 비치환된 안트라세닐기, 치환 또는 비치환된 페난트레닐기, 치환 또는 비치환된 플루오레닐기, 치환 또는 비치환된 스파이로플루오레닐기, 치환 또는 비치환된 파이레닐기, 또는 치환 또는 비치환된 페릴레닐기일 수 있다.Examples of the substituted or unsubstituted C6 to C30 aryl group include a substituted or unsubstituted phenyl group, a substituted or unsubstituted biphenyl group, a substituted or unsubstituted terphenyl group, a substituted or unsubstituted naphthalenyl group, a substituted or unsubstituted naphthalenyl group, A substituted or unsubstituted phenanthrenyl group, a substituted or unsubstituted fluorenyl group, a substituted or unsubstituted spirobifluorenyl group, a substituted or unsubstituted pyrenyl group, or a substituted or unsubstituted furanyl group, Lt; / RTI >

상기 치환 또는 비치환된 C2 내지 C30 헤테로아릴기의 예는 치환 또는 비치환된 피리디닐기, 치환 또는 비치환된 피리미디닐기, 치환 또는 비치환된 트리아지닐기, 치환 또는 비치환된 싸이오페닐기, 치환 또는 비치환된 피롤릴기, 치환 또는 비치환된 벤조싸이오페닐기, 치환 또는 비치환된 인돌릴기, 치환 또는 비치환된 이미다조[1,2-a]피리디닐기, 치환 또는 비치환된 벤지이미다졸릴기, 치환 또는 비치환된 인다졸릴기, 치환 또는 비치환된 페노티아지닐기, 치환 또는 비치환된 페나지닐기, 치환 또는 비치환된 카바졸릴기, 치환 또는 비치환된 디벤조싸이오페닐기, 치환 또는 비치환된 이미다졸릴기, 치환 또는 비치환된 트리아졸릴기, 치환 또는 비치환된 테트라졸릴기, 치환 또는 비치환된 옥사다이아졸릴기, 치환 또는 비치환된 옥사트리아졸릴기, 치환 또는 비치환된 싸이아트리아졸릴기, 치환 또는 비치환된 벤조트리아졸릴기, 치환 또는 비치환된 피라지닐기, 치환 또는 비치환된 피리다지닐기, 치환 또는 비치환된 퓨리닐기, 치환 또는 비치환된 퀴놀리닐기, 치환 또는 비치환된 이소퀴놀리닐기, 치환 또는 비치환된 프탈라지닐기, 치환 또는 비치환된 나프피리디닐기, 치환 또는 비치환된 퀴녹살리닐기, 치환 또는 비치환된 퀴나졸리닐기, 치환 또는 비치환된 아크리디닐기, 또는 치환 또는 비치환된 페난트롤리닐기, 바람직하게는 치환 또는 비치환된 피리디닐기, 치환 또는 비치환된 피리미디닐기, 치환 또는 비치환된 트리아지닐기, 치환 또는 비치환된 싸이오페닐기, 치환 또는 비치환된 피롤릴기, 치환 또는 비치환된 벤조싸이오페닐기, 치환 또는 비치환된 인돌릴기, 치환 또는 비치환된 이미다조[1,2-a]피리디닐기, 치환 또는 비치환된 벤지이미다졸릴기, 치환 또는 비치환된 인다졸릴기, 치환 또는 비치환된 페노티아지닐기, 치환 또는 비치환된 페나지닐기, 치환 또는 비치환된 카바졸릴기, 또는 치환 또는 비치환된 디벤조싸이오페닐기일 수 있다.Examples of the substituted or unsubstituted C2 to C30 heteroaryl group include a substituted or unsubstituted pyridinyl group, a substituted or unsubstituted pyrimidinyl group, a substituted or unsubstituted thiazinyl group, a substituted or unsubstituted thiophenyl group , A substituted or unsubstituted pyrrolyl group, a substituted or unsubstituted benzothiophenyl group, a substituted or unsubstituted indolyl group, a substituted or unsubstituted imidazo [1,2-a] pyridinyl group, a substituted or unsubstituted A substituted or unsubstituted indazolyl group, a substituted or unsubstituted phenothiazinyl group, a substituted or unsubstituted phenazinyl group, a substituted or unsubstituted carbazolyl group, a substituted or unsubstituted dibenzoyl group, Substituted or unsubstituted imidazolyl groups, substituted or unsubstituted thiazolyl groups, substituted or unsubstituted tetrazolyl groups, substituted or unsubstituted oxadiazolyl groups, substituted or unsubstituted oxatriazolyl groups, However, A substituted or unsubstituted thiazolyl group, a substituted or unsubstituted benzothiazolyl group, a substituted or unsubstituted pyrazinyl group, a substituted or unsubstituted pyridazinyl group, a substituted or unsubstituted furyl group, a substituted or unsubstituted thiazolyl group, A substituted or unsubstituted quinoxalinyl group, a substituted or unsubstituted quinolinyl group, a substituted or unsubstituted quinolinyl group, a substituted or unsubstituted quinoxalinyl group, a substituted or unsubstituted phthalazinyl group, a substituted or unsubstituted naphthyridinyl group, Or a substituted or unsubstituted phenanthrolinyl group, preferably a substituted or unsubstituted pyridinyl group, a substituted or unsubstituted pyrimidinyl group, a substituted or unsubstituted aryidinyl group, a substituted or unsubstituted pyrazolinyl group, A substituted or unsubstituted thiazolyl group, a substituted or unsubstituted thiophenyl group, a substituted or unsubstituted pyrrolyl group, a substituted or unsubstituted benzothiophenyl group, a substituted or unsubstituted indolyl group, A substituted or unsubstituted benzothiazolyl group, a substituted or unsubstituted phenothiazyl group, a substituted or unsubstituted phenazinyl group, a substituted or unsubstituted benzothiazolyl group, , A substituted or unsubstituted carbazolyl group, or a substituted or unsubstituted dibenzothiophenyl group.

상기 유기전계발광소자용 화합물은 하기 화학식으로 표시되는 화합물 1 내지 441 중에서 선택된 어느 하나일 수 있다.The compound for an organic electroluminescence device may be any one selected from compounds 1 to 441 represented by the following formulas.

Figure pat00068
Figure pat00068

Figure pat00069
Figure pat00069

Figure pat00070
Figure pat00070

Figure pat00071
Figure pat00071

Figure pat00072
Figure pat00072

Figure pat00073
Figure pat00073

Figure pat00074
Figure pat00074

Figure pat00075
Figure pat00075

Figure pat00076
Figure pat00076

Figure pat00077
Figure pat00077

Figure pat00078
Figure pat00078

Figure pat00079
Figure pat00079

Figure pat00080
Figure pat00080

Figure pat00081
Figure pat00081

Figure pat00082
Figure pat00082

Figure pat00083
Figure pat00083

Figure pat00084
Figure pat00084

Figure pat00085
Figure pat00085

Figure pat00086
Figure pat00086

Figure pat00087
Figure pat00087

Figure pat00088
Figure pat00088

Figure pat00089
Figure pat00089

Figure pat00090
Figure pat00090

Figure pat00091
Figure pat00091

Figure pat00092
Figure pat00092

Figure pat00093
Figure pat00093

Figure pat00094
Figure pat00094

Figure pat00095
Figure pat00095

Figure pat00096
Figure pat00096

Figure pat00097
Figure pat00097

Figure pat00098
Figure pat00098

Figure pat00099
Figure pat00099

Figure pat00100
Figure pat00100

Figure pat00101
Figure pat00101

Figure pat00102
Figure pat00102

Figure pat00103
Figure pat00103

Figure pat00104
Figure pat00104

Figure pat00105
Figure pat00105

Figure pat00106
Figure pat00106

Figure pat00107
Figure pat00107

본 발명의 다른 측면에 따르면, 상기 유기전계발광소자용 화합물을 포함하는 유기전계발광소자가 제공될 수 있다.According to another aspect of the present invention, there is provided an organic electroluminescent device comprising the compound for an organic electroluminescent device.

본 발명의 또 다른 측면에 따르면, 제1전극, 제2전극 및 상기 제1전극과 제2전극 사이에 단수 또는 복수의 유기물층을 포함하는 유기전계발광소자에 있어서, 상기 단수 또는 복수의 유기물층 중에서 선택된 1종 이상의 유기물층은 상기 유기전계발광소자용 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자가 제공될 수 있다.According to another aspect of the present invention, there is provided an organic electroluminescent device comprising a first electrode, a second electrode, and a single or a plurality of organic layers between the first electrode and the second electrode, The organic electroluminescent device may further include at least one organic compound layer including the organic electroluminescent compound.

상기 단수 또는 복수의 유기물층은 발광층을 포함할 수 있다.The singular or plural organic layers may include a light emitting layer.

상기 복수의 유기물층은 발광층을 포함하고, 상기 복수의 유기물층은 전자주입층, 전자수송층, 정공차단층, 전자차단층, 정공수송층 및 정공주입층 중에서 선택된 1종 이상을 추가로 포함할 수 있다.The plurality of organic layers may include a light emitting layer, and the plurality of organic layers may further include at least one selected from an electron injecting layer, an electron transporting layer, a hole blocking layer, an electron blocking layer, a hole transporting layer, and a hole injecting layer.

상기 발광층은 호스트와 도펀트를 포함할 수 있다.The light emitting layer may include a host and a dopant.

본 발명은 전기적 안정성 및 전자와 홀 수송능력이 우수하며, 삼중항 상태 에너지가 높아 인광발광재료의 발광효율을 향상 시킬 수 있는 호스트로서 발광층에 사용 될 수 있는 유기전계발광소자용 화합물 및 이를 포함하는 유기전기발광소자를 제공할 수 있다.The present invention relates to a compound for an organic electroluminescent device which can be used for a light emitting layer as a host which is excellent in electrical stability and electron and hole transporting ability and has high triplet state energy and can improve the luminous efficiency of a phosphorescent light emitting material, An organic electroluminescent device can be provided.

또한 본 발명은 유기전계발광소자의 전자수송재료나, 정공수송재료에 사용될 수 있는 유기전계발광소자용 화합물 및 이를 포함하는 유기전계발광소자를 제공할 수 있다.In addition, the present invention can provide an organic electroluminescent compound which can be used for an electron transporting material and a hole transporting material of an organic electroluminescent device, and an organic electroluminescent device including the same.

도 1은 본 발명의 일 실시예에 따른 유기전계발광소자의 단면을 나타낸 단면도이다.
도 2는 본 발명의 다른 일 실시예에 따른 유기전계발광소자의 단면을 나타낸 단면도이다.
1 is a cross-sectional view illustrating an organic electroluminescent device according to an embodiment of the present invention.
2 is a cross-sectional view illustrating an organic electroluminescent device according to another embodiment of the present invention.

본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.The invention is capable of various modifications and may have various embodiments, and particular embodiments are exemplified and will be described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.

또한, 이하에서 사용될 제1, 제2 등과 같이 서수를 포함하는 용어는 다양한 구성요소들을 설명하는데 사용될 수 있지만, 상기 구성요소들은 상기 용어들에 의해 한정되지는 않는다. 상기 용어들은 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다. 예를 들어, 본 발명의 권리 범위를 벗어나지 않으면서 제1 구성요소는 제2 구성요소로 명명될 수 있고, 유사하게 제2 구성요소도 제1 구성요소로 명명될 수 있다. Furthermore, terms including an ordinal number such as first, second, etc. to be used below can be used to describe various elements, but the constituent elements are not limited by the terms. The terms are used only for the purpose of distinguishing one component from another. For example, without departing from the scope of the present invention, the first component may be referred to as a second component, and similarly, the second component may also be referred to as a first component.

또한, 어떤 구성요소가 다른 구성요소 상에 "형성되어" 있다거나 "적층되어" 있다고 언급된 때에는, 그 다른 구성요소의 표면 상의 전면 또는 일면에 직접 부착되어 형성되어 있거나 적층되어 있을 수도 있지만, 중간에 다른 구성요소가 더 존재할 수도 있다고 이해되어야 할 것이다.Also, when an element is referred to as being "formed" or "laminated" on another element, it may be directly attached or laminated to the front surface or one surface of the other element, It will be appreciated that other components may be present in the < / RTI >

단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 출원에서, "포함하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The singular expressions include plural expressions unless the context clearly dictates otherwise. In the present application, the terms "comprises" or "having" and the like are used to specify that there is a feature, a number, a step, an operation, an element, a component or a combination thereof described in the specification, But do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or combinations thereof.

본 명세서에서 "원자가결합"이란 별도의 정의가 없는 한, 단일결합, 이중결합 또는 삼중결합을 의미한다.As used herein, "atomic bond" means a single bond, a double bond or a triple bond, unless otherwise defined.

본 명세서에서 "치환"이란 별도의 정의가 없는 한, 치환기 또는 화합물 중의 적어도 하나의 수소가 중수소, 할로겐기, 히드록시기, 아미노기, C1 내지 C30 아민기, 니트로기, C1 내지 C30 실릴기, C1 내지 C30 알킬기, C1 내지 C30 알킬실릴기, C3 내지 C30 시클로알킬기, C1 내지 C30 헤테로시클로알킬기, C6 내지 C30 아릴기, C1 내지 C30 헤테로 아릴기, C1 내지 C20 알콕시기, C1 내지 C10 트리플루오로알킬기 또는 시아노기로 치환된 것을 의미한다.As used herein, unless otherwise defined, "substituent" means that at least one hydrogen in the substituent or compound is substituted with one or more substituents selected from the group consisting of deuterium, a halogen group, a hydroxy group, an amino group, a C1 to C30 amine group, a nitro group, a C1 to C30 silyl group, An alkyl group, a C1 to C30 alkylsilyl group, a C3 to C30 cycloalkyl group, a C1 to C30 heterocycloalkyl group, a C6 to C30 aryl group, a C1 to C30 heteroaryl group, a C1 to C20 alkoxy group, a C1 to C10 trifluoroalkyl group, It means that it has been replaced by anger.

또한 상기 치환된 할로겐기, 히드록시기, 아미노기, C1 내지 C30 아민기, C3 내지 C30 실릴기, C1 내지 C30 알킬기, C1 내지 C30 알킬실릴기, C3 내지 C30 시클로알킬기, C6 내지 C30 아릴기, C1 내지 C20 알콕시기, C1 내지 C10 트리플루오로알킬기 또는 시아노기 중 인접한 두 개의 치환기가 융합되어 고리를 형성할 수도 있다.A C1 to C30 alkyl group, a C1 to C30 alkylsilyl group, a C3 to C30 cycloalkyl group, a C6 to C30 aryl group, a C1 to C20 aryl group, a C1 to C30 aryl group, a C1 to C30 aryl group, An alkoxy group, a C1 to C10 trifluoroalkyl group or a cyano group may be fused to form a ring.

본 명세서에서 "헤테로"란 별도의 정의가 없는 한, 하나의 작용기 내에 N, O, S 및 P로 이루어진 군에서 선택되는 헤테로 원자를 1 내지 4개 함유하고, 나머지는 탄소인 것을 의미한다.As used herein, unless otherwise defined, it is meant that one functional group contains 1 to 4 heteroatoms selected from the group consisting of N, O, S, and P, and the remainder is carbon.

본 명세서에서 "이들의 조합"이란 별도의 정의가 없는 한, 둘 이상의 치환기가 연결기로 결합되어 있거나, 둘 이상의 치환기가 축합하여 결합되어 있는 것을 의미한다.In the present specification, the term "combination thereof" means that two or more substituents are bonded to each other via a linking group or two or more substituents are condensed and bonded.

본 명세서에서 "수소"란 별도의 정의가 없는 한, 일중수소, 이중수소, 또는 삼중수소를 의미한다. As used herein, "hydrogen" means monohydrogen, double hydrogen, or tritium, unless otherwise defined.

본 명세서에서 "알킬(alkyl)기"란 별도의 정의가 없는 한, 지방족 탄화수소기를 의미한다. As used herein, unless otherwise defined, the term "alkyl group" means an aliphatic hydrocarbon group.

알킬기는 어떠한 이중결합이나 삼중결합을 포함하고 있지 않은 "포화 알킬(saturated alkyl)기" 일 수 있다. The alkyl group may be a "saturated alkyl group" which does not contain any double or triple bonds.

알킬기는 적어도 하나의 이중결합 또는 삼중결합을 포함하고 있는 "불포화 알킬(unsaturated alkyl)기"일 수도 있다. The alkyl group may be an "unsaturated alkyl group" comprising at least one double bond or triple bond.

"알케닐렌(alkenylene)기"는 적어도 두 개의 탄소원자가 적어도 하나의 탄소-탄소 이중 결합으로 이루어진 작용기를 의미하며, "알키닐렌(alkynylene)기" 는 적어도 두 개의 탄소원자가 적어도 하나의 탄소-탄소 삼중 결합으로 이루어진 작용기를 의미한다. 포화이든 불포화이든 간에 알킬기는 분지형, 직쇄형 또는 환형일 수 있다. "Alkynylene group" means a functional group in which at least two carbon atoms are composed of at least one carbon-carbon double bond, and "alkynylene group" means that at least two carbon atoms have at least one carbon- Quot; means a functional group formed by bonding. The alkyl group, whether saturated or unsaturated, can be branched, straight chain or cyclic.

알킬기는 C1 내지 C30 알킬기일 수 있다. 보다 구체적으로 알킬기는 C1 내지 C20 알킬기, C1 내지 C10 알킬기 또는 C1 내지 C6 알킬기일 수도 있다.The alkyl group may be a C1 to C30 alkyl group. More specifically, the alkyl group may be a C1 to C20 alkyl group, a C1 to C10 alkyl group or a C1 to C6 alkyl group.

예를 들어, C1 내지 C4 알킬기는 알킬쇄에 1 내지 4 개의 탄소원자, 즉, 알킬쇄는 메틸, 에틸, 프로필, 이소-프로필, n-부틸, 이소-부틸, sec-부틸 및 t-부틸로 이루어진 군에서 선택됨을 나타낸다.For example, the C1 to C4 alkyl groups may have 1 to 4 carbon atoms in the alkyl chain, i.e., the alkyl chain may be optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, Indicating that they are selected from the group.

구체적인 예를 들어 상기 알킬기는 메틸기, 에틸기, 프로필기, 이소프로필기, 부틸기, 이소부틸기, t-부틸기, 펜틸기, 헥실기, 에테닐기, 프로페닐기, 부테닐기, 시클로프로필기, 시클로부틸기, 시클로펜틸기, 시클로헥실기 등을 의미한다.Specific examples of the alkyl group include a methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, t-butyl group, pentyl group, hexyl group, ethenyl group, Butyl group, cyclopentyl group, cyclohexyl group, and the like.

"아민기"는 아릴아민기, 알킬아민기, 아릴알킬아민기, 또는 알킬아릴아민기를 포함한다.The "amine group" includes an arylamine group, an alkylamine group, an arylalkylamine group, or an alkylarylamine group.

"시클로알킬(cycloalkyl)기"는 모노시클릭 또는 융합고리 폴리시클릭(즉, 탄소원자들의 인접한 쌍들을 나눠 가지는 고리) 작용기를 포함한다."Cycloalkyl group" includes monocyclic or fused-ring polycyclic (i. E., Rings that divide adjacent pairs of carbon atoms) functional groups.

"헤테로시클로알킬(heterocycloalkyl)기"는 시클로알킬기 내에 N, O, S 및 P로 이루어진 군에서 선택되는 헤테로원자를 1 내지 4개 함유하고, 나머지는 탄소인 것을 의미한다. 상기 헤테로시클로알킬기가 융합된 고리(fused ring)인 경우, 융합된 고리 중 적어도 하나의 고리가 상기 헤테로 원자를 1 내지 4개 포함할 수 있다."Heterocycloalkyl group" means that the cycloalkyl group contains 1 to 4 hetero atoms selected from the group consisting of N, O, S and P in the cycloalkyl group, and the remainder is carbon. When the heterocycloalkyl group is a fused ring, at least one ring of the fused rings may contain from 1 to 4 heteroatoms.

"방향족(aromatic)기"는 고리 형태인 작용기의 모든 원소가 p-오비탈을 가지고 있으며, 이들 p-오비탈이 공액(conjugation)을 형성하고 있는 작용기를 의미한다. 구체적인 예로 아릴기와 헤테로아릴기가 있다. "An aromatic group" means a functional group in which all elements of a functional group in the form of a ring have a p-orbital, and these p-orbital forms a conjugation. Specific examples thereof include an aryl group and a heteroaryl group.

"아릴(aryl)기"는 모노시클릭 또는 융합 고리 폴리시클릭(즉, 탄소원자들의 인접한 쌍들을 나눠 가지는 고리) 작용기를 포함한다. An "aryl group" includes a monocyclic or fused ring polycyclic (i. E., A ring that divides adjacent pairs of carbon atoms) functional groups.

"헤테로아릴(heteroaryl)기"는 아릴기 내에 N, O, S 및 P로 이루어진 군에서 선택되는 헤테로원자를 1 내지 4개 함유하고, 나머지는 탄소인 것을 의미한다. 상기 헤테로아릴기가 융합된 고리(fused ring)인 경우, 융합된 고리 중 적어도 하나의 고리가 상기 헤테로 원자를 1 내지 4개 포함할 수 있다. "Heteroaryl group" means that the aryl group contains 1 to 4 hetero atoms selected from the group consisting of N, O, S and P, and the remainder is carbon. When the heteroaryl group is a fused ring, at least one ring of the fused rings may contain from 1 to 4 heteroatoms.

아릴기 및 헤테로아릴기에서 고리의 원자수는 탄소수 및 비탄소원자수의 합이다.In the aryl group and the heteroaryl group, the number of atoms in the ring is the sum of carbon number and non-carbon atom number.

"알킬아릴기" 또는 "아릴알킬기"와 같이 조합하여 사용할 때, 상기에 든 각각의 알킬 및 아릴의 용어는 상기 나타낸 의미와 내용을 가진다.When used in combination, such as "alkylaryl" or "arylalkyl group ", the terms alkyl and aryl of each of the above have the meanings and contents indicated above.

"아릴알킬기"이란 용어는 벤질과 같은 아릴 치환된 알킬 라디칼을 의미하며 알킬기에 포함된다.The term "arylalkyl group " means an aryl substituted alkyl radical, such as benzyl, and is included in the alkyl group.

"알킬아릴기"이란 용어는 알킬 치환된 아릴 라디칼을 의미하며 아릴기에 포함된다.The term "alkylaryl group " means an alkyl substituted aryl radical and is included in the aryl group.

이하, 본 발명의 실시예를 첨부도면을 참조하여 설명하기로 하며, 첨부 도면을 참조하여 설명함에 있어, 동일하거나 대응하는 구성 요소는 동일한 도면번호를 부여하고 이에 대한 중복되는 설명은 생략하기로 한다.DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. Referring to the accompanying drawings, the same or corresponding components are denoted by the same reference numerals, .

도 1 및 2를 참고하면, 본 발명의 실시예에 따르면 본 발명에 따른 유기전계발광소자용 화합물을 포함하는 유기전계발광소자(1)가 제공될 수 있다.Referring to FIGS. 1 and 2, an organic electroluminescent device 1 including the compound for an organic electroluminescent device according to the present invention can be provided according to an embodiment of the present invention.

본 발명의 다른 실시예에 따르면, 상기 유기전계발광소자는 제1전극(110); 제2전극(150); 및 상기 제1전극과 제2전극 사이에 단수 또는 복수의 유기물층(130)을 포함하며, 상기 단수 또는 복수의 유기물층(130) 중에서 선택된 1종 이상의 유기물층은 본 발명에 따른 유기발광소자용 화합물을 포함할 수 있다.According to another embodiment of the present invention, the organic electroluminescent device includes a first electrode 110; A second electrode (150); And one or more organic layers 130 between the first and second electrodes and at least one organic layer selected from the single or plurality of organic layers 130 include the compound for an organic light emitting device according to the present invention can do.

여기서, 상기 단수 또는 복수의 유기물층(130)은 발광층(134)을 포함할 수 있다. Here, the single or plural organic layers 130 may include a light emitting layer 134.

또한 상기 복수의 유기물층(130)은 발광층(134)을 포함하고, 상기 복수의 유기물층은 전자주입층(131), 전자수송층(132), 정공차단층(133), 전자차단층(135), 정공수송층(136) 및 정공주입층(137) 중에서 선택된 1종 이상을 추가로 포함할 수 있다.The plurality of organic layers 130 may include a light emitting layer 134 and the plurality of organic layers may include an electron injection layer 131, an electron transport layer 132, a hole blocking layer 133, an electron blocking layer 135, Transporting layer 136 and hole-injecting layer 137 may be further included.

상기 발광층(134)은 호스트와 도펀트를 포함할 수 있다.The light emitting layer 134 may include a host and a dopant.

상기 유기전계발광소자는 바람직하게는 투명기판에 의하여 지지된다. 투명기판의 재료로는 양호한 기계적 강도, 열안정성 및 투명성을 갖는 한 특별한 제한은 없다. 구체적인 예를 들면, 유리, 투명 플라스틱 필름 등을 사용할 수 있다.The organic electroluminescent device is preferably supported by a transparent substrate. The material of the transparent substrate is not particularly limited as long as it has good mechanical strength, thermal stability and transparency. Specific examples thereof include glass, transparent plastic film, and the like.

본 발명의 유기전계발광소자의 양극재료로서는 4eV 이상의 일함수를 갖는 금속, 합금, 전기전도성 화합물 또는 이의 혼합물을 사용할 수 있다. 구체적으로는 금속인 Au 또는 CuI, ITO(인듐 주석 산화물), SnO2 및 ZnO와 같은 투명 전도성 재료를 들 수 있다. 양극 필름의 두께는 10 내지 200nm 가 바람직하다.As the cathode material of the organic electroluminescent device of the present invention, a metal, an alloy, an electroconductive compound or a mixture thereof having a work function of 4 eV or more can be used. Specifically, transparent conductive materials such as Au or CuI, ITO (indium tin oxide), SnO 2 and ZnO, which are metals, can be mentioned. The thickness of the positive electrode film is preferably 10 to 200 nm.

본 발명의 유기전계발광소자의 음극 재료로서는 4eV 미만의 일함수를 갖는 금속, 합금, 전기 전도성 화합물 또는 이의 혼합물을 사용할 수 있다. 구체적으로는, Na, Na-K 합금, 칼슘, 마그네슘, 리튬, 리튬 합금, 인듐, 알루미늄, 마그네슘 합금, 알루미늄 합금을 들 수 있다. 이외에, 알루미늄/AlO2, 알루미늄/리튬, 마그네슘/은 또는 마그네슘/인듐 등도 사용될 수 있다. 음극필름의 두께는 10 내지 200nm 가 바람직하다.As the anode material of the organic electroluminescent device of the present invention, a metal, an alloy, an electrically conductive compound or a mixture thereof having a work function of less than 4 eV may be used. Specifically, Na, Na-K alloy, calcium, magnesium, lithium, lithium alloy, indium, aluminum, magnesium alloy and aluminum alloy can be mentioned. In addition, aluminum / AlO 2 , aluminum / lithium, magnesium / silver or magnesium / indium may be used. The thickness of the negative electrode film is preferably 10 to 200 nm.

유기 EL 소자의 발광효율을 높이기 위해서는 하나 이상의 전극은 바람직하게는 10% 이상의 광투과율을 가지는 것이 바람직하다. 전극의 쉬트저항은 바람직하게는 수백 Ω/mm 이하이다. 전극의 두께는 10nm 내지 1㎛, 보다 바람직하게는 10 내지 400nm 이다. 이러한 전극은 화학적 기상증착(CVD), 물리적 기상증착(PVD) 등의 기상증착법 또는 스퍼터링법을 통하여 상기한 전극 재료를 박막으로 형성하여 제조할 수 있다.In order to increase the luminous efficiency of the organic EL device, at least one electrode preferably has a light transmittance of 10% or more. The sheet resistance of the electrode is preferably several hundreds? / Mm or less. The thickness of the electrode is 10 nm to 1 탆, more preferably 10 to 400 nm. Such an electrode can be manufactured by forming the electrode material into a thin film by a vapor deposition method such as chemical vapor deposition (CVD) or physical vapor deposition (PVD) or a sputtering method.

또한 본 발명의 목적에 적합하게 본 발명의 유기전계발광소자용 화합물이 사용될 때, 공지된 정공수송 물질, 정공주입 물질, 발광층 물질, 발광층의 호스트 물질, 전자수송 물질, 및 전자주입 물질이 상기 각각의 유기물층에서 단독으로 사용되거나 또는 본 발명의 유기전계발광소자용 화합물과 선택적으로 병행하여 사용될 수 있다.When the compound for an organic electroluminescence device of the present invention is used for the purpose of the present invention, the known hole transporting material, hole injecting material, light emitting layer material, host material of the light emitting layer, electron transporting material, Or may be used in combination with the organic electroluminescent device compound of the present invention selectively.

정공 수송 물질로서 N,N-dicarbazolyl-3,5-benzene(mCP), poly(3,4-ethylenedioxythiophene):polystyrenesulfonate (PEDOT:PSS), N, N’-di(1-naphthyl)-N,N’-diphenylbenzidine(NPD), N,N'-디페닐-N,N'-디(3-메틸페닐)-4,4'-디아미노비페닐(TPD), N,N'-디페닐-N,N'-디나프틸-4,4'-디아미노비페닐, N,N,N'N'-테트라-p-톨릴-4,4'-디아미노비페닐, N,N,N'N'-테트라페닐-4,4'-디아미노비페닐, 코퍼(II)1,10,15,20-테트라페닐-21H,23H-포피린 등과 같은 포피린(porphyrin)화합물 유도체, 주쇄 또는 측쇄내에 방향족 3차아민을 갖는 중합체, 1,1-비스(4-디-p-톨릴아미노페닐)시클로헥산, N,N,N-트리(p-톨릴)아민, 4, 4', 4'-트리스[N-(3-메틸페닐)-N-페닐아미노]트리페닐아민과 같은 트리아릴아민 유도체, N-페닐카르바졸 및 폴리비닐카르바졸과 같은 카르바졸 유도체, 무금속 프탈로시아닌, 구리프탈로시아닌과 같은 프탈로시아닌 유도체, 스타버스트 아민 유도체, 엔아민스틸벤계 유도체, 방향족 삼급아민과 스티릴 아민 화합물의 유도체, 및 폴리실란 등을 들 수 있다.N-dicarbazolyl-3,5-benzene (mCP), poly (3,4-ethylenedioxythiophene): polystyrenesulfonate (PEDOT: PSS), N, N'- (NPD), N, N'-diphenyl-N, N'-di (3-methylphenyl) -4,4'- diaminobiphenyl (TPD) N, N'N'-tetra-p-tolyl-4,4'-diaminobiphenyl, N, N'N'N'N'- Porphyrin compound derivatives such as tetraphenyl-4,4'-diaminobiphenyl, copper (II) 1,10,15,20-tetraphenyl-21H, 23H-porphyrin and the like, aromatic tertiary (4-di-p-tolylaminophenyl) cyclohexane, N, N, N-tri (3-methylphenyl) -N-phenylamino] triphenylamine, carbazole derivatives such as N-phenylcarbazole and polyvinylcarbazole, phthalocyanine derivatives such as nonmetal phthalocyanine and copper phthalocyanine, An aminostilbene derivative, a derivative of an aromatic tertiary amine and a styrylamine compound, and polysilane.

전자 수송 물질로서 diphenylphosphine oxide-4-(triphenylsilyl)phenyl (TSPO1), Alq3, 2,5-디아릴 실롤 유도체(PyPySPyPy), 퍼플루오리네이티드 화합물(PF-6P), Octasubstituted cyclooctatetraene 화합물(COTs)을 들 수 있다.The diphenylphosphine oxide-4- (triphenylsilyl) phenyl (TSPO1), Alq 3, 2,5- diaryl silole derivatives (PyPySPyPy), perfluoro rineyi suited compound (PF-6P), Octasubstituted cyclooctatetraene compound (COTs) as an electron transport material .

본 발명의 유기전계발광소자에 있어서, 전자 주입층, 전자 수송층, 정공 수송층 및 정공 주입층은 상기한 화합물의 하나 이상의 종류를 함유하는 단일 층으로 형성되거나, 또는 상호 적층된, 상이한 종류의 화합물을 함유하는 복수의 층으로 구성될 수 있다.In the organic electroluminescent device of the present invention, the electron injecting layer, the electron transporting layer, the hole transporting layer, and the hole injecting layer may be formed of a single layer containing at least one kind of the above-mentioned compounds, And the like.

발광재료로서 예를 들면 축광 형광재료, 형광증백제, 레이저 색소, 유기 신틸레이터 및 형광 분석용 시약을 들 수 있다. 구체적으로는, 카바졸계 화합물, 포스핀옥사이드계 화합물, 카바졸계 포스핀옥사이드 화합물, bis((3,5-difluoro-4-cyanophenyl)pyridine) iridium picolinate(FCNIrpic), tris(8-hydroxyquinoline) aluminum(Alq3), 안트라센, 페난트렌, 피렌, 크리센, 페릴렌, 코로넨, 루브렌 및 퀴나크리돈과 같은 폴리아로마틱 화합물, 퀴터페닐과 같은 올리고페닐렌 화합물, 1,4-비스 (2-메틸스티릴)벤젠, 1,4-비스(4-메틸스티릴)벤젠, 1,4-비스(4-메틸-5-페닐-2-옥사졸릴)벤젠, 1,4-비스(5-페닐-2-옥사졸릴)벤젠, 2,5-비스(5-t-부틸-2-벤즈옥사졸릴)사이오펜, 1,4-디페닐-1,3-부타디엔, 1,6-디페닐-1,3,5-헥사트리엔,1,1,4,4-테트라페닐-1,3-부타디엔과 같은 액체신틸레이션용 신틸레이터, 옥신 유도체의 금속착체, 쿠마린 색소, 디시아노메틸렌피란 색소, 디시아노메틸렌사이오피란 색소, 폴리메틴 색소, 옥소벤즈안트라센 색소, 크산텐 색소, 카르보스티릴 색소, 페릴렌 색소, 옥사진 화합물, 스틸벤 유도체, 스피로 화합물, 옥사디아졸 화합물 등을 들 수 있다.Examples of the light emitting material include a phosphorescent fluorescent material, a fluorescent whitening agent, a laser dye, an organic scintillator, and a reagent for fluorescence analysis. Specifically, a carbazole compound, a phosphine oxide compound, a carbazole-based phosphine oxide compound, bis (3,5-difluoro-4-cyanophenyl) pyridine, iridium picolinate (FCNIrpic), tris (8-hydroxyquinoline) aluminum Alq 3 ), polyaromatic compounds such as anthracene, phenanthrene, pyrene, chrysene, perylene, coronene, rubrene and quinacridone, oligophenylene compounds such as quaterphenyl, 1,4- Bis (4-methylstyryl) benzene, 1,4-bis (4-methyl- Bis (5-t-butyl-2-benzoxazolyl) thiophene, 1,4-diphenyl-1,3-butadiene, 1,6- Liquid scintillation scintillators such as 3,5-hexatriene and 1,1,4,4-tetraphenyl-1,3-butadiene, metal complexes of oxine derivatives, coumarin dyes, dicyanomethylenepyran dyes, dicyanomethylene Cyopyran pigment, polymethine pigment, oxobenzanthracene There may be mentioned a colorant, a xanthene colorant, a carbostyryl colorant, a perylene colorant, an oxazine compound, a stilbene derivative, a spiro compound, and an oxadiazole compound.

본 발명의 유기 EL 소자를 구성하는 각 층은 진공 증착, 스핀 코팅 또는 캐스팅과 같은 공지된 방법을 통하여 박막으로 형성시키거나, 각 층에서 사용되는 재료를 이용하여 제조할 수 있다. 이들 각층의 막두께에 대해서는 특별한 제한은 없으며, 재료의 특성에 따라 알맞게 선택할 수 있으나, 보통 2nm 내지 5,000nm의 범위에서 결정될 수 있다.Each layer constituting the organic EL device of the present invention can be formed into a thin film through a known method such as vacuum deposition, spin coating or casting, or can be manufactured using a material used in each layer. The thickness of each of these layers is not particularly limited and may be appropriately selected according to the characteristics of the material, but may be determined usually in the range of 2 nm to 5,000 nm.

본 발명의 따른 유기전계발광소자용 화합물은 진공 증착법에 의하여 형성될 수 있으므로, 박막 형성 공정이 간편하고, 핀홀(pin hole)이 거의 없는 균질한 박막으로 용이하게 얻을 수 있는 장점이 있다.
The compound for an organic electroluminescence device according to the present invention can be formed by a vacuum deposition method, so that it is advantageous that a thin film forming process is simple and a homogeneous thin film having almost no pinhole can be easily obtained.

[실시예] [Example]

이하, 실시예를 통하여 본 발명에 따른 유기전계발광소자용 화합물 및 이를 포함하는 유기전계발광소자의 제조방법을 더욱 구체적으로 설명한다. 그러나 이는 예시를 위한 것으로서 이에 의하여 본 발명의 범위가 한정되는 것이 아니다.Hereinafter, the compound for an organic electroluminescent device according to the present invention and the method for manufacturing the organic electroluminescent device including the same will be described in more detail with reference to the following examples. However, this is for the purpose of illustration only and is not intended to limit the scope of the invention.

실시예Example 1: 화합물 1 합성 1: Synthesis of compound 1

(1) (One) 제조예Manufacturing example 1-1: 중간체 1-1 합성 1-1: Intermediate 1-1 Synthesis

Figure pat00108
Figure pat00108

2,7-dibromophenanthrene(10.5g, 0.032 mol/sigma Aldrich)를 Hexane 200ml하에 넣었다. TMEDA(24ml, 0.16mol/sigma Aldrich), n-BuLi(1.6M, 100ml, 0.16mol)를 dropping funnel을 통해서 넣었다. N2 하에서 3시간 교반시킨 후 S2Cl2(6.4ml, 0.08mol /sigma Aldrich)를 천천히 넣고, 상온에서 24시간 반응시켰다. 반응 혼합물을 냉각시킨 후 H20:methylene chloride(MC) 하에서 층 분리 시킨 후 컬럼정제(n-Hexane : methylene chloride)하여 중간체 1-1을 7.1g(수율 60%)을 수득하였다.2,7-dibromophenanthrene (10.5 g, 0.032 mol / sigma Aldrich) was placed under 200 ml of hexane. TMEDA (24ml, 0.16mol / Sigma Aldrich), n-BuLi (1.6M, 100ml, 0.16mol) was placed through the dropping funnel. After stirring for 3 hours under N 2 , S2Cl2 (6.4 ml, 0.08 mol / Sigma Aldrich) was slowly added and reacted at room temperature for 24 hours. The reaction mixture was cooled, layered under H 2 O: methylene chloride (MC), and subjected to column purification (n-hexane: methylene chloride) to obtain 7.1 g (yield: 60%) of Intermediate 1-1.

LC/MS: m/z=366[(M+1)+]LC / MS: m / z = 366 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 1-2: 화합물 1 합성 1-2: Compound 1 synthesis

Figure pat00109
Figure pat00109

중간체 1-1(7.1g, 0.019mol)에 phenyl-boronic acid(5.7g, 0.0465mol/sigma Aldrich), Pd(pph3)4 (1.1g, 0.001mol/P&H TECH), potassium carbonate(7.9g, 0.057mol/sigma Aldrich)에 THF 260ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 1을 4.6g(수율 67%) 수득하였다.Pd (PPh3) 4 (1.1 g, 0.001 mol / P & H TECH) and potassium carbonate (7.9 g, 0.057 mol) were added to Intermediate 1-1 (7.1 g, 0.019 mol) mol / Sigma Aldrich) was added 260 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.6 g (yield 67%) of Compound 1.

H-NMR(200MHz, CDCl3):δ ppm, 2H(7.41/M, 8.34/S, 7.71/D, 8.10/S) 4H (7.51/M, 7.52/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.41 / M, 8.34 / S, 7.71 / D, 8.10 / S) 4H (7.51 / M, 7.52 / D)

LC/MS: m/z=361[(M+1)+] LC / MS: m / z = 361 [(M + 1) < + &

실시예Example 2: 화합물 2 합성 2: Synthesis of compound 2

Figure pat00110
Figure pat00110

중간체 1-1(7.1g, 0.019mol)에 naphthalen-2-ylboronic acid (8.0g, 0.0465mol /sigma Aldrich), Pd(pph3)4 (1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 300ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 2를 5.3g(수율 61%) 수득하였다.2-ylboronic acid (8.0 g, 0.0465 mol / sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, 0.057 mol ), 300 ml of THF was added, and the mixture was reacted at 65 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 5.3 g (yield: 61%) of Compound 2.

H-NMR (200MHz, CDCl3): δ ppm, 2H(7.92/D, 7.73/D, 7.58/S, 8.34/S, 7.71/D, 8.10/S) 4H(7.59/M, 8.00/D)(7.59 / M, 8.00 / D): 1 H-NMR (200 MHz, CDCl 3 ):? Ppm, 2H (7.92 / D, 7.73 / D, 7.58 /

LC/MS: m/z=461[(M+1)+] LC / MS: m / z = 461 [(M + 1) < + &

실시예Example 3: 화합물 3 합성 3: Synthesis of compound 3

Figure pat00111
Figure pat00111

중간체 1-1(7.1g, 0.019mol)에 9H-carbazol (7.8g, 0.0465mol/sigma Aldrich), Pd(dba)2(0.9g, 0.001mol/p&h tech), sodium-tert-butoxide(5.5g, 0.057mol/sigma aldrich)에 Tol 340ml를 넣고 95℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 3을 6.5g(64%)수득하였다.Pd (dba) 2 (0.9 g, 0.001 mol / p & h tech) and sodium tert-butoxide (5.5 g, 0.0465 mol) were added to Intermediate 1-1 (7.1 g, 0.019 mol) , 0.057 mol / sigma aldrich), and the mixture was reacted at 95 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and subjected to column separation on H 2 O: MC, followed by column purification (n-hexane: MC) to obtain 6.5 g (64%) of Compound 3.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.94/D, 7.33/M, 7.25/M, 8.55/D, 8.12/D, 7.29/M, 7.50/M, 7.63/D, 7.70/D, 8.10/S, 7.90/S) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.94 / D, 7.33 / M, 7.25 / M, 8.55 / D, 8.12 / D, 7.29 / M, 7.50 / M, 7.63 / D, 7.70 / D , 8.10 / S, 7.90 / S)

LC/MS: m/z=539[(M+1)+] LC / MS: m / z = 539 [(M + 1) < + &

실시예Example 4: 화합물 4 합성 4: Synthesis of compound 4

Figure pat00112
Figure pat00112

중간체 1-1(7.1g, 0.019mol)에 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenylboronic acid(14.6g, 0.0465mol/sigma Aldrich), Pd(pph3)4 (1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 420ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 4를 8.4g(수율 59%) 수득하였다.Phenylboronic acid (14.6 g, 0.0465 mol / sigma Aldrich), Pd (PPh3) 4 (0.1 g, 0.019 mol) was added to Intermediate 1-1 1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 420 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC, and subjected to column purification (n-hexane: MC) to obtain 8.4 g (yield: 59%) of Compound 4.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.41/M, 7.59/D, 8.56/D, 7.71/D, 8.34/S, 8.10/S) 4H(7.22/M, 7.51/M, 8.28/D, 7.79/D, 7.68/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.41 / M, 7.59 / D, 8.56 / D, 7.71 / D, 8.34 / S, 8.10 / S) 4H (7.22 / M, 7.51 / M, 8.28 / D, 7.79 / D, 7.68 / D)

LC/MS: m/z=745[(M+1)+] LC / MS: m / z = 745 [(M + 1) < + &

실시예Example 5: 화합물 5 합성 5: Synthesis of compound 5

Figure pat00113
Figure pat00113

중간체 1-1(7.1g, 0.019mol)에 dibenzo[b,d]thiophen-1-ylboronic acid (10.6g, 0.0465mol/sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 340ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 5를 6.1g(수율 56%) 수득하였다.Dibenzo [b, d] thiophen-1-ylboronic acid (10.6 g, 0.0465 mol / Sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, 0.057 mol), 340 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC, and subjected to column purification (n-hexane: MC) to obtain 6.1 g (yield: 56%) of Compound 5.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.50/M, 7.94/D, 7.56/M, 7.98/D, 7.52/M, 7.71/D, 7.82/D, 8.45/D, 8.34/S, 8.10/S) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.50 / M, 7.94 / D, 7.56 / M, 7.98 / D, 7.52 / M, 7.71 / D, 7.82 / D, 8.45 / D, 8.34 / S , 8.10 / S)

LC/MS: m/z=573[(M+1)+] LC / MS: m / z = 573 [(M + 1) < + &

실시예Example 6: 화합물 6 합성 6: Synthesis of Compound 6

Figure pat00114
Figure pat00114

중간체 1-1(7.1g, 0.019mol)에 2,6-diphenylpyridin-4-ylboronic acid (12.8g, 0.0465mol/ sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 400ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 6을 6.3g(수율 50%) 수득하였다.4-ylboronic acid (12.8 g, 0.0465 mol / sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, g, 0.057 mol), 400 ml of THF was added, and the mixture was reacted at 65 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and column-purified (n-hexane: MC) to obtain 6.3 g (yield 50%) of Compound 6.

H-NMR (200MHz, CDCl3): δ ppm, 2H(8.10/S, 8.34/S, 7.71/D) 4H (7.47/M, 8.20/S) 8H(7.54/M, 8.30/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.10 / S, 8.34 / S, 7.71 / D) 4H (7.47 / M, 8.20 / S) 8H (7.54 / M, 8.30 / D)

LC/MS: m/z=667[(M+1)+] LC / MS: m / z = 667 [(M + 1) < + &

실시예Example 7: 화합물 7 합성 7: Synthesis of Compound 7

Figure pat00115
Figure pat00115

중간체 1-1(7.1g, 0.019mol)에 9-phenyl-9H-carbazol-2-ylboronic acid (13.4g, 0.0465mol/sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 400ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 7을 7.1g(수율 54%) 수득하였다.Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (13.4 g, 0.0465 mol / Sigma Aldrich), 9-phenyl-9H-carbazol-2-ylboronic acid (7.1 g, 0.019 mol) (7.9 g, 0.057 mol), 400 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 7.1 g (yield: 54%) of Compound 7.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.45/M, 7.94/D, 7.33/M, 7.25/M, 8.55/D, 7.62/S, 8.18/D, 7.79/D, 8.10/S, 8.34/S, 7.71/D) 4H(7.50/D, 7.58/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.45 / M, 7.94 / D, 7.33 / M, 7.25 / M, 8.55 / D, 7.62 / S, 8.18 / D, 7.79 / D, 8.10 / S , 8.34 / S, 7.71 / D) 4H (7.50 / D, 7.58 / M)

LC/MS: m/z=691[(M+1)+] LC / MS: m / z = 691 [(M + 1) < + &

실시예Example 8: 화합물 8 합성 8: Compound 8 Synthesis

Figure pat00116
Figure pat00116

중간체 1-1(7.1g, 0.019mol)에 3,5-diphenyl-4H-1,2,4-triazole (10.3g, 0.0465mol/sigma Aldrich), Pd(dba)2(0.9g, 0.001mol), sodium-tert-butoxide(5.5g, 0.057mol)에 Tol 340ml를 넣고 95℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 8을 7.2g(수율 59%) 수득하였다.3,5-diphenyl-4H-1,2,4-triazole (10.3 g, 0.0465 mol / sigma Aldrich) and Pd (dba) 2 (0.9 g, 0.001 mol) were added to Intermediate 1-1 (7.1 g, 0.019 mol) and sodium-tert-butoxide (5.5 g, 0.057 mol), and the mixture was reacted at 95 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and subjected to column separation on H 2 O: MC, followed by column purification (n-hexane: MC) to obtain 7.2 g (yield: 59%) of Compound 8.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.9/S, 7.7/D, 8.1/S) 4H(7.41/M) 8H(8.28/D, 7.51/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.9 / S, 7.7 / D, 8.1 / S) 4H (7.41 / M) 8H (8.28 / D, 7.51 / M)

LC/MS: m/z=647[(M+1)+] LC / MS: m / z = 647 [(M + 1) < + &

실시예Example 9: 화합물 9 합성 9: Synthesis of Compound 9

Figure pat00117
Figure pat00117

중간체 1-1(7.1g, 0.019mol)에 4-(3,5-diphenyl-4H-1,2,4-triazol-4-yl)phenylboronic acid(15.9g, 0.0465mol/sigma Aldrich), Pd(pph3)4 (1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 460ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 9를 8.5g(수율 56%)수득하였다.4- (3,5-diphenyl-4H-1,2,4-triazol-4-yl) phenylboronic acid (15.9 g, 0.0465 mol / sigma Aldrich), Pd pph3) 4 (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 460 ml of THF and reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 8.5 g (yield: 56%) of Compound 9.

H-NMR (200MHz, CDCl3):δ ppm, 2H (8.10/S ,8.34/S ,7.71/D ) 4H (7.41/M ,7.68/D ,7.79/D ) 8H (8.28/D )7.51/M ) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.10 / S, 8.34 / S, 7.71 / D) 4H (7.41 / M, 7.68 / D, 7.79 / D) 8H (8.28 / D) 7.51 / M )

LC/MS: m/z=799[(M+1)+] LC / MS: m / z = 799 [(M + 1) < + &

실시예Example 10: 화합물 10 합성 10: Compound 10 Synthesis

Figure pat00118
Figure pat00118

중간체 1-1(7.1g, 0.019mol)에 6-(9H-carbazol-9-yl)pyridin-2-ylboronic acid (13.4g, 0.0465mol/sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 400ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 10을 7.8g(수율 59%)수득하였다.Pyridine-2-ylboronic acid (13.4 g, 0.0465 mol / Sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 400 ml of THF and reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC, and subjected to column purification (n-hexane: MC) to obtain 7.8 g (yield: 59%) of Compound 10.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.94/D, 7.33/M, 7.25/M, 8.55/D, 8.12/D, 7.29/M, 7.50/M, 7.63/D, 7.38/M, 7.26/D, 7.50/D, 8.61/S, 8.85/S, 7.71/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.94 / D, 7.33 / M, 7.25 / M, 8.55 / D, 8.12 / D, 7.29 / M, 7.50 / M, 7.63 / D, 7.38 / M , 7.26 / D, 7.50 / D, 8.61 / S, 8.85 / S, 7.71 / D)

LC/MS: m/z=693[(M+1)+] LC / MS: m / z = 693 [(M + 1) < + &

실시예Example 11: 화합물 11 합성 11: Compound 11 Synthesis

(1) (One) 제조예Manufacturing example 11-1: 중간체 11-1 합성 11-1: Intermediate 11-1 Synthesis

Figure pat00119
Figure pat00119

1,3,6,8-tetrabromophenanthrene(15.8g, 0.032 mol/ sigma Aldrich)를 Hexane 300ml하에 넣는다. TMEDA(24ml, 0.16mol), n-BuLi(1.6M, 100ml, 0.16mol)를 dropping funnel을 통해서 넣는다. N2 하에서 3시간 교반시킨 후 S2Cl2(6.4ml, 0.08mol)를 천천히 넣고, 상온에서 24시간 반응시켰다. 반응 혼합물을 냉각시킨 후 H20: methylene chloride(MC) 하에서 층 분리 시킨 후 컬럼정제(n-Hexane : methylene chloride)하여 중간체 11-1을 9.3g(수율 55%) 수득하였다.1,3,6,8-tetrabromophenanthrene (15.8 g, 0.032 mol / sigma Aldrich) is placed under 300 ml of hexane. Add TMEDA (24 ml, 0.16 mol) and n-BuLi (1.6 M, 100 ml, 0.16 mol) through the dropping funnel. After stirring for 3 hours under N 2 , S 2 Cl 2 (6.4 ml, 0.08 mol) was slowly added and reacted at room temperature for 24 hours. The reaction mixture was cooled, layered under H 2 O: methylene chloride (MC), and subjected to column purification (n-hexane: methylene chloride) to obtain 9.3 g (yield: 55%) of intermediate 11-1.

LC/MS: m/z=524 [(M+1)+] LC / MS: m / z = 524 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 11-2: 화합물 11 합성 11-2: Compound 11 Synthesis

Figure pat00120
Figure pat00120

중간체 11-1(9.3g, 0.018mol)에 phenyl-boronic acid(10.5g, 0.0864mol)Pd(pph3)4(1.0g, 0.0009mol), potassium carbonate(7.4g, 0.054mol)에 THF 380ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 11을 4.8g(수율 52%) 수득하였다.To the intermediate 11-1 (9.3 g, 0.018 mol) was added 380 ml of THF to phenylboronic acid (10.5 g, 0.0864 mol), Pd (pph3) 4 (1.0 g, 0.0009 mol) and potassium carbonate (7.4 g, 0.054 mol) The mixture was stirred at 65 캜 for 4 hours to react. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.8 g (yield: 52%) of Compound 11.

H-NMR(200MHz, CDCl3): δ ppm, 2H(8.26/S, 7.71/D) 4H(7.41/M) 8H(7.51/M, 7.79/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.26 / S, 7.71 / D) 4H (7.41 / M) 8H (7.51 / M, 7.79 / D)

LC/MS: m/z=513[(M+1)+] LC / MS: m / z = 513 [(M + 1) < + &

실시예Example 12: 화합물 12 합성 12: Compound 12 Synthesis

Figure pat00121
Figure pat00121

중간체 11-1(9.3g, 0.018mol)에 naphthalen-2-ylboronic acid (14.9g, 0.0864mol), Pd(pph3)4(1.0g, 0.0009mol), potassium carbonate(7.4g, 0.054mol)에 THF 480ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20: MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 12를 8.1g(수율 63%)수득하였다.2-ylboronic acid (14.9g, 0.0864mol), Pd (PPh3) 4 (1.0g, 0.0009mol) and potassium carbonate (7.4g, 0.054mol) were added to intermediate 11-1 (9.3g, 0.018mol) And the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 8.1 g (yield: 63%) of Compound 12.

H-NMR(200MHz, CDCl3): δ ppm, 2H(8.26/S, 7.71/D) 4H(7.58/S, 7.73/D, 7.92/D) 8H(8.00/D, 7.59/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.26 / S, 7.71 / D) 4H (7.58 / S, 7.73 / D, 7.92 / D) 8H (8.00 / D, 7.59 / M)

LC/MS: m/z=713[(M+1)+] LC / MS: m / z = 713 [(M + 1) < + &

실시예Example 13: 화합물 13 합성 13: Compound 13 Synthesis

Figure pat00122
Figure pat00122

중간체 11-1(9.3g, 0.018mol)에 benzo[b]thiophen-2-ylboronic acid (15.4g, 0.0864mol/sigma aldrich), Pd(pph3)4(1.0g, 0.0009mol), potassium carbonate(7.4g, 0.054mol)에 THF 480ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 13을 8.4g(수율 63%) 수득하였다.Benzo [b] thiophen-2-ylboronic acid (15.4 g, 0.0864 mol / sigma aldrich), Pd (PPh3) 4 (1.0 g, 0.0009 mol), potassium carbonate (7.4 g, 0.054 mol), 480 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and column-purified (n-hexane: MC) to obtain 8.4 g (yield: 63%) of Compound 13.

H-NMR (200MHz, CDCl3): δ ppm, 2H(8.26/S, 7.71/D) 4H(7.98/D, 7.50/M, 7.52/M, 7.79/D, 7.30/S) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.26 / S, 7.71 / D) 4H (7.98 / D, 7.50 / M, 7.52 / M, 7.79 / D, 7.30 / S)

LC/MS: m/z=738[(M+1)+] LC / MS: m / z = 738 [(M + 1) < + &

실시예Example 14: 화합물 14 합성 14: Compound 14 Synthesis

Figure pat00123
Figure pat00123

중간체 11-1(9.3g, 0.018mol)에 benzo[b]thiophen-2-ylboronic acid (15.4g, 0.0864mol), Pd(pph3)4(1.0g, 0.0009mol), potassium carbonate(7.4g, 0.054mol)에 THF 480ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20: MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 14를 10.8g(수율 64%) 수득하였다.To the intermediate 11-1 (9.3 g, 0.018 mol) was added benzo [b] thiophen-2-ylboronic acid (15.4 g, 0.0864 mol), Pd (PPh3) 4 (1.0 g, 0.0009 mol) mol), 480 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain Compound (14) (10.8 g, yield 64%).

H-NMR(200MHz, CDCl3): δ ppm, 2H(8.26/S, 7.71/D) 4H(7.98/D, 7.50/M, 7.52/M, 8.45/D, 8.41/D, 7.58/M, 8.20/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.26 / S, 7.71 / D) 4H (7.98 / D, 7.50 / M, 7.52 / M, 8.45 / D, 8.41 / D, 7.58 / M, 8.20 / D)

LC/MS: m/z=938[(M+1)+] LC / MS: m / z = 938 [(M + 1) < + &

실시예Example 15: 화합물 15 합성 15: Compound 15 Synthesis

Figure pat00124
Figure pat00124

중간체 1-1(7.1g, 0.019mol)에 benzo[d]phenanthro[9,10-b]thiophene-10-ylboronic acid(15.3g, 0.0465mol/sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 440ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 15를 5.3g(수율 53%) 수득하였다.Benzo [d] phenanthro [9,10-b] thiophene-10-ylboronic acid (15.3 g, 0.0465 mol / sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.019 mol) 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 440 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and column-purified (n-hexane: MC) to obtain 5.3 g (yield: 53%) of Compound 15.

H-NMR(200MHz, CDCl3): δ ppm, 2H(8.10/S, 7.71/D, 8.34/S, 7.58/M, 8.41/D) 4H(8.93/D, 7.88/M, 7.82/M, 8.12/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.10 / S, 7.71 / D, 8.34 / S, 7.58 / M, 8.41 / D) 4H (8.93 / D, 7.88 / M, 7.82 / M, 8.12 / D)

LC/MS: m/z=774[(M+1)+] LC / MS: m / z = 774 [(M + 1) < + &

실시예Example 16: 화합물 16 합성 16: Compound 16 Synthesis

(1) (One) 제조예Manufacturing example 16-1: 중간체 16-1 합성 16-1: Synthesis of intermediate 16-1

Figure pat00125
Figure pat00125

중간체 1-1(7.1g, 0.019mol)에 dibenzo[b,d]thiophene-4-ylboronic acid (5.2g, 0.0228mol/sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 240ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 16-1을 5.3g(수율 59%) 수득하였다.4-ylboronic acid (5.2 g, 0.0228 mol / Sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, 0.057 mol), 240 ml of THF was added, and the mixture was reacted at 65 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 5.3 g (yield: 59%) of intermediate 16-1.

LC/MS: m/z=470 [(M+1)+] LC / MS: m / z = 470 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 16-2: 화합물 16 합성 16-2: Compound 16 Synthesis

Figure pat00126
Figure pat00126

중간체 16-1(5.3g, 0.011mol)에 1-phenyl-1H-benzo[d]imidazol-2-ylboronic acid(3.1g, 0.0132mol/sigma Aldrich), Pd(pph3)4(0.6g, 0.0006mol), potassium carbonate(4.5g, 0.033mol)에 THF 160ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 16을 3.8g(수율 59%) 수득하였다.2-ylboronic acid (3.1 g, 0.0132 mol / sigma Aldrich) and Pd (PPh3) 4 (0.6 g, 0.0006 mol) were added to Intermediate 16-1 (5.3 g, 0.011 mol) ) and potassium carbonate (4.5 g, 0.033 mol) were added 160 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC, and subjected to column purification (n-hexane: MC) to obtain 3.8 g (yield: 59%) of Compound 16.

H-NMR(200MHz, CDCl3): δ ppm, 1H(7.45/M, 8.56/D, 7.59/D, 8.20/M, 8.41/D, 8.45/D, 7.52/M, 7.50/M, 7.98/D) 2H(7.71/D, 8.34/S, 7.22/M, 8.10/S, 7.50/D) 3H(7.58/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / M, 8.56 / D, 7.59 / D, 8.20 / M, 8.41 / D, 8.45 / D, 7.52 / M, 7.50 / M, 7.98 / D ) 2H (7.71 / D, 8.34 / S, 7.22 / M, 8.10 / S, 7.50 / D)

LC/MS: m/z=583[(M+1)+] LC / MS: m / z = 583 [(M + 1) < + &

실시예Example 17: 화합물 17 합성 17: Compound 17 Synthesis

Figure pat00127
Figure pat00127

중간체 16-1(5.3g, 0.011mol)에 5-(9H-carbazol-9-yl)-1-phenyl-1H-benzo[d]imidazol-2-ylboronic acid(5.3g, 0.0132mol/sigma Aldrich), Pd(pph3)4 (0.6g, 0.0006mol), potassium carbonate(4.5g, 0.033mol)에 THF 200ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 17을 5.1g(수율 62%) 수득하였다.D] imidazol-2-ylboronic acid (5.3 g, 0.0132 mol / sigma Aldrich) was added to Intermediate 16-1 (5.3 g, 0.011 mol) , Pd (pph3) 4 (0.6 g, 0.0006 mol) and potassium carbonate (4.5 g, 0.033 mol) were added 200 ml of THF and reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and subjected to column separation on H 2 O: MC, followed by column purification (n-hexane: MC) to obtain 5.1 g (yield: 62%) of Compound 17.

H-NMR (200MHz, CDCl3): δ ppm, 1H(7.45/M, 8.41/D, 8.45/D, 7.52/M, 7.50/M, 7.98/D, 8.20/D, 7.59/D, 7.15/D, 7.63/D, 7.50/M, 7.29/M, 8.12/D, 8.55/D, 7.25/M, 7.33/M, 7.94/D, 7.70/S) 2H(8.10/S, 7.71/D, 8.34/S, 7.50/D) 3H(7.58/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / M, 8.41 / D, 8.45 / D, 7.52 / M, 7.50 / M, 7.98 / D, 8.20 / D, 7.59 / D, 7.15 / D , 7.63 / D, 7.50 / M, 7.29 / M, 8.12 / D, 8.55 / D, 7.25 / M, 7.33 / M, 7.94 / D, 7.70 / , 7.50 / D) 3H (7.58 / M)

LC/MS: m/z=748[(M+1)+] LC / MS: m / z = 748 [(M + 1) < + &

실시예Example 18: 화합물 18 합성 18: Compound 18 Synthesis

(1) (One) 제조예Manufacturing example 18-1: 중간체 18-1 합성 18-1: Synthesis of Intermediate 18-1

Figure pat00128
Figure pat00128

중간체 1-1(7.1g, 0.019mol)에 9H-carbazol (3.8g, 0.0228mol), Pd(dba)2(0.9g, 0.001mol), sodium-tert-butoxide(5.5g, 0.057mol)에 Tol 340ml를 넣고 95℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 중간체 18-1을 5.3g(수율 62%) 수득하였다.Tert-butoxide (5.5 g, 0.057 mol) was added to 9 g of Intermediate 1-1 (7.1 g, 0.019 mol) in the presence of 9H-carbazole (3.8 g, 0.0228 mol), Pd (dba) And the mixture was reacted at 95 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 5.3 g (yield: 62%) of Intermediate 18-1.

LC/MS: m/z=453 [(M+1)+] LC / MS: m / z = 453 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 18-2: 화합물 18 합성 18-2: Compound 18 Synthesis

Figure pat00129
Figure pat00129

중간체 18-1(5.3g, 0.011mol)에 naphthalen-2-ylboronic acid(5.3g, 0.0132mol /sigma Aldrich), Pd(pph3)4(0.6g, 0.0006mol), potassium carbonate(4.5g, 0.033mol)에 THF 200ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 18을 4.7g(수율 58%) 수득하였다.2-ylboronic acid (5.3 g, 0.0132 mol / sigma Aldrich), Pd (PPh3) 4 (0.6 g, 0.0006 mol) and potassium carbonate (4.5 g, 0.033 mol) were added to Intermediate 18-1 ), 200 ml of THF was added and the mixture was reacted at 65 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.7 g (yield: 58%) of Compound 18.

H-NMR(200MHz, CDCl3): δ ppm, 1H(7.70/S, 8.30/S, 7.90/S, 7.15/D, 7.59/D, 7.45/M) 2H(7.58/M, 7.70/D, 7.50/D, 7.50/M, 7.29/M, 8.12/D, 7.63/D, 8.55/D, 7.25/M, 7.33/M, 7.94/D, 8.10/S) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.70 / S, 8.30 / S, 7.90 / S, 7.15 / D, 7.59 / D, 7.45 / M) 2H (7.58 / M, 7.70 / D, 7.50 D, 7.50 / M, 7.29 / M, 8.12 / D, 7.63 / D, 8.55 / D, 7.25 / M, 7.33 /

LC/MS: m/z=731[(M+1)+] LC / MS: m / z = 731 [(M + 1) < + &

실시예Example 19: 화합물 19 합성 19: Compound 19 Synthesis

(1) (One) 제조예Manufacturing example 19-1: 중간체 19-1 합성 19-1: Synthesis of intermediate 19-1

Figure pat00130
Figure pat00130

중간체 1-1(7.1g, 0.019mol)에 4-(9-phenyl-9H-fluoren-9-yl)phenylboronic acid(8.3g, 0.0228mol/sigma Aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 300ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 19-1를 6.6g(수율 58%) 수득하였다.Phenylboronic acid (8.3 g, 0.0228 mol / sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol) was added to Intermediate 1-1 (7.1 g, 0.019 mol) mol) and potassium carbonate (7.9 g, 0.057 mol) were added 300 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and column-purified (n-hexane: MC) to obtain 6.6 g (yield: 58%) of Intermediate 19-1.

LC/MS: m/z=604[(M+1)+] LC / MS: m / z = 604 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 19-2: 화합물 19 합성 19-2: Compound 19 Synthesis

Figure pat00131
Figure pat00131

중간체 19-1(6.6g, 0.011mol)에 4,6-diphenyl-1,3,5-triazin-2-ylboronic acid (3.7g, 0.0132mol/sigma Aldrich), Pd(pph3)4(0.6g, 0.0006mol), potassium carbonate(4.5g, 0.033mol)에 THF 200ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 19를 3.8g(수율 46%) 수득하였다.4,6-diphenyl-1,3,5-triazin-2-ylboronic acid (3.7 g, 0.0132 mol / sigma Aldrich) and Pd (PPh3) 4 (0.6 g, 0.011 mol) were added to Intermediate 19-1 0.0006 mol) and potassium carbonate (4.5 g, 0.033 mol) were added 200 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 3.8 g (yield: 46%) of Compound 19.

H-NMR(200MHz, CDCl3): δ ppm, 1H(7.26/M) 2H(7.29/D, 7.28/M, 7.38/M, 7.87/D, 7.11/D, 7.55/D, 8.10/S, 8.34/S, 7.71/D, 7.41/M, 7.33/M, 7.33/D) 4H(8.28/D, 7.51/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.26 / M) 2H (7.29 / D, 7.28 / M, 7.38 / M, 7.87 / D, 7.11 / D, 7.55 / D, 8.10 / S, 8.34 7.41 / M, 7.33 / D) 4H (8.28 / D, 7.51 / M)

LC/MS: m/z=756[(M+1)+] LC / MS: m / z = 756 [(M + 1) < + &

실시예Example 20: 화합물 20 합성 20: Compound 20 Synthesis

Figure pat00132
Figure pat00132

중간체 1-1(7.1g, 0.019mol)에 4-(9-phenyl-9H-fluoren-9-yl)phenylboronic acid(16.7g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 460ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 20을 10.9g(수율 68%)수득하였다.Phenylboronic acid (16.7 g, 0.0465 mol), Pd (PPh3) 4 (1.1 g, 0.001 mol), 4- (9-phenyl-9H- Potassium carbonate (7.9 g, 0.057 mol) was added with 460 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 10.9 g (yield: 68%) of Compound 20.

H-NMR (200MHz, CDCl3): δ ppm, 2H(7.63/D, 7.93/D, 7.87/D, 7.38/M, 7.28/M, 8.10/S, 8.34/S, 7.71/D) 4H(7.26/M, 7.55/D) 8H(7.11/D, 7.33/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.63 / D, 7.93 / D, 7.87 / D, 7.38 / M, 7.28 / M, 8.10 / S, 8.34 / S, 7.71 / D) 4H (7.26 / M, 7.55 / D) 8H (7.11 / D, 7.33 / M)

LC/MS: m/z=842[(M+1)+] LC / MS: m / z = 842 [(M + 1) < + &

실시예Example 21: 화합물 21 합성 21: Compound 21 Synthesis

(1) (One) 제조예Manufacturing example 21-1: 중간체 21-1 합성 21-1: Synthesis of Intermediate 21-1

Figure pat00133
Figure pat00133

2-bromophenanthrene(8.2g, 0.032 mol/sigma Aldrich)를 Hexane 160ml하에 넣는다. TMEDA(24ml, 0.16mol), n-BuLi(1.6M, 100ml, 0.16mol)를 dropping funnel을 통해서 넣는다. N2 하에서 3시간 교반시킨 후 S2Cl2(6.4ml, 0.08mol)를 천천히 넣고, 상온에서 24시간 반응시켰다. 반응 혼합물을 냉각시킨 후 H20:methylene chloride(MC) 하에서 층 분리 시킨 후 컬럼정제(n-Hexane : methylene chloride)하여 중간체 21-1을 5.4g(수율 59%)을 수득하였다.2-bromophenanthrene (8.2 g, 0.032 mol / sigma Aldrich) is placed under 160 ml of hexane. Add TMEDA (24 ml, 0.16 mol) and n-BuLi (1.6 M, 100 ml, 0.16 mol) through the dropping funnel. N 2 , S 2 Cl 2 (6.4 ml, 0.08 mol) was added slowly, and the reaction was allowed to proceed at room temperature for 24 hours. The reaction mixture was cooled, layered under H 2 O: methylene chloride (MC), and subjected to column purification (n-hexane: methylene chloride) to obtain 5.4 g (yield: 59%) of Intermediate 21-1.

LC/MS: m/z=287[(M+1)+] LC / MS: m / z = 287 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 21-2: 화합물 21 합성 21-2: Compound 21 Synthesis

Figure pat00134
Figure pat00134

중간체 21-1(5.4g, 0.019mol)에 4-(dibenzo[b,d]thiophen-4-yl)phenylboronic acid(6.9g, 0.0228mol/sigma Aldrich), Pd(pph3)4(1.1g ,0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 220ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 21을 4.6g(수율 52%) 수득하였다.(Dibenzo [b, d] thiophen-4-yl) phenylboronic acid (6.9 g, 0.0228 mol / Sigma Aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 220 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.6 g (yield: 52%) of Compound 21.

H-NMR(200MHz, CDCl3): δ ppm, 1H(8.10/S, 8.34/S, 7.88/D, 7.82/M, 8.12/D, 7.98/D, 7.50/M, 7.52/M, 8.45/D, 8.41/D, 7.58/M, 8.20/D) 2H(7.71/D) 4H(7.25/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.10 / S, 8.34 / S, 7.88 / D, 7.82 / M, 8.12 / D, 7.98 / D, 7.50 / M, 7.52 / M, 8.45 / D , 8.41 / D, 7.58 / M, 8.20 / D) 2H (7.71 / D)

LC/MS: m/z=467[(M+1)+] LC / MS: m / z = 467 [(M + 1) < + &

실시예Example 22: 화합물 22 합성 22: Compound 22 Synthesis

Figure pat00135
Figure pat00135

중간체 21-1(5.4g, 0.019mol)에 4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenylboronic acid (7.2g, 0.0228mol/sigma Aldrich), Pd(pph3)4 (1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 240ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 22를 5.9g(수율 65%) 수득하였다.Phenylboronic acid (7.2 g, 0.0228 mol / sigma Aldrich), Pd (PPh3) 4 (5.4 g, 0.019 mol) 1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 240 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 5.9 g (yield: 65%) of Compound 22.

H-NMR(200MHz, CDCl3): δ ppm, 1H(8.56/D, 7.45/M, 7.59/D, 8.10/S, 8.34/S, 7.88/D, 7.82/M, 8.12/D) 2H(7.25/D, 7.85/D, 7.50/D, 7.58/M, 7.22/M, 7.71/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / D, 7.45 / M, 7.59 / D, 8.10 / S, 8.34 / S, 7.88 / D, 7.82 / M, 8.12 / D) 2H (7.25 / D, 7.85 / D, 7.50 / D, 7.58 / M, 7.22 / M, 7.71 / D)

LC/MS: m/z=477[(M+1)+] LC / MS: m / z = 477 [(M + 1) < + &

실시예Example 23: 화합물 23 합성 23: Compound 23 Synthesis

(1) (One) 제조예Manufacturing example 23-1: 중간체 23-1 합성 23-1: Synthesis of Intermediate 23-1

Figure pat00136
Figure pat00136

3,8-dibromo-4,7-phenanthroline(10.8g, 0.032 mol/sigma Aldrich)를 Hexane 200ml하에 넣는다. TMEDA(24ml, 0.16mol), n-BuLi(1.6M, 100ml, 0.16mol)를 dropping funnel을 통해서 넣는다. N2하에서 3시간 교반시킨 후 S2Cl2(6.4ml, 0.08mol)를 천천히 넣고, 상온에서 24시간 반응시켰다. 반응 혼합물을 냉각시킨 후 H20:methylene chloride(MC) 하에서 층 분리 시킨 후 컬럼정제(n-Hexane : methylene chloride)하여 중간체 23-1을 7.0g(수율 59%) 수득하였다.3,8-dibromo-4,7-phenanthroline (10.8 g, 0.032 mol / sigma Aldrich) is placed under 200 ml of hexane. Add TMEDA (24 ml, 0.16 mol) and n-BuLi (1.6 M, 100 ml, 0.16 mol) through the dropping funnel. After stirring for 3 hours under N 2 , S 2 Cl 2 (6.4 ml, 0.08 mol) was slowly added and reacted at room temperature for 24 hours. The reaction mixture was cooled, layered under H 2 O: methylene chloride (MC), and subjected to column purification (n-hexane: methylene chloride) to obtain 7.0 g (yield: 59%) of Intermediate 23-1.

LC/MS: m/z=368[(M+1)+] LC / MS: m / z = 368 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 23-2: 화합물 23 합성 23-2: Compound 23 Synthesis

Figure pat00137
Figure pat00137

중간체 23-1(7.0g, 0.019mol)에 phenylboronic acid (5.7g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 220ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 23을 4.5g(수율 65%) 수득하였다.220 ml of THF was added to intermediate 23-1 (7.0 g, 0.019 mol), phenylboronic acid (5.7 g, 0.0465 mol), Pd (pph3) 4 (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, C < / RTI > for 4 hours. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC, and subjected to column purification (n-hexane: MC) to obtain 4.5 g of Compound 23 (yield 65%).

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.47/M, 7.42/S, 7.76/D) 4H(8.30/D, 7.54/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.47 / M, 7.42 / S, 7.76 / D) 4H (8.30 / D, 7.54 / M)

LC/MS: m/z=363[(M+1)+] LC / MS: m / z = 363 [(M + 1) < + &

실시예Example 24: 화합물 24 합성 24: Compound 24 Synthesis

Figure pat00138
Figure pat00138

중간체 23-1(7.0g, 0.019mol)에 2-boronobenzo[b]thiophen-6-ylium (8.0g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 300ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 24를 4.9g(수율 54%) 수득하였다.2-boronobenzo [b] thiophen-6-ylium (8.0 g, 0.0465 mol), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, 0.057 mol), 300 ml of THF was added, and the mixture was reacted at 65 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.9 g (yield: 54%) of Compound 24.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.98/D, 7.50/M, 7.52/M, 7.79/D, 7.30/S, 7.76/D, 7.48/S) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.98 / D, 7.50 / M, 7.52 / M, 7.79 / D, 7.30 / S, 7.76 / D, 7.48 / S)

LC/MS: m/z=475[(M+1)+] LC / MS: m / z = 475 [(M + 1) < + &

실시예Example 25: 화합물 25 합성 25: Compound 25 Synthesis

Figure pat00139
Figure pat00139

중간체 23-1(7.0g, 0.019mol)에 9H-carbazol (7.8g, 0.0465mol), Pd(dba)2(0.9g, 0.001mol), sodium-tert-butoxide(5.5g, 0.057mol)에 Tol 340ml를 넣고 95℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 25를 5.7g(수율 55%) 수득하였다.To the intermediate 23-1 (7.0 g, 0.019 mol), 9H-carbazole (7.8 g, 0.0465 mol), Pd (dba) 2 (0.9 g, 0.001 mol) and sodium tert- And the mixture was reacted at 95 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 5.7 g (yield: 55%) of Compound 25.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.63/D, 7.50/M, 7.29/M, 8.12/D, 8.55/D, 7.25/M, 7.33/M, 7.94/D, 7.30/S, 7.76/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.63 / D, 7.50 / M, 7.29 / M, 8.12 / D, 8.55 / D, 7.25 / M, 7.33 / M, 7.94 / D, 7.30 / S , 7.76 / D)

LC/MS: m/z=541[(M+1)+] LC / MS: m / z = 541 [(M + 1) < + &

실시예Example 26: 화합물 26 합성 26: Compound 26 Synthesis

Figure pat00140
Figure pat00140

중간체 23-1(7.0g, 0.019mol)에 1-phenyl-3a,7a-dihydro-1H-benzo[d]imidazol-2-ylboronic acid(11.2g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 360ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 26을 6.0g(수율 53%) 수득하였다.1-phenyl-3a, 7a-dihydro-1H-benzo [d] imidazol-2-ylboronic acid (11.2 g, 0.0465 mol) and Pd (PPh3) 4 (1.1 g , 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 360 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 6.0 g of Compound 26 (yield: 53%).

H-NMR (200MHz, CDCl3): δ ppm, 2H(7.48/S, 7.76/D, 8.56/D, 7.59/D, 7.45/M) 4H(7.50/D, 7.22/M, 7.58/M)(7.50 / D, 7.22 / M, 7.58 / M): 1 H-NMR (200 MHz, CDCl 3 ):? Ppm, 2H (7.48 / S, 7.76 / D, 8.56 / D, 7.59 / D, 7.45 /

LC/MS: m/z=595[(M+1)+] LC / MS: m / z = 595 [(M + 1) < + &

실시예Example 27: 화합물 27 합성 27: Compound 27 Synthesis

Figure pat00141
Figure pat00141

중간체 23-1(7.0g, 0.019mol)에 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenylboronic acid(14.6g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 420ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 27을 8.3g(수율 58%) 수득하였다.Phenylboronic acid (14.6 g, 0.0465 mol), Pd (PPh3) 4 (1.1 g, 0.06 mol) was added to Intermediate 23-1 (7.0 g, 0.019 mol) 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol), 420 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 8.3 g (yield: 58%) of Compound 27.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.42/S, 7.76/D, 7.41/M, 7.59/D, 8.56/D) 4H(8.30/D, 7.71/D, 7.51/M, 8.28/D, 7.22/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.42 / S, 7.76 / D, 7.41 / M, 7.59 / D, 8.56 / D) 4H (8.30 / D, 7.71 / D, 7.51 / M, 8.28 / D, 7.22 / M)

LC/MS: m/z=747[(M+1)+] LC / MS: m / z = 747 [(M + 1) < + &

실시예Example 28: 화합물 28 합성 28: Compound 28 Synthesis

Figure pat00142
Figure pat00142

중간체 23-1(7.0g, 0.019mol)에 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenylboronic acid(10.6g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 340ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 28을 6.8g(수율 62%) 수득하였다.Phenylboronic acid (10.6 g, 0.0465 mol), Pd (PPh3) 4 (1.1 g, 0.0465 mol) was added to Intermediate 23-1 (7.0 g, 0.019 mol) 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 340 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 6.8 g (yield: 62%) of Compound 28.

H-NMR(200MHz, CDCl3): δ ppm, 2H(8.33/D, 7.59/M, 8.00/D, 7.98/D, 7.50/M, 7.52/M, 8.45/D, 7.76/D, 7.42/S) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.33 / D, 7.59 / M, 8.00 / D, 7.98 / D, 7.50 / M, 7.52 / M, 8.45 / D, 7.76 / D, 7.42 / S )

LC/MS: m/z=575[(M+1)+] LC / MS: m / z = 575 [(M + 1) < + &

실시예Example 29: 화합물 29 합성 29: Compound 29 Synthesis

Figure pat00143
Figure pat00143

중간체 23-1(7.0g, 0.019mol)에 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenylboronic acid(12.9g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 220ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 29를 7.3g(수율 57%) 수득하였다.Phenylboronic acid (12.9 g, 0.0465 mol), Pd (PPh3) 4 (1.1 g, 0.0465 mol) was added to Intermediate 23-1 (7.0 g, 0.019 mol) 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol), 220 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and subjected to column separation on H 2 O: MC, followed by column purification (n-hexane: MC) to obtain 7.3 g (yield: 57%) of Compound 29.

H-NMR (200MHz, CDCl3): δ ppm, 2H(7.48/S, 7.76/D) 4H(7.41/M) 8H (8.28/D, 7.51/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.48 / S, 7.76 / D) 4H (7.41 / M) 8H (8.28 / D, 7.51 / M)

LC/MS: m/z=673[(M+1)+] LC / MS: m / z = 673 [(M + 1) < + &

실시예Example 30: 화합물 30 합성 30: Compound 30 Synthesis

Figure pat00144
Figure pat00144

중간체 23-1(7.0g, 0.019mol)에 9-phenyl-9H-carbazol-2-ylboronic acid (13.3g, 0.0465mol/sigma aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 400ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 30을 8.8g(수율 67%) 수득하였다.(13.3 g, 0.0465 mol / sigma aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol), and potassium carbonate (7.9 g, 0.057 mol), 400 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 8.8 g (yield 67%) of Compound 30.

H-NMR (200MHz, CDCl3): δ ppm, 2H(7.42/S, 7.76/D, 7.45/M, 8.30/D, 8.21/D, 8.13/S, 8.55/D, 7.25/M, 7.33/M, 7.94/D) 4H(7.50/D, 7.58/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.42 / S, 7.76 / D, 7.45 / M, 8.30 / D, 8.21 / D, 8.13 / S, 8.55 / D, 7.25 / M, 7.33 / M , 7.94 / D) 4H (7.50 / D, 7.58 / M)

LC/MS: m/z=693[(M+1)+] LC / MS: m / z = 693 [(M + 1) < + &

실시예Example 31: 화합물 31 합성 31: Compound 31 Synthesis

Figure pat00145
Figure pat00145

중간체 23-1(7.0g, 0.019mol)에 4-(3,5-diphenyl-4H-1,2,4-triazol-4-yl)phenylboronic acid(15.9g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 440ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 31을 8.9g(수율 58%) 수득하였다.4-yl) phenylboronic acid (15.9 g, 0.0465 mol), Pd (PPh3) 4 (0.1 g, (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 440 ml of THF and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and subjected to column separation on H 2 O: MC, followed by column purification (n-hexane: MC) to obtain 8.9 g (yield: 58%) of Compound 31.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.42/S, 7.76/D) 4H(8.30/D, 7.71/D, 7.41/M) 8H(8.28/D, 7.51/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.42 / S, 7.76 / D) 4H (8.30 / D, 7.71 / D, 7.41 / M) 8H (8.28 / D, 7.51 / M)

LC/MS: m/z=801[(M+1)+] LC / MS: m / z = 801 [(M + 1) < + &

실시예Example 32: 화합물 32 합성 32: Compound 32 Synthesis

Figure pat00146
Figure pat00146

중간체 23-1(7.0g, 0.019mol)에 6-(9H-carbazol-9-yl)pyridin-2-ylboronic acid(13.4g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 400ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 32를 7.9g(수율 60%) 수득하였다.Pyrrolidin-2-ylboronic acid (13.4g, 0.0465mol), Pd (PPh3) 4 (1.1g, 0.001mol) was added to Intermediate 23-1 (7.0g, 0.019mol) 400 ml of THF was added to potassium carbonate (7.9 g, 0.057 mol), and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 7.9 g (yield: 60%) of Compound 32.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.76/D, 8.38/S, 7.94/D, 7.33/M, 7.25/M, 8.55/D, 8.12/D, 7.29/M, 7.50/M, 7.63/D, 7.64/D, 7.57/M, 9.30/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.76 / D, 8.38 / S, 7.94 / D, 7.33 / M, 7.25 / M, 8.55 / D, 8.12 / D, 7.29 / M, 7.50 / M , 7.63 / D, 7.64 / D, 7.57 / M, 9.30 / D)

LC/MS: m/z=695[(M+1)+] LC / MS: m / z = 695 [(M + 1) < + &

실시예Example 33: 화합물 33 합성 33: Compound 33 Synthesis

Figure pat00147
Figure pat00147

중간체 23-1(7.0g, 0.019mol)에 3-(9-phenyl-9H-fluoren-9-yl)phenylboronic acid(16.8g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 220ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 33을 8.0g(수율 50%) 수득하였다.3- (9-phenyl-9H-fluoren-9-yl) phenylboronic acid (16.8 g, 0.0465 mol), Pd (pph3) 4 (1.1 g, 0.001 mol) 220 ml of THF was added to potassium carbonate (7.9 g, 0.057 mol), and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 8.0 g (yield: 50%) of Compound 33.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.42/S, 7.42/M, 8.11/D, 8.30/D, 7.26/M, 7.76/D, 7.13/D) 4H(7.87/D, 7.38/M, 7.28/M, 7.55/D, 7.11/D, 7.33/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.42 / S, 7.42 / M, 8.11 / D, 8.30 / D, 7.26 / M, 7.76 / D, 7.13 / D) 4H (7.87 / D, 7.38 / M, 7.28 / M, 7.55 / D, 7.11 / D, 7.33 / M)

LC/MS: m/z=844[(M+1)+] LC / MS: m / z = 844 [(M + 1) < + &

실시예Example 34: 화합물 34 합성 34: Compound 34 Synthesis

(1) (One) 제조예Manufacturing example 34-1: 중간체 34-1 합성 34-1: Synthesis of Intermediate 34-1

Figure pat00148
Figure pat00148

중간체 23-1(7.0g, 0.019mol)에 dibenzo[b,d]thiophen-4-ylboronic acid (5.2g, 0.0228mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g ,0.057mol)에 THF 240ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 34-1을 5.9g(수율 66%) 수득하였다.Dibenzo [b, d] thiophen-4-ylboronic acid (5.2 g, 0.0228 mol), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, , 0.057 mol) was added 240 ml of THF, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 5.9 g (yield: 66%) of Intermediate 34-1.

LC/MS: m/z=472 [(M+1)+] LC / MS: m / z = 472 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 34-2: 화합물 34 합성 34-2: Compound 34 Synthesis

Figure pat00149
Figure pat00149

중간체 34-1(5.9g, 0.012mol)에 1-phenyl-1H-benzo[d]imidazol-2-ylboronic acid(3.4g, 0.0144mol), Pd(pph3)4(0.7g, 0.0006mol), potassium carbonate(4.9g, 0.036mol)에 THF 180ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 34를 4.1g(수율 58%) 수득하였다.1-phenyl-1H-benzo [d] imidazol-2-ylboronic acid (3.4 g, 0.0144 mol), Pd (PPh3) 4 (0.7 g, 0.0006 mol), potassium (4.9 g, 0.036 mol), and the mixture was reacted at 65 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.1 g (yield: 58%) of Compound 34.

H-NMR(200MHz, CDCl3): δ ppm, 1H(7.42/S, 8.31/D, 7.61/M, 8.47/D, 8.45/D, 7.52/M, 7.50/M, 7.98/D, 7.54/D, 7.98/D, 7.45/M, 8.56/D, 7.59/D, 7.48/S) 2H (7.50/D, 7.58/M, 7.22/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.42 / S, 8.31 / D, 7.61 / M, 8.47 / D, 8.45 / D, 7.52 / M, 7.50 / M, 7.98 / D, 7.54 / D 7.58 / M, 7.26 / M), 7.98 / D, 7.45 /

LC/MS: m/z=585[(M+1)+] LC / MS: m / z = 585 [(M + 1) < + &

실시예Example 35: 화합물 35 합성 35: Compound 35 Synthesis

Figure pat00150
Figure pat00150

중간체 23-1(7.0g, 0.019mol)에 5-(9H-carbazol-9-yl)-1-phenyl-1H-benzo[d]imidazol-2-ylboronic acid(18.8g, 0.0465mol/sigma aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 500ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 35를 8.0g(수율 46%) 수득하였다.Yl) -1H-benzo [d] imidazol-2-ylboronic acid (18.8g, 0.0465mol / Sigma aldrich) was added to Intermediate 23-1 (7.0g, 0.019mol) , Pd (pph3) 4 (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 500 ml of THF and reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 8.0 g (yield: 46%) of Compound 35.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.76/D, 7.48/S, 7.70/S, 7.63/D, 7.50/M, 7.29/M, 8.12/D, 8.55/D, 7.25/M, 7.33/M, 7.94/D, 7.15/D, 7.59/D) 4H(7.50/D, 7.58/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.76 / D, 7.48 / S, 7.70 / S, 7.63 / D, 7.50 / M, 7.29 / M, 8.12 / D, 8.55 / D, 7.25 / M , 7.33 / M, 7.94 / D, 7.15 / D, 7.59 / D) 4H (7.50 / D, 7.58 /

LC/MS: m/z=926[(M+1)+] LC / MS: m / z = 926 [(M + 1) < + &

실시예Example 36: 화합물 36 합성 36: Compound 36 Synthesis

Figure pat00151
Figure pat00151

중간체 23-1(7.0g, 0.019mol)에 4-(triphenylsilyl)phenylboronic acid (17.7g, 0.0465mol/sigma aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 480ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 36을 8.8g(수율 53%)수득하였다.4- (triphenylsilyl) phenylboronic acid (17.7 g, 0.0465 mol / sigma aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol), potassium carbonate (7.9 g, 0.057 mol), 480 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and subjected to column separation on H 2 O: MC, followed by column purification (n-hexane: MC) to obtain 8.8 g (yield: 53%) of Compound 36.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.42/S, 7.76/D) 4H(7.55/M, 8.40/D) 16H(7.46/D, 7.37/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.42 / S, 7.76 / D) 4H (7.55 / M, 8.40 / D) 16H (7.46 / D, 7.37 / M)

LC/MS: m/z=880[(M+1)+] LC / MS: m / z = 880 [(M + 1) < + &

실시예Example 37: 화합물 37 합성 37: Compound 37 Synthesis

Figure pat00152
Figure pat00152

중간체 23-1(7.0g, 0.019mol)에 2-phenyl-5H-pyrido[3,2-b]indol-5-ylboronic acid(13.4g, 0.0465mol/sigma aldrich), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 400ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 37을 7.3g(수율 55%)수득하였다.2-phenyl-5H-pyrido [3,2-b] indol-5-ylboronic acid (13.4 g, 0.0465 mol / sigma aldrich), Pd (PPh3) 4 (1.1 g, 0.001 mol) and potassium carbonate (7.9 g, 0.057 mol) were added 400 ml of THF and reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 7.3 g (yield: 55%) of Compound 37.

H-NMR(200MHz, CDCl3): δ ppm, 2H(7.30/S, 7.76/D, 7.94/D, 7.33/M, 7.25/M, 8.74/D, 7.90/D, 7.97/D, 7.47/M) 4H(7.54/M, 8.30/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.30 / S, 7.76 / D, 7.94 / D, 7.33 / M, 7.25 / M, 8.74 / D, 7.90 / D, 7.97 / D, 7.47 / M ) 4H (7.54 / M, 8.30 / D)

LC/MS: m/z=695[(M+1)+] LC / MS: m / z = 695 [(M + 1) < + &

실시예Example 38: 화합물 38 합성 38: Compound 38 Synthesis

Figure pat00153
Figure pat00153

중간체 23-1(7.0g, 0.019mol)에 9,9-diphenyl-9H-fluoren-2-ylboronic acid (16.8g, 0.0465mol), Pd(pph3)4(1.1g, 0.001mol), potassium carbonate(7.9g, 0.057mol)에 THF 460ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 38을 10.0g(수율 62%) 수득하였다.To the intermediate 23-1 (7.0 g, 0.019 mol) was added 9,9-diphenyl-9H-fluoren-2-ylboronic acid (16.8 g, 0.0465 mol), Pd (PPh3) 4 (1.1 g, 0.001 mol) 7.9 g, 0.057 mol), 460 ml of THF was added, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and column-purified (n-hexane: MC) to obtain 10.0 g (yield: 62%) of Compound 38.

H-NMR (200MHz, CDCl3): δ ppm, 2H(7.42/S, 7.76/D, 8.14/D, 7.96/D, 7.87/D, 7.38/M, 7.28/M, 8.28/S, 7.55/D) 4H(7.26/M) 8H(7.11/D, 7.33/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (7.42 / S, 7.76 / D, 8.14 / D, 7.96 / D, 7.87 / D, 7.38 / M, 7.28 / M, 8.28 / S, 7.55 / D ) 4H (7.26 / M) 8H (7.11 / D, 7.33 / M)

LC/MS: m/z=844[(M+1)+] LC / MS: m / z = 844 [(M + 1) < + &

실시예Example 39: 화합물 39 합성 39: Compound 39 Synthesis

(1) (One) 제조예Manufacturing example 39-1: 중간체 39-1 합성 39-1: Synthesis of Intermediate 39-1

Figure pat00154
Figure pat00154

3-bromo-4,7-phenanthroline(8.3g, 0.032 mol/sigma Aldrich)를 Hexane 160ml하에 넣는다. TMEDA(24ml, 0.16mol), n-BuLi(1.6M, 100ml, 0.16mol)를 dropping funnel을 통해서 넣는다. N2하에서 3시간 교반시킨 후 S2Cl2(6.4ml, 0.08mol)를 천천히 넣고, 상온에서 24시간 반응시켰다. 반응 혼합물을 냉각시킨 후 H20:methylene chloride(MC) 하에서 층 분리 시킨 후 컬럼정제(n-Hexane : methylene chloride)하여 중간체 39-1을 3.4g(수율 34%)을 수득하였다.3-bromo-4,7-phenanthroline (8.3 g, 0.032 mol / sigma Aldrich) is placed under 160 ml of hexane. Add TMEDA (24 ml, 0.16 mol) and n-BuLi (1.6 M, 100 ml, 0.16 mol) through the dropping funnel. After stirring for 3 hours under N 2 , S 2 Cl 2 (6.4 ml, 0.08 mol) was slowly added and reacted at room temperature for 24 hours. The reaction mixture was cooled, layered under H 2 O: methylene chloride (MC), and subjected to column purification (n-hexane: methylene chloride) to obtain 3.4 g (yield: 34%) of Intermediate 39-1.

LC/MS: m/z=290[(M+1)+] LC / MS: m / z = 290 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 39-2: 화합물 39 합성 39-2: Compound 39 Synthesis

Figure pat00155
Figure pat00155

중간체 39-1(3.4g, 0.011mol)에 4-(dibenzo[b,d]thiophen-4-yl)phenylboronic acid(4.0g, 0.0132mol), Pd(pph3)4(0.6g, 0.0006mol), potassium carbonate(4.5g, 0.033mol)에 THF 140ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane:MC)하여 화합물 39를 2.9g(수율 56%) 수득하였다.(Dibenzo [b, d] thiophen-4-yl) phenylboronic acid (4.0 g, 0.0132 mol), Pd (PPh3) 4 (0.6 g, 0.0006 mol) 140 ml of THF was added to potassium carbonate (4.5 g, 0.033 mol), and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 2.9 g (yield: 56%) of Compound 39.

H-NMR(200MHz, CDCl3): δ ppm, 1H(7.50/M, 7.52/M, 8.45/D, 8.41/D, 7.58/M, 8.20/D, 7.42/S, 7.26/D, 8.83/D, 7.54/D) 2H(8.81/D, 7.28/D, 7.98/D) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.50 / M, 7.52 / M, 8.45 / D, 8.41 / D, 7.58 / M, 8.20 / D, 7.42 / S, 7.26 / D, 8.83 / D , 7.54 / D) 2H (8.81 / D, 7.28 / D, 7.98 / D)

LC/MS: m/z=469[(M+1)+] LC / MS: m / z = 469 [(M + 1) < + &

실시예Example 40: 화합물 40 합성 40: Compound 40 Synthesis

Figure pat00156
Figure pat00156

중간체 39-1(3.4g, 0.011mol)에 4-(9,9-diphenyl-9H-fluoren-2-yl)phenylboronic acid(5.8g, 0.0132mol/sigma aldrich), Pd(pph3)4 (0.6g, 0.0006mol), potassium carbonate(4.5g, 0.033mol)에 THF 180ml를 넣고 65℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20:MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 40을 4.3g(수율 65%) 수득하였다.4- (9,9-diphenyl-9H-fluoren-2-yl) phenylboronic acid (5.8 g, 0.0132 mol / sigma aldrich) and Pd (PPh3) 4 (0.6 g , 0.0006 mol) and potassium carbonate (4.5 g, 0.033 mol) were added 180 ml of THF, and the mixture was reacted at 65 ° C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.3 g (yield 65%) of Compound 40.

H-NMR(200MHz, CDCl3): δ ppm, 1H(7.63/D, 7.93/D, 7.87/D, 7.38/M, 7.28/M, 7.55/D, 7.42/S, 7.26/D, 8.83/D, 7.54/D, 7.98/D, 7.77/D) 2H(7.26/M, 7.88/D, 8.81/D) 4H(97.11/D, 7.33/M) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.63 / D, 7.93 / D, 7.87 / D, 7.38 / M, 7.28 / M, 7.55 / D, 7.42 / S, 7.26 / D, 8.83 / D , 7.54 / D, 7.98 / D, 7.77 / D) 2H (7.26 / M, 7.88 / D, 8.81 / D)

LC/MS: m/z=603[(M+1)+] LC / MS: m / z = 603 [(M + 1) < + &

실시예Example 41: 화합물 41 합성 41: Compound 41 Synthesis

(1) (One) 제조예Manufacturing example 41-1: 중간체 41-1 합성  41-1: Synthesis of Intermediate 41-1

Figure pat00157
Figure pat00157

6H-benzo[def]carbazole(5.0g, 0.026mol/sigma Aldrich), bromine(18.3g, 0.11mol /sigma Aldrich)에 tetrachloride 800ml넣고 1시간동안 상온에서 교반시켰다. 반응물을 재결정을 통해서 중간체 41-1, 6.7g (수율 83%)을 얻었다.800 ml of tetrachloride was added to 6-H-benzo [def] carbazole (5.0 g, 0.026 mol / sigma Aldrich) and bromine (18.3 g, 0.11 mol / sigma Aldrich) and stirred at room temperature for 1 hour. The reaction product was recrystallized to obtain 6.7 g (yield: 83%) of Intermediate 41-1.

LC/MS: m/z=349[(M+1)+]LC / MS: m / z = 349 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 41-2: 중간체 41-2 합성  41-2: Intermediate 41-2 Synthesis

Figure pat00158
Figure pat00158

중간체 41-1(5.0g, 0.014mol)에 bromobenzene(2.2g, 0.014mol /sigma Aldrich), Pd(dba)2(0.6g, 0.0007mol/P&H TECH), sodium-tert-butoxide(2.7g, 0.028mol /sigma Aldrich)에 Toluene 160ml를 넣고 95℃에서 24시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 41-2를 4.1g(수율 69%)수득하였다.Pd (dba) 2 (0.6 g, 0.0007 mol / P & H TECH) and sodium tert-butoxide (2.7 g, 0.028 mol) were added to intermediate 41-1 (5.0 g, 0.014 mol) mol / Sigma Aldrich), and the mixture was reacted at 95 DEG C for 24 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.1 g (yield: 69%) of Intermediate 41-2.

LC/MS: m/z=425[(M+1)+]LC / MS: m / z = 425 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 41-3: 화합물 41 합성  41-3: Compound 41 Synthesis

Figure pat00159
Figure pat00159

중간체 41-2(5.0g, 0.011mol), phenyl-boronic acid(3.2g, 0.026mol /TCI), Pd(pph3)4(0.6g, 0.0006mol/P&H TECH), potassium carbonate(3.0g, 0.022mol /sigma Aldrich)에 THF 100ml를 넣고 65℃에서 18시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 화합물 41을 3.3g(수율 72%) 수득하였다.Pd (PPh3) 4 (0.6g, 0.0006mol / P & H TECH), potassium carbonate (3.0g, 0.022mol) were added to a solution of intermediate 41-2 (5.0g, 0.011mol) / sigma Aldrich), 100 ml of THF was added, and the mixture was reacted at 65 DEG C for 18 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC, and subjected to column purification (n-hexane: MC) to obtain 3.3 g (yield: 72%) of Compound 41.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.45/m) 2H(8.34/s, 8.10/s, 7.71/d, 7.58/m, 7.50/d, 7.41/m) 4H(7.52/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / m) 2H (8.34 / s, 8.10 / s, 7.71 / d, 7.58 / m, 7.50 / d, 7.41 / m) 4H (7.52 / d , 7.51 / m)

LC/MS: m/z=420[(M+1)+] LC / MS: m / z = 420 [(M + 1) < + &

실시예Example 42: 화합물 42 합성 42: Compound 42 Synthesis

Figure pat00160
Figure pat00160

중간체 41-2(5.0g, 0.011mol), 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenylboronic acid(8.2g, 0.026mol /TCI)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 42, 6.5g(수율 73%)을 얻었다.To a solution of Intermediate 41-2 (5.0 g, 0.011 mol) and 4- (2-phenyl-1H-benzo [d] imidazol-1-yl) phenylboronic acid (8.2 g, 0.026 mol / Synthesis was carried out in the same manner as used to give 42, 6.5 g (yield 73%) of the compound.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.45/m) 2H(8.56/d, 8.34/d, 8.10/s, 7.71/m, 7.59/d, 7.58/m, 7.50/d, 7.41/m) 4H(8.28/d, 7.79/d, 7.68/d, 7.51/m, 7.22/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / m) 2H (8.56 / d, 8.34 / d, 8.10 / s, 7.71 / m, 7.59 / d, 7.58 / m, 7.50 / d, 7.41 / m) 4H (8.28 / d, 7.79 / d, 7.68 / d, 7.51 / m, 7.22 /

LC/MS: m/z= 804[(M+1)+] LC / MS: m / z = 804 [(M + 1) < + &

실시예Example 43: 화합물 43 합성  43: Compound 43 Synthesis

Figure pat00161
Figure pat00161

중간체 41-2(5.0g, 0.011mol), triphenylen-2-ylboronic acid(7.1g, 0.026mol /ark pharm)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 43, 5.9g(수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 41-2 (5.0 g, 0.011 mol) and triphenylen-2-ylboronic acid (7.1 g, 0.026 mol / 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.45/m) 2H(9.15/s, 8.34/s, 8.18/d, 8.10/s, 8.04/d, 7.71/m, 7.58/m, 7.50/d) 4H(8.93/d, 8.12/d, 7.88/m, 7.82/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / m) 2H (9.15 / s, 8.34 / s, 8.18 / d, 8.10 / s, 8.04 / d, 7.71 / m, 7.58 / m, 7.50 / d) 4H (8.93 / d, 8.12 / d, 7.88 / m, 7.82 / m)

LC/MS: m/z= 720[(M+1)+] LC / MS: m / z = 720 [(M + 1) < + &

실시예Example 44: 화합물 44 합성  44: Compound 44 Synthesis

(1) (One) 제조예Manufacturing example 44-1: 중간체 44-1 합성 44-1: Synthesis of Intermediate 44-1

Figure pat00162
Figure pat00162

3,5-dichlorophenylboronic acid(5.0g, 0.026mol/Chemosyntha), phenyl boronic acid (7.1g, 0.031mol / TCI)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 44-1, 5.1g(수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3 using 3,5-dichlorophenylboronic acid (5.0 g, 0.026 mol / Chemosyntha) and phenyl boronic acid (7.1 g, 0.031 mol / TCI) (Yield: 71%).

LC/MS: m/z= 277[(M+1)+] LC / MS: m / z = 277 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 44-2: 화합물 44 합성 44-2: Compound 44 Synthesis

Figure pat00163
Figure pat00163

중간체 41-2(5.0g, 0.011mol), 중간체 44-1(3.7g, 0.013mol)을 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 44, 5.6g(수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, from the intermediate 41-2 (5.0 g, 0.011 mol) and the intermediate 44-1 (3.7 g, 0.013 mol) to obtain 5.44 g .

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.45/m) 2H(8.34/s, 8.10/s, 7.71/d, 7.58/m, 7.50/d) 4H(7.41/m) 8H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / m) 2H (8.34 / s, 8.10 / s, 7.71 / d, 7.58 / m, 7.50 / d) 4H (7.41 / m) 8H (8.28 / d, 7.51 / m)

LC/MS: m/z= 730[(M+1)+] LC / MS: m / z = 730 [(M + 1) < + &

실시예Example 45: 화합물 45 합성  45: Compound 45 Synthesis

(1) (One) 제조예Manufacturing example 45-1: 중간체 45-1 합성 45-1: Synthesis of Intermediate 45-1

Figure pat00164
Figure pat00164

4-bromo-9H-carbazole(5.0g, 0.020mol), bromobenzene(3.2g, 0.020mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 45-1, 4.5g(수율 70%)을 얻었다.4.5 g (yield 70%) of Intermediate 45-1 was obtained by the same method as in Production Example 41-2, except that 4-bromo-9H-carbazole (5.0 g, 0.020 mol) and bromobenzene (3.2 g, ≪ / RTI >

LC/MS: m/z= 322[(M+1)+] LC / MS: m / z = 322 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 45-2: 중간체 45-2 합성 45-2: Intermediate 45-2 Synthesis

Figure pat00165
Figure pat00165

중간체 45-1(5g, 0.016mol)을 THF 100ml에 녹이고 -78℃에서 2M n-buLi 8ml(0.001mol)를 dropping하고, 1시간 교반 후 trimethylborate 3ml(0.027mol)를 넣고 상온에서 12시간 교반시켰다. 반응 종료 후 냉각하여 H+0 : MC에 층분리 후 컬럼정제(n-Hexane :MC)하여 중간체 45-2를 2.3g(수율 51%)수득하였다.Intermediate 45-1 (5 g, 0.016 mol) was dissolved in THF (100 ml), and 8 ml (0.001 mol) of 2M n-buLi was dropwise added thereto at -78 ° C. After stirring for 1 hour, trimethylborate (3 ml, 0.027 mol) was added and stirred at room temperature for 12 hours . After completion of the reaction, the reaction product was cooled, and the product was separated into H + 0: MC and column-purified (n-hexane: MC) to obtain 2.3 g (yield: 51%) of Intermediate 45-2.

LC/MS: m/z= 287[(M+1)+] LC / MS: m / z = 287 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 45-3: 화합물 45 합성 45-3: Compound 45 Synthesis

Figure pat00166
Figure pat00166

중간체 41-2(5.0g, 0.011mol), 중간체 45-2(3.3g, 0.013mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 45, 5.8g(수율 70%)을 얻었다.Intermediate 41-2 (5.0 g, 0.011 mol) and Intermediate 45-2 (3.3 g, 0.013 mol) were added to the residue to obtain 45 (5.8 g, yield 70%) of the compound 45 .

H-NMR (200MHz, CDCl3):δ ppm, 2H(8.55/d ,8.34/s ,8.10/s ,7.94/d ,7.79/d ,7.71/d ,7.59/d ,7.43/m ,7.33/m ,7.25/m ) 3H(7.45/m ) 6H(7.58/m ,7.50/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.55 / d, 8.34 / s, 8.10 / s, 7.94 / d, 7.79 / d, 7.71 / d, 7.59 / d, 7.43 / m, 7.33 / m , 7.25 / m) 3H (7.45 / m) 6H (7.58 / m, 7.50 / d)

LC/MS: m/z= 750[(M+1)+] LC / MS: m / z = 750 [(M + 1) < + &

실시예Example 46: 화합물 46 합성 46: Compound 46 Synthesis

(1) (One) 제조예Manufacturing example 46-1: 중간체 46-1 합성 46-1: Synthesis of Intermediate 46-1

Figure pat00167
Figure pat00167

6H-benzo[def]carbazole(5.0g, 0.026 mol), bromine(36.6g, 0.22mol)에 tetrachloride 1100ml를 넣고 1시간 동안 상온에서 교반시켰다. 반응물을 재결정을 통해서 중간체 46-1, 10.5g (수율 80%)을 얻었다.1100 ml of tetrachloride was added to 6-benzo [def] carbazole (5.0 g, 0.026 mol) and bromine (36.6 g, 0.22 mol) and the mixture was stirred at room temperature for 1 hour. The reaction product was recrystallized to obtain 10.5 g (yield: 80%) of Intermediate 46-1.

LC/MS: m/z= 506[(M+1)+] LC / MS: m / z = 506 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 46-2: 중간체 46-2 합성 46-2: Intermediate 46-2 Synthesis

Figure pat00168
Figure pat00168

중간체 46-1(5.0g, 0.010mol), bromobenzene(1.6g, 0.011mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 46-2, 4.3g(수율 67%)을 얻었다.Intermediate 46-1 (5.0 g, 0.010 mol) and bromobenzene (1.6 g, 0.011 mol) were added and the compound was synthesized by the same method as in Production Example 41-2 to give 4.3 g (yield 67%) of Compound 46-2.

LC/MS: m/z= 583[(M+1)+] LC / MS: m / z = 583 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 46-3: 화합물 46 합성 46-3: Compound 46 Synthesis

Figure pat00169
Figure pat00169

중간체 46-2(5.0g, 0.009mol), 9H-carbazole(5.7g, 0.034mol /TCI)를 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 46, 5.9g(수율 70%)을 얻었다.The compound 46 (5.9 g, yield 70%) was synthesized by the same method as in Production Example 41-2 except that Intermediate 46-2 (5.0 g, 0.009 mol) and 9H-carbazole (5.7 g, 0.034 mol / .

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.45/m ) 2H(7.80/s ,7.70/d ,7.58/m ) 4H(8.55/d ,8.12/d ,7.94/d ,7.63/d ,7.33/m ,7.29/m ,7.25/m ) 6H(7.50/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.45 / m) 2H (7.80 / s, 7.70 / d, 7.58 / m) 4H (8.55 / d, 8.12 / d, 7.94 / d, 7.63 / d , 7.33 / m, 7.29 / m, 7.25 / m) 6H (7.50 / m)

LC/MS: m/z= 929[(M+1)+] LC / MS: m / z = 929 [(M + 1) < + &

실시예Example 47: 화합물 47 합성  47: Compound 47 Synthesis

(1) (One) 제조예Manufacturing example 47-1: 중간체 47-1 합성 47-1: Intermediate 47-1 Synthesis

Figure pat00170
Figure pat00170

중간체 41-2(5.0g, 0.011mol), dibenzo[b,d]thiophen-4-ylboronic acid (3.0g, 0.013mol / TCI )를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 47-1, 4.3g(수율 74%)을 얻었다.(m/z=529)4-ylboronic acid (3.0 g, 0.013 mol / TCI) was added to a solution of Intermediate 41-2 (5.0 g, 0.011 mol) and dibenzo [b, d] thiophen- -1, 4.3 g (yield: 74%). (M / z = 529)

LC/MS: m/z= 529[(M+1)+] LC / MS: m / z = 529 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 47-2: 화합물 47 합성 47-2: Compound 47 Synthesis

Figure pat00171
Figure pat00171

중간체 47-1(5.0g, 0.010mol), triphenylen-2-ylboronic acid (3.3g, 0.012mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 47, 4.8g(수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, except that Intermediate 47-1 (5.0 g, 0.010 mol) and triphenylen-2-ylboronic acid (3.3 g, 0.012 mol) ≪ / RTI >

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.45/d, 8.41/d, 8.20/d, 8.18/d, 8.04/d, 7.98/d, 7.52/m, 7.45/m) 2H(8.93/d, 8.34/s, 8.12/d, 8.10/s, 7.88/m, 7.82/m, 7.71/d) 3H(7.58/m, 7.50/dㄴ) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.45 / d, 8.41 / d, 8.20 / d, 8.18 / d, 8.04 / d, 7.98 / d, 7.52 / m, 7.45 / m (7.58 / m, 7.50 / d)) 2H (8.93 / d, 8.34 / s, 8.12 / d, 8.10 / s, 7.88 /

LC/MS: m/z=676[(M+1)+] LC / MS: m / z = 676 [(M + 1) < + &

실시예Example 48: 화합물 48 합성 48: Compound 48 Synthesis

(1) (One) 제조예Manufacturing example 48-1: 중간체 48-1 합성 48-1: Synthesis of Intermediate 48-1

Figure pat00172
Figure pat00172

중간체 41-2(5.0g, 0.011mol), 중간체 44-1(3.7g, 0.013mol)을 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 48-1, 4.5g(수율 71%)을 얻었다. Intermediate 48-1 (4.5 g, 71%) was synthesized in the same manner as in Production Example 41-3, except that Intermediate 41-2 (5.0 g, 0.011 mol) and Intermediate 44-1 (3.7 g, 0.013 mol) ≪ / RTI >

LC/MS: m/z=578[(M+1)+] LC / MS: m / z = 578 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 48-2: 중간체 48-2 합성 48-2: Intermediate 48-2 Synthesis

Figure pat00173
Figure pat00173

5-bromo-1-phenyl-1H-benzo[d]imidazol-2-ylboronic acid(5.0g, 0.016mol/matrix scientific), 9H-carbazole(2.7g, 0.016mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 48-2, 4.7g(수율 73%)을 얻었다.(5.0 g, 0.016 mol / matrix scientific) and 9H-carbazole (2.7 g, 0.016 mol) were added to a solution of (Yield: 73%) of Intermediate 48-2.

LC/MS: m/z=403[(M+1)+]LC / MS: m / z = 403 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 48-3: 화합물 48 합성 48-3: Compound 48 Synthesis

Figure pat00174
Figure pat00174

중간체 48-1(5.0g, 0.009mol), 중간체 48-2(4.4g, 0.011mol를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 48, 5.6g(수율 73%)을 얻었다.Intermediate 48-1 (5.0 g, 0.009 mol) and Intermediate 48-2 (4.4 g, 0.011 mol) were added and the compound 48 was synthesized in the same manner as in Production Example 41-3 to give 5.6 g (yield 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.12/d, 7.94/d, 7.70/s, 7.63/d, 7.59/d, 7.50/m, 7.33/m, 7.29/m, 7.25/m, 7.15/d) 2H(8.34/s, 8.10/s, 7.71/d, 7.45/m, 7.41/m) 4H(8.28/d, 7.58/m, 7.51/m, 7.50/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.12 / d, 7.94 / d, 7.70 / s, 7.63 / d, 7.59 / d, 7.50 / m, 7.33 / m, 7.29 / m M, 7.55 / d) 2H (8.34 / s, 8.10 / s, 7.71 / d, 7.45 / m, 7.41 /

LC/MS: m/z=856[(M+1)+] LC / MS: m / z = 856 [(M + 1) < + &

실시예Example 49: 화합물 49 합성  49: Compound 49 Synthesis

(1) (One) 제조예Manufacturing example 49-1: 중간체 49-1 합성  49-1: Synthesis of intermediate 49-1

Figure pat00175
Figure pat00175

6H-benzo[def]carbazole(5.0g, 0.026mol), bromine(9.2g, 0.06mol)에 tetrachloride 400ml넣고 1시간 동안 상온에서 교반시킨다. 반응물을 재결정을 통해서 중간체 49-1, 5.4g (수율 77%)을 얻었다.Tetrachloride (400 ml) was added to 6-benzo [def] carbazole (5.0 g, 0.026 mol) and bromine (9.2 g, 0.06 mol) and the mixture was stirred at room temperature for 1 hour. The reaction product was recrystallized to obtain 5.4 g (yield: 77%) of Intermediate 49-1.

LC/MS: m/z=270[(M+1)+] LC / MS: m / z = 270 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 49-2: 중간체 49-2 합성 49-2: Intermediate 49-2 Synthesis

Figure pat00176
Figure pat00176

중간체 49-1(5.0g, 0.019mol), bromobenzene(15.9g, 0.0465mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 49-2, 4.7g(수율 71%)을 얻었다.Intermediate 49-1 (5.0 g, 0.019 mol) and bromobenzene (15.9 g, 0.0465 mol) were added and the reaction mixture was reacted in the same manner as in Production Example 41-2 to give intermediate 49-2 (yield: 71%).

LC/MS: m/z=346[(M+1)+] LC / MS: m / z = 346 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 49-3: 화합물 49 합성 49-3: Compound 49 Synthesis

Figure pat00177
Figure pat00177

중간체 49-2(5.0g, 0.014mol), 중간체 44-1(4.7g, 0.017mol)을 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 49, 5.7g(수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, from Intermediate 49-2 (5.0 g, 0.014 mol) and Intermediate 44-1 (4.7 g, 0.017 mol) to obtain Compound 49 (5.7 g, 71% .

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/s ,7.45/m) 2H(8.12/d ,7.88/d ,7.85/d ,7.82/m ,7.58/m ,7.50/d ,7.41/m ,7.25/d ) 4H(8.28/d ,7.51/m ) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / s, 7.45 / m) 2H (8.12 / d, 7.88 / d, 7.85 / d, 7.82 / m, 7.58 / m, 7.50 / d, 7.41 / m, 7.25 / d) 4H (8.28 / d, 7.51 / m)

LC/MS: m/z= 575[(M+1)+] LC / MS: m / z = 575 [(M + 1) < + &

실시예Example 50: 화합물 50 합성 50: Compound 50 Synthesis

(1) (One) 제조예Manufacturing example 50-1: 중간체 50-1 합성 50-1: Synthesis of Intermediate 50-1

Figure pat00178
Figure pat00178

triphenylen-2-ylboronic acid(5.0g, 0.018mol), 4-(triphenylen-2-yl)phenylboronic acid(4.2g, 0.021mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 50-1, 4.5g(수율 72%)을 얻었다.2-ylboronic acid (5.0 g, 0.018 mol) and 4- (triphenylen-2-yl) phenylboronic acid (4.2 g, 0.021 mol) 1, 4.5 g (yield: 72%).

LC/MS: m/z= 348[(M+1)+] LC / MS: m / z = 348 [(M + 1) < + &

(1) (One) 제조예Manufacturing example 50-2: 화합물 50 합성 50-2: Compound 50 Synthesis

Figure pat00179
Figure pat00179

중간체 49-2(5.0g, 0.014mol), 중간체 50-1(5.9g, 0.017mol)을 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 50, 5.7g(수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 49-2 (5.0 g, 0.014 mol) and Intermediate 50-1 (5.9 g, 0.017 mol) added thereto to obtain 5.7 g (yield 72% .

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s ,8.18/d ,8.04/d ,7.93/s ,7.45/m ) 2H(8.93/d ,7.58/m ,7.50/d ) 4H((8.12/d ,7.88/d ,7.82/m ,7.25/d ) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.93 / s, 7.45 / m) 2H (8.93 / d, 7.58 / m, 7.50 / d) 4H (8.12 / d, 7.88 / d, 7.82 / m, 7.25 / d)

LC/MS: m/z= 570[(M+1)+] LC / MS: m / z = 570 [(M + 1) < + &

실시예Example 51: 화합물 57 합성 51: Compound 57 Synthesis

(1) (One) 제조예Manufacturing example 51-1: 중간체 57-1 합성 51-1: Intermediate 57-1 Synthesis

Figure pat00180
Figure pat00180

중간체 49-2(5.0g, 0.014mol), 4-bromophenylboronic acid(3.4g, 0.017mol /TCI)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 57-1, 4.4g(수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 49-2 (5.0 g, 0.014 mol) and 4-bromophenylboronic acid (3.4 g, 0.017 mol / TCI) %).

LC/MS: m/z= 422[(M+1)+] LC / MS: m / z = 422 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 51-2: 화합물 57 합성 51-2: Compound 57 Synthesis

Figure pat00181
Figure pat00181

중간체 57-1(5.0g, 0.012mol), N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(4.3g, 0.012mol/matrix science)를 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 57, 5.7g(수율 67%)을 얻었다.(4.3 g, 0.012 mol / matrix science) was added to a solution of Intermediate 57-1 (5.0 g, 0.012 mol) and N- (biphenyl-4-yl) -9,9- -2, the compound 57 (5.7 g, yield 67%) was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/s,7.87/d ,7.62/d ,7.55/d ,7.45/m ,7.41/m ,7.38/m ,7.28/m ,6.75/s ,6.58/d ) 2H(8.12/d ,7.88/d ,7.82/m ,7.58/m ,7.52/d ,7.51/m ,7.50/d ,1.72/s ) 4H(7.54/d ,6.69/d ) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / s, 7.87 / d, 7.62 / d, 7.55 / d, 7.45 / m, 7.41 / m, 7.38 / m, 7.28 / m, 6.75 / s 7.58 d) 2H (8.12 / d, 7.88 / d, 7.82 / m, 7.58 / m, 7.52 / d, 7.51 / m, 7.50 / d, 1.72 / s)

LC/MS: m/z= 703[(M+1)+] LC / MS: m / z = 703 [(M + 1) < + &

실시예Example 52: 화합물 58 합성 52: Compound 58 Synthesis

Figure pat00182
Figure pat00182

중간체 55-1(5.0g, 0.012mol), N-(biphenyl-4-yl)-9,9-dimethyl-7-phenyl-9H-fluoren-2-amine(5.3g, 0.012mol/2daybiochem)를 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 58, 6.8g(수율 73%)을 얻었다.(5.0 g, 0.012 mol) and N- (biphenyl-4-yl) -9,9-dimethyl-7-phenyl-9H-fluoren-2-amine (5.3 g, 0.012 mol / 2daybiochem) Synthesis was conducted in the same manner as in Production Example 41-2 to give compound 58 (6.8 g, yield 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/s, 7.93/d, 7.77/s, 7.63/d, 7.62/d, 7.45/m, 6.75/s, 6.58/d) 2H(8.12/d, 7.88/d, 7.82/m, 7.58/m, 7.50/d, 7.41/m, 1.72/s) 4H(7.54/d, 7.52/d, 7.51/m, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / s, 7.93 / d, 7.77 / s, 7.63 / d, 7.62 / d, 7.45 / m, 6.75 / s, 6.58 / d) 2H (8.12 7.58 / d, 7.51 / m, 6.69 / d), 7.48 / d, 7.88 / d, 7.82 /

LC/MS: m/z=779[(M+1)+] LC / MS: m / z = 779 [(M + 1) < + &

실시예Example 53: 화합물 59 합성 53: Compound 59 Synthesis

(1) (One) 제조예Manufacturing example 53-1: 중간체 59-1 합성 53-1: Synthesis of intermediate 59-1

Figure pat00183
Figure pat00183

9,9-dimethyl-9H-fluoren-2-amine(5.0g, 0.024mol/2daybiochem), 9,9-dimethyl-9H-fluoren-2-amine(4.7g, 0.024mol/2daybiochem)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 59-1, 5.7g(수율 71%)을 얻었다.9,9-dimethyl-9H-fluoren-2-amine (5.0g, 0.024mol / 2daybiochem) and 9,9-dimethyl-9H- -2, 5.7 g (71%) of the intermediate 59-1 was obtained.

LC/MS: m/z=324[(M+1)+] LC / MS: m / z = 324 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 53-2: 중간체 59-2 합성 53-2: Intermediate 59-2 Synthesis

Figure pat00184
Figure pat00184

중간체 55-1(5.0g, 0.012mol), 중간체 59-1(3.9g, 0.012mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 59-2, 5.7g(수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2, except that Intermediate 55-1 (5.0 g, 0.012 mol) and Intermediate 59-1 (3.9 g, 0.012 mol) were added and the intermediate 59-2 and 5.7 g (71% ≪ / RTI >

LC/MS: m/z=665[(M+1)+] LC / MS: m / z = 665 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 53-3: 화합물 59 합성 53-3: Compound 59 Synthesis

Figure pat00185
Figure pat00185

중간체 59-2(5.0g, 0.008mol), 4-bromobiphenyl(1.9g, 0.011mol/sigma aldrich)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 59, 4.6g(수율 72%)을 얻었다.The compound 59 (4.6 g, Yield: 72%) was synthesized in the same manner as in Production Example 41-2, except that Intermediate 59-2 (5.0 g, 0.008 mol) and 4-bromobiphenyl (1.9 g, 0.011 mol / ≪ / RTI >

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.94/d, 7.93/d, 7.87/d, 7.60/s, 7.55/d, 7.50/d, 7.45/m, 7.41/m, 7.38/m, 7.33/m, 7.25/m, 6.75/d, 6.58/d) 2H(8.12/d, 7.88/d, 7.82/m, 7.79/d, 7.68/d, 7.62/d, 7.58/m, 7.54/d, 7.52/d, 7.51/m, 7.50/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.94 / d, 7.93 / d, 7.87 / d, 7.60 / s, 7.55 / d, 7.50 / d, 7.45 / m, 7.41 / m, 7.38 / m D, 7.88 / d, 7.82 / d, 7.62 / d, 7.62 / d, 7.58 / m, 7.54 / d , 7.52 / d, 7.51 / m, 7.50 / d, 6.69 / d, 1.72 / s)

LC/MS: m/z= 805[(M+1)+] LC / MS: m / z = 805 [(M + 1) < + &

실시예Example 54: 화합물 60 합성 54: Compound 60 Synthesis

(1) (One) 제조예Manufacturing example 54-1: 중간체 60-1 합성 54-1: Synthesis of intermediate 60-1

Figure pat00186
Figure pat00186

2-(4-chlorophenyl)-9,9-dimethyl-9H-fluorene(5.0g, 0.016mol/2day biochem), 4-(9,9-dimethyl-9H-fluoren-2-yl)aniline(4.6g, 0.016mol/2day biochem)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 60-1, 5.6g(수율 63%)을 얻었다.9,9-dimethyl-9H-fluorene (5.0g, 0.016mol / 2day biochem), 4- (9,9-dimethyl-9H- fluoren- 2- yl) aniline (4.6g, 0.016 mol / 2day biochem) was added thereto to obtain Intermediate 60-1, 5.6 g (yield: 63%) by the same method as in Production Example 41-2.

LC/MS: m/z= 553[(M+1)+] LC / MS: m / z = 553 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 54-2: 화합물 60 합성 54-2: Compound 60 Synthesis

Figure pat00187
Figure pat00187

중간체 55-1(5.0g, 0.012mol), 중간체 60-1(6.6g, 0.012mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 60, 7.5g(수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2, except that Intermediate 55-1 (5.0 g, 0.012 mol) and Intermediate 60-1 (6.6 g, 0.012 mol) were added to obtain Compound 60 (7.5 g, yield 70% .

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/d, 7.45/m) 2H(8.12/d, 7.93/d, 7.88/d, 7.87/d, 7.82/m, 7.77/s, 7.63/d, 7.58/m, 7.55/d, 7.50/d, 7.38/m, 7.28/m) 4H(1.72/s) 6H(7.54/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / d, 7.45 / m) 2H (8.12 / d, 7.93 / d, 7.88 / d, 7.87 / d, 7.82 / m, 7.77 / s, 7.63 7.58 / d, 7.50 / d, 7.38 / 7.28 / m) 4H (1.72 / s) 6H (7.54 / d, 6.69 / d)

LC/MS: m/z= 896[(M+1)+] LC / MS: m / z = 896 [(M + 1) < + &

실시예Example 55: 화합물 51 합성 55: Compound 51 Synthesis

(1) (One) 제조예Manufacturing example 55-1: 중간체 51-1 합성 55-1: Synthesis of Intermediate 51-1

Figure pat00188
Figure pat00188

중간체 55-1(5.0g, 0.012mol), 3,6-dibromo-9H-carbazole(3.9g, 0.012mol/sigma aldrich)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 51-1, 5.4g(수율 68%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2, except that Intermediate 55-1 (5.0 g, 0.012 mol) and 3,6-dibromo-9H-carbazole (3.9 g, 0.012 mol / , 5.4 g (yield: 68%).

LC/MS: m/z= 666[(M+1)+] LC / MS: m / z = 666 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 55-2: 화합물 51 합성 55-2: Compound 51 Synthesis

Figure pat00189
Figure pat00189

중간체 55-1(5.0g, 0.008mol), 9H-carbazole(2.6g, 0.016mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 51, 5.0g(수율 75%)을 얻었다.The compound 51 (5.0 g, 0.008 mol) and 9H-carbazole (2.6 g, 0.016 mol) were added to the reaction mixture to obtain the compound 51 (5.0 g, yield 75%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/s, 7.63/d, 7.62/d, 7.45/m, 7.31/d) 2H(8.55/d, 7.88/d, 7.82/m, 7.79/d, 7.68/d, 7.63/d, 7.58/m, 7.50/s, 7.50/d, 7.50/m, 7.33/m, 7.29/m, 7.25/m) 3H(7.94/d) 4H(8.12/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / s, 7.63 / d, 7.62 / d, 7.45 / m, 7.31 / d) 2H (8.55 / d, 7.88 / d, 7.82 / m, 7.79 7.50 / d, 7.50 / d, 7.50 / m, 7.33 / m, 7.29 / m, 7.25 / )

LC/MS: m/z=839 [(M+1)+] LC / MS: m / z = 839 [(M + 1) < + &

실시예Example 56: 화합물 52 합성 56: Compound 52 Synthesis

(1) (One) 제조예Manufacturing example 56-1: 중간체 52-1 합성 56-1: Synthesis of Intermediate 52-1

Figure pat00190
Figure pat00190

중간체 55-1(5.0g, 0.012mol), 3-bromo-9H-carbazole(3.0g, 0.011mol/sigma aldrich)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 52-1, 5.4g(수율 76%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2 except that Intermediate 55-1 (5.0 g, 0.012 mol) and 3-bromo-9H-carbazole (3.0 g, 0.011 mol / g (yield: 76%).

LC/MS: m/z=587 [(M+1)+] LC / MS: m / z = 587 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 56-2: 화합물 52 합성 56-2: Compound 52 Synthesis

Figure pat00191
Figure pat00191

중간체 52-1(5.0g, 0.009mol), 2-phenyl-1H-benzo[d]imidazole(1.7g, 0.009mol/sigma aldrich)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 52, 4.7g(수율 75%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2, except that Intermediate 52-1 (5.0 g, 0.009 mol) and 2-phenyl-1H-benzo [d] imidazole (1.7 g, 0.009 mol / , 4.7 g (75% yield).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 8.55/d, 7.94/d, 7.93/d, 7.63/d, 7.59/d, 7.50/s, 7.45/m, 7.41/m, 7.33/m, 7.31/d, 7.25/m) 2H(8.28/d, 8.12/d, 7.88/d, 7.82/m, 7.79/d, 7.68/d, 7.58/m, 7.51/m, 7.50/d, 7.22/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 8.55 / d, 7.94 / d, 7.93 / d, 7.63 / d, 7.59 / d, 7.50 / s, 7.45 / m, 7.41 / m M, 7.31 / d, 7.25 / m) 2H (8.28 d, 8.12 d, 7.88 d, 7.82 m, 7.79 d, 7.68 d, 7.58 m, 7.51 m, , 7.22 / m)

LC/MS: m/z= 701[(M+1)+] LC / MS: m / z = 701 [(M + 1) < + &

실시예Example 57: 화합물 54 합성 57: Compound 54 Synthesis

(1) (One) 제조예Manufacturing example 57-1: 중간체 54-1 합성 57-1: Synthesis of Intermediate 54-1

Figure pat00192
Figure pat00192

9H-carbazol-3-ylboronic acid(5.0g, 0.024mol/TCI), 2-chloro-4,6-diphenyl-1,3,5-triazine(6.4g, 0.017mol /TCI)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 54-1, 7.3g(수율 70%)을 얻었다.3-ylboronic acid (5.0 g, 0.024 mol / TCI) and 2-chloro-4,6-diphenyl-1,3,5-triazine (6.4 g, 0.017 mol / 2, 7.3 g (yield 70%) of Intermediate 54-1 was obtained.

LC/MS: m/z= 442[(M+1)+] LC / MS: m / z = 442 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 57-2: 화합물 54 합성 57-2: Compound 54 Synthesis

Figure pat00193
Figure pat00193

중간체 49-2(5.0g, 0.014mol), 중간체 54-1(7.5g, 0.017mol)을 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 54, 6.2g(수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 49-2 (5.0 g, 0.014 mol) and Intermediate 54-1 (7.5 g, 0.017 mol) added thereto to obtain 6.25 g (74% .

H-NMR (200MHz, CDCl3):δ ppm,1H(8.55/d, 7.94/d, 7.93/s, 7.87/d, 7.77/s, 7.69/d, 7.45/m, 7.33/m, 7.25/m) 2H(8.12/d, 7.88/d, 7.82/m, 7.58/m, 7.50/d, 7.41/m) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.93 / s, 7.87 / d, 7.77 / s, 7.69 / d, 7.45 / m, 7.33 / m, 7.25 / m 7.58 / d, 7.88 / d, 7.8 / m, 7.58 /

LC/MS: m/z=664 [(M+1)+] LC / MS: m / z = 664 [(M + 1) < + &

실시예Example 58: 화합물 55 합성 58: Compound 55 Synthesis

(1) (One) 제조예Manufacturing example 58-1: 중간체 55-1 합성 58-1: Intermediate 55-1 Synthesis

Figure pat00194
Figure pat00194

중간체 49-2(5.0g, 0.014mol), 3,5-dibromophenylboronic acid(4.8g, 0.017mol /sigma aldrich)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 55-1, 5.4g(수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, except that Intermediate 49-2 (5.0 g, 0.014 mol) and 3,5-dibromophenylboronic acid (4.8 g, 0.017 mol / sigma aldrich) (Yield: 74%).

LC/MS: m/z=521 [(M+1)+] LC / MS: m / z = 521 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 58-2: 화합물 55 합성 58-2: Compound 55 Synthesis

Figure pat00195
Figure pat00195

중간체 55-1(5.0g, 0.010mol), 2-phenyl-1H-benzo[d]imidazole(1.8g, 0.010mol)를 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 55, 5.3g(수율 73%)을 얻었다.Compound 55 (5.3 g, 0.010 mol) was synthesized by the same method as in Production Example 41-2, except that Intermediate 55-1 (5.0 g, 0.010 mol) and 2-phenyl-1H-benzo [d] imidazole (Yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/d, 7.45/m, 7.2/s) 2H(8.56/d, 8.12/d, 8.09/d, 7.88/d, 7.82/m, 7.59/d, 7.58/m, 7.50/d, 7.41/m) 4H(8.28/d, 7.51/m, 7.22/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / d, 7.45 / m, 7.2 / s) 2H (8.56 / d, 8.12 / d, 8.09 / d, 7.88 / d, 7.82 / m, 7.59 7.58 / d, 7.41 / m) 4H (8.28 / d, 7.51 / m, 7.22 /

LC/MS: m/z=728[(M+1)+] LC / MS: m / z = 728 [(M + 1) < + &

실시예Example 59: 화합물 56 합성 59: Compound 56 Synthesis

(1) (One) 제조예Manufacturing example 59-1: 중간체 56-1 합성 59-1: Intermediate 56-1 Synthesis

Figure pat00196
Figure pat00196

중간체 55-1(5.0g, 0.012mol), 5-bromo-2-phenyl-1H-benzo[d]imidazole(3.3g, 0.012mol/ark pharm)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 56-1, 5.2g(수율 70%)을 얻었다.(3.3 g, 0.012 mol / ark pharm) was added to a solution of the intermediate 55-1 (5.0 g, 0.012 mol) and 5-bromo-2-phenyl-1H- To obtain 5.2 g (yield 70%) of Intermediate 56-1.

LC/MS: m/z=614[(M+1)+]LC / MS: m / z = 614 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 59-2: 화합물 56 합성 59-2: Compound 56 Synthesis

Figure pat00197
Figure pat00197

중간체 56-1(5.0g, 0.008mol), 2-phenyl-1H-benzo[d]imidazole(1.5g, 0.010mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 56, 4.0g(수율 69%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2 except that Intermediate 56-1 (5.0 g, 0.008 mol) and 2-phenyl-1H-benzo [d] imidazole (1.5 g, 0.010 mol) (Yield 69%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.56/d, 7.93/s, 7.70/s, 7.45/m, 7.15/d) 2H(8.12/d, 7.88/d, 7.82/m, 7.79/d, 7.68/d, 7.59/d, 7.58/m, 7.50/d, 7.41/m, 7.22/m) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.56 / d, 7.93 / s, 7.70 / s, 7.45 / m, 7.15 / d) 2H (8.12 / d, 7.88 / d, 7.82 / m, 7.79 7.58 / d, 7.58 / d, 7.50 / d, 7.41 / m, 7.22 /

LC/MS: m/z= 728[(M+1)+] LC / MS: m / z = 728 [(M + 1) < + &

실시예Example 60: 화합물 53 합성 60: Compound 53 Synthesis

(1) (One) 제조예Manufacturing example 60-1: 중간체 53- 60-1: Intermediate 53- 1합성1 synthesis

Figure pat00198
Figure pat00198

중간체 49-1(5.0g, 0.019mol), 4-bromodibenzo[b,d]thiophene(5.0g, 0.019mol) 을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 중간체 53-1, 6.1g(수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-2 except that Intermediate 49-1 (5.0 g, 0.019 mol) and 4-bromodibenzo [b, d] thiophene (5.0 g, 0.019 mol) (Yield: 71%).

LC/MS: m/z= 452[(M+1)+] LC / MS: m / z = 452 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 60-2: 화합물 53 합성 60-2: Compound 53 Synthesis

Figure pat00199
Figure pat00199

중간체 53-1(5.0g, 0.011mol), triphenylen-2-ylboronic acid(3.6g, 0.013mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 53, 4.9g(수율 74%)을 얻었다.(Yield: 74%) was obtained by the same method as in Production Example 41-3, with the intermediate 53-1 (5.0 g, 0.011 mol) and triphenylen-2-ylboronic acid (3.6 g, ≪ / RTI >

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.98/d, 7.93/s, 7.50/m, 7.3/d) 2H(8.93/d, 8.45/d, 7.52/m) 4H(8.12/d, 7.88/d, 7.82/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.98 / d, 7.93 / s, 7.50 / m, 7.3 / d) 2H (8.93 / d, 8.45 / d, 7.52 / m) 4H (8.12 / d, 7.88 / d, 7.82 / m)

LC/MS: m/z= 600[(M+1)+] LC / MS: m / z = 600 [(M + 1) < + &

실시예Example 61: 화합물 61 합성 61: Compound 61 Synthesis

(1) (One) 제조예Manufacturing example 61-1: 중간체 61-1 합성 61-1: Synthesis of intermediate 61-1

Figure pat00200
Figure pat00200

phenanthro[4,5-bcd]furan(5.0g, 0.026 mol / TCI), bromine(18.3g, 0.11mol)에 tetrachloride 800ml넣고 1시간 동안 상온에서 교반시켰다. 반응물을 재결정을 통해서 중간체 61-1, 7.4g (수율 81%)을 얻었다.800 ml of tetrachloride was added to phenanthro [4,5-bcd] furan (5.0 g, 0.026 mol / TCI) and bromine (18.3 g, 0.11 mol) and stirred at room temperature for 1 hour. The reaction product was recrystallized to obtain Intermediate 61-1 (7.4 g, yield: 81%).

LC/MS: m/z= 350[(M+1)+] LC / MS: m / z = 350 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 61-2: 화합물 61 합성 61-2: Compound 61 Synthesis

Figure pat00201
Figure pat00201

중간체 61-1(5.0g, 0.011mol), phenyl boronic acid(7.1g, 0.026mol /ark pharm)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 61, 2.7g(수율 70%)을 얻었다.The compound 61 (2.7 g, yield 70%) was synthesized by the same method as in Production Example 41-3, with the intermediate 61-1 (5.0 g, 0.011 mol) and phenyl boronic acid (7.1 g, 0.026 mol / ≪ / RTI >

H-NMR (200MHz, CDCl3):δ ppm, 2H(8.34/s, 8.10/s, 7.71/m, 7.41/m) 4H(7.52/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.34 / s, 8.10 / s, 7.71 / m, 7.41 / m) 4H (7.52 / d, 7.51 / m)

LC/MS: m/z= 345[(M+1)+] LC / MS: m / z = 345 [(M + 1) < + &

실시예Example 62: 화합물 62 합성 62: Compound 62 Synthesis

Figure pat00202
Figure pat00202

중간체 61-1(5.0g, 0.011mol), 중간체 44-1(7.4g, 0.026mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 62, 5.3g(수율 74%)을 얻었다.Synthesis was conducted according to the same method as in Production Example 41-3, from Intermediate 61-1 (5.0 g, 0.011 mol) and Intermediate 44-1 (7.4 g, 0.026 mol) to obtain 62 (5.3 g, 74% .

H-NMR (200MHz, CDCl3):δ ppm, 2H(8.34/s, 8.10/s, 7.71/d) 4H(7.41/m) 8H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.34 / s, 8.10 / s, 7.71 / d) 4H (7.41 / m) 8H (8.28 / d, 7.51 / m)

LC/MS: m/z=655[(M+1)+] LC / MS: m / z = 655 [(M + 1) < + &

실시예Example 63: 화합물 63 합성 63: Compound 63 Synthesis

(1) (One) 제조예Manufacturing example 63-1: 중간체 63-1 합성 63-1: Synthesis of intermediate 63-1

Figure pat00203
Figure pat00203

phenanthro[4,5-bcd]furan(5.0g, 0.026mol), bromine(36.6g, 0.22mol)에 tetrachloride 1100ml넣고 1시간 동안 상온에서 교반시켰다. 반응물을 재결정을 통해서 중간체 63-1 10.9g (수율 83%)을 얻었다.phenanthro [4,5-bcd] furan (5.0 g, 0.026 mol) and bromine (36.6 g, 0.22 mol) were added 1100 ml of tetrachloride and stirred at room temperature for 1 hour. The reaction product was recrystallized to obtain 10.9 g (83% yield) of Intermediate 63-1.

LC/MS: m/z=507[(M+1)+] LC / MS: m / z = 507 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 63-2: 화합물 63 합성 63-2: Compound 63 Synthesis

Figure pat00204
Figure pat00204

중간체 63-1(5.0g, 0.011mol), triphenylen-2-ylboronic acid(14.2g, 0.052mol /ark pharm)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 63, 5.0g(수율 75%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 63-1 (5.0 g, 0.011 mol) and triphenylen-2-ylboronic acid (14.2 g, 0.052 mol / 75%).

H-NMR (200MHz, CDCl3):δ ppm, 2H(8.26/s, 7.71/d) 4H(8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.58/m, 7.52/m, 7.50/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.26 / s, 7.71 / d) 4H (8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.58 / m, 7.52 / m, 7.50 / m)

LC/MS: m/z=601[(M+1)+] LC / MS: m / z = 601 [(M + 1) < + &

실시예Example 64: 화합물 64 합성 64: Compound 64 Synthesis

(1) (One) 제조예Manufacturing example 64-1: 중간체 64-1 합성 64-1: Synthesis of intermediate 64-1

Figure pat00205
Figure pat00205

중간체 61-1(5.0g, 0.011mol), dibenzo[b,d]thiophen-4-ylboronic acid(3.0g, 0.013mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 64-1, 3.7g(수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 61-1 (5.0 g, 0.011 mol) and dibenzo [b, d] thiophen-4-ylboronic acid (3.0 g, 0.013 mol) , 3.7 g (yield: 74%).

LC/MS: m/z=454[(M+1)+] LC / MS: m / z = 454 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 64-2: 화합물 64 합성 64-2: Compound 64 Synthesis

Figure pat00206
Figure pat00206

중간체 64-1(5.0g, 0.011mol), triphenylen-2-ylboronic acid(3.6g, 0.013mol /ark pharm)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 화합물 64, 13.7g(수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Production Example 41-3, with the intermediate 64-1 (5.0 g, 0.011 mol) and triphenylen-2-ylboronic acid (3.6 g, 0.013 mol / 74%).

H-NMR (200MHz, CDCl3):δ ppm, 2H(8.26/s, 7.71/d) 4H(8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.58/m, 7.52/m, 7.50/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 2H (8.26 / s, 7.71 / d) 4H (8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.58 / m, 7.52 / m, 7.50 / m)

LC/MS: m/z=922[(M+1)+] LC / MS: m / z = 922 [(M + 1) < + &

실시예Example 65: 화합물 68 합성 65: Compound 68 Synthesis

(1) (One) 제조예Manufacturing example 65-1: 중간체 68-1 합성 65-1: Synthesis of Intermediate 68-1

Figure pat00207
Figure pat00207

phenanthro[4,5-bcd]furan(5.0g, 0.026mol), bromine(9.2g, 0.06mol)에 tetrachloride 400ml넣고 1시간 동안 상온에서 교반시킨다. 반응물을 재결정을 통해서 중간체 68-1, 5.4g (수율 77%)을 얻었다.phenanthro [4,5-bcd] furan (5.0 g, 0.026 mol) and bromine (9.2 g, 0.06 mol) were added 400 ml of tetrachloride and stirred at room temperature for 1 hour. The reaction product was recrystallized to obtain 5.4 g (yield: 77%) of Intermediate 68-1.

LC/MS: m/z=271[(M+1)+] LC / MS: m / z = 271 [(M + 1) < + &

(2) (2) 제조예Manufacturing example 65-2: 중간체 68-2 합성 65-2: Intermediate 68-2 Synthesis

Figure pat00208
Figure pat00208

중간체 68-1(5.0g, 0.018mol), 4-bromophenylboronic acid(3.5g, 0.021mol)를 넣고 제조예 41-3에서 사용된 동일한 방법으로 합성하여 중간체 68-2, 4.6g(수율 74%)을 얻었다.(Yield: 74%) was obtained by the same method as in Production Example 41-3, except that Intermediate 68-1 (5.0 g, 0.018 mol) and 4-bromophenylboronic acid (3.5 g, ≪ / RTI >

LC/MS: m/z=347[(M+1)+] LC / MS: m / z = 347 [(M + 1) < + &

(3) (3) 제조예Manufacturing example 65-3: 화합물 68 합성 65-3: Compound 68 Synthesis

Figure pat00209
Figure pat00209

중간체 68-2(5.0g, 0.014mol), N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(5.1g, 0.014mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 68, 5.0g(수율 68%)을 얻었다.4-yl) -9,9-dimethyl-9H-fluoren-2-amine (5.1 g, 0.014 mol) was added to a solution of Intermediate 68-2 (5.0 g, 0.014 mol) Synthesis was carried out in the same manner as used to obtain 68, 5.0 g (yield 68%) of compound 68.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/s, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.28/m, 6.75/s, 6.58/d) 2H(8.12/d, 7.88/d, 7.82/m, 7.52/d, 7.51/m, 1.72/s) 4H(7.54/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / s, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.28 / m, 6.75 / s, 6.58 / d ) 2H (8.12 / d, 7.88 / d, 7.82 / m, 7.52 / d, 7.51 /

LC/MS: m/z ; 628[(M+1)+] LC / MS: m / z; 628 < RTI ID = 0.0 > [(M + 1) + ]

실시예Example 66: 화합물 69 합성 66: Compound 69 Synthesis

Figure pat00210
Figure pat00210

중간체 68-2(5.0g, 0.014mol), bis(9,9-dimethyl-7-phenyl-9H-fluoren-2-yl)amine(7.8g, 0.014mol)을 넣고 제조예 41-2에서 사용된 동일한 방법으로 합성하여 화합물 69, 7.7g(수율 67%)을 얻었다.(5.0 g, 0.014 mol) and bis (9,9-dimethyl-7-phenyl-9H-fluoren-2-yl) amine (7.8 g, 0.014 mol) Synthesis was conducted in the same manner as above to obtain Compound 69 (7.7 g, yield 67%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.93/s) 2H(8.12/d, 7.93/d, 7.88/d, 7.82/m, 7.77/s, 7.63/d, 7.62/d, 7.54/d, 7.41/m, 6.75/s, 6.69/d, 6.58/d) 4H(7.52/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.93 / s) 2H (8.12 / d, 7.93 / d, 7.88 / d, 7.82 / m, 7.77 / s, 7.63 / d, 7.62 / d, 7.54 (7.52 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=821[(M+1)+]
LC / MS: m / z = 821 [(M + 1) < + &

본 발명의 실시예에서 쓰이는 약어는 아래와 같다.Abbreviations used in the embodiment of the present invention are as follows.

NPB: N,N'-Bis(naphthalen-1-yl)-N,N'-bis(phenyl)benzidineNPB: N, N'-bis (naphthalen-1-yl) -N,

Ir(ppy)3: Iridium, tris(2-phenylpyidine)Ir (ppy) 3 : Iridium, tris (2-phenylpyidine)

Balq: Bis(2-methyl-8-quinolinolato-N1,O8)-(1,1'-Biphenyl-4-olato)aluminumBalq: Bis (2-methyl-8-quinolinolato-N1, O8) - (1,1'-Biphenyl-4-olato) aluminum

Alq3: tris(8-quinolinolato)-aluminium(III)Alq 3 : tris (8-quinolinolato) -aluminium (III)

CBP: (4,4-N,N-dicarbazole)biphenyl
CBP: (4,4-N, N-dicarbazole) biphenyl

소자실시예Device Example 1: 화합물 1을  1: Compound 1 발광층의The light- 호스트 재료로 하여  As a host material 유기전계발광소자Organic electroluminescent device 제조 Produce

ITO로 코팅된 유리기판 위에 NPB를 증착하여 120nm의 정공수송층을 형성하였으며, 이어서 Ir(ppy)3을 도펀트로 하여 화합물 1의 증착속도를 0.1nm/sec, Ir(ppy)3 증착속도를 0.009nm/sec로 증착하고, 증착속도 비율이 9%가 되도록 Ir(ppy)3을 도핑하여 정공수송층 상에 발광층을 30nm 두께로 형성하였다.Depositing NPB on the glass substrate coated with ITO to form a hole transport layer was of 120nm, followed by Ir (ppy) the deposition rate of the compounds 1 to 3 as the dopant 0.1nm / sec, Ir (ppy) 3 deposition rate 0.009nm / sec, and Ir (ppy) 3 was doped so that the deposition rate ratio was 9% to form a light emitting layer with a thickness of 30 nm on the hole transport layer.

그 위에 Balq를 10nm 두께로 증착하여 정공이 발광층을 지나 전자수송층으로 이동하는 것을 방지하는 정공차단층을 형성하고, 그 위에 Alq3를 증착하여 40nm의 전자수송층을 형성하였으며, 그 위에 불화리튬을 증착하여 1nm의 전자주입층을 형성하였다. 전자주입층 상에 알루미늄을 증착하여 120nm의 음극을 형성하여 유기전계발광소자를 제조하였다.Balq was deposited thereon to a thickness of 10 nm to form a hole blocking layer for preventing holes from moving to the electron transporting layer through the light emitting layer, and Alq3 was deposited thereon to form an electron transporting layer of 40 nm, and lithium fluoride was deposited thereon Thereby forming an electron injection layer having a thickness of 1 nm. Aluminum was deposited on the electron injecting layer to form a 120 nm cathode, thereby fabricating an organic electroluminescent device.

이때, 각 물질의 증착속도는 유기물질인, 화합물 1, NPB, Alq3, Balq는 0.1 nm/sec, 불화리튬은 0.01 nm/sec, 알루미늄은 0.5 nm/sec로 하였다.At this time, the deposition rate of each material was set to 0.1 nm / sec for compound 1, NPB, Alq 3 , Balq, 0.01 nm / sec for lithium fluoride, and 0.5 nm / sec for aluminum.

소자실시예Device Example 2 내지 66 2 to 66

화합물 2 대신에 하기 표 1에 기재된 발광재료를 사용한 것을 제외하고는 소자실시예 1과 동일한 방법으로 소자실시예 2 내지 66의 유기전계발광소자를 제조하였다.Organic electroluminescent devices of Device Examples 2 to 66 were fabricated in the same manner as in the device example 1, except that the luminescent material described in the following Table 1 was used in place of the compound 2.

소자비교예Device comparison example 1 One

상기 화합물 2 대신 (4,4-N,N-dicarbazole)biphenyl(CBP)를 발광재료로 사용한 것을 제외하고는 소자실시예 1과 동일한 방법으로 소자비교예 1의 유기전계발광소자를 제조하였다.An organic electroluminescent device of Comparative Example 1 was manufactured in the same manner as in Example 1 except that (4,4-N, N-dicarbazole) biphenyl (CBP)

이하, 상기 소자실시예 1 내지 66과 소자비교예 1에 따라 제조된 유기전계발광소자의 특성을 비교한 결과를 하기 표 1에 나타내었다.Table 1 shows the results of comparing the characteristics of the organic electroluminescent devices manufactured according to the device embodiments 1 to 66 and the device comparison example 1.

구분division 발광재료Emitting material 구동전압(V)
(at 1000cd/m2)
The driving voltage (V)
(at 1000 cd / m 2 )
발광효율
(cd/A)
Luminous efficiency
(cd / A)
색좌표
CIE_(x,y)
Color coordinates
CIE_ (x, y)
소자실시예 1Device Embodiment 1 화합물 1Compound 1 4.54.5 2828 0.31, 0.620.31, 0.62 소자실시예 2Device Example 2 화합물 2Compound 2 5.55.5 2222 0.30, 0.600.30, 0.60 소자실시예 3Device Embodiment 3 화합물 3Compound 3 5.05.0 2424 0.32, 0.650.32, 0.65 소자실시예 4Device Example 4 화합물 4Compound 4 5.15.1 2424 0.33, 0.600.33, 0.60 소자실시예 5Element Embodiment 5 화합물 5Compound 5 5.35.3 2424 0.33, 0.610.33, 0.61 소자실시예 6Device Example 6 화합물 6Compound 6 5.65.6 2121 0.32, 0.630.32, 0.63 소자실시예 7Device Example 7 화합물 7Compound 7 5.15.1 2323 0.33, 0.620.33, 0.62 소자실시예 8Device Example 8 화합물 8Compound 8 5.55.5 2222 0.30, 0.640.30, 0.64 소자실시예 9Device Example 9 화합물 9Compound 9 5.65.6 2121 0.30, 0.660.30, 0.66 소자실시예 10Element Embodiment 10 화합물 10Compound 10 5.15.1 2424 0.33, 0.630.33, 0.63 소자실시예 11Element Embodiment 11 화합물 11Compound 11 5.05.0 2424 0.32, 0.620.32, 0.62 소자실시예 12Device Example 12 화합물 12Compound 12 4.94.9 2424 0.31, 0.630.31, 0.63 소자실시예 13Device Embodiment 13 화합물 13Compound 13 4.54.5 2828 0.32, 0.620.32, 0.62 소자실시예 14Device Embodiment 14 화합물 14Compound 14 4.34.3 2929 0.32, 0.650.32, 0.65 소자실시예 15Device Example 15 화합물 15Compound 15 4.54.5 2929 0.33, 0.600.33, 0.60 소자실시예 16Device Embodiment 16 화합물 16Compound 16 4.84.8 2525 0.33, 0.610.33, 0.61 소자실시예 17Device Example 17 화합물 17Compound 17 5.05.0 2424 0.32, 0.630.32, 0.63 소자실시예 18Element Embodiment 18 화합물 18Compound 18 5.05.0 2424 0.33, 0.630.33, 0.63 소자실시예 19Element Embodiment 19 화합물 19Compound 19 5.15.1 2424 0.32, 0.630.32, 0.63 소자실시예 20Device Embodiment 20 화합물 20Compound 20 5.65.6 2222 0.33, 0.620.33, 0.62 소자실시예 21Device Example 21 화합물 21Compound 21 4.14.1 4040 0.30, 0.640.30, 0.64 소자실시예 22Device Embodiment 22 화합물 22Compound 22 4.14.1 3131 0.30, 0.660.30, 0.66 소자실시예 23Device Example 23 화합물 23Compound 23 4.24.2 3030 0.33, 0.630.33, 0.63 소자실시예 24Device Embodiment 24 화합물 24Compound 24 4.04.0 3030 0.32, 0.620.32, 0.62 소자실시예 25Device Example 25 화합물 25Compound 25 4.84.8 2424 0.30, 0.640.30, 0.64 소자실시예 26Device Embodiment 26 화합물 26Compound 26 4.24.2 3030 0.30, 0.660.30, 0.66 소자실시예 27Device Example 27 화합물 27Compound 27 4.14.1 4949 0.33, 0.620.33, 0.62 소자실시예 28Device Example 28 화합물 28Compound 28 4.04.0 3030 0.30, 0.640.30, 0.64 소자실시예 29Element Embodiment 29 화합물 29Compound 29 3.83.8 2828 0.30, 0.660.30, 0.66 소자실시예 30 Device Example 30 화합물 30Compound 30 4.84.8 2525 0.30, 0.660.30, 0.66 소자실시예 31Element Embodiment 31 화합물 31Compound 31 4.34.3 2929 0.33, 0.630.33, 0.63 소자실시예 32Device Example 32 화합물 32Compound 32 4.54.5 3030 0.33, 0.620.33, 0.62 소자실시예 33Device Example 33 화합물 33Compound 33 4.84.8 2525 0.33, 0.620.33, 0.62 소자실시예 34Device Example 34 화합물 34Compound 34 4.84.8 2525 0.30, 0.640.30, 0.64 소자실시예 35Device Example 35 화합물 35Compound 35 4.34.3 2929 0.30, 0.660.30, 0.66 소자실시예 36Device Example 36 화합물 36Compound 36 4.84.8 2626 0.30, 0.640.30, 0.64 소자실시예 37Device Example 37 화합물 37Compound 37 4.24.2 3939 0.30, 0.640.30, 0.64 소자실시예 38Device Example 38 화합물 38Compound 38 4.94.9 2424 0.30, 0.660.30, 0.66 소자실시예 39Device Example 39 화합물 39Compound 39 5.15.1 2424 0.33, 0.620.33, 0.62 소자실시예 40Device Example 40 화합물 40Compound 40 5.25.2 2323 0.30, 0.640.30, 0.64 소자실시예 41Device Example 41 화합물 41Compound 41 5.35.3 3131 0.33, 0.640.33, 0.64 소자실시예 42Device Example 42 화합물 42Compound 42 4.64.6 4343 0.30, 0.630.30, 0.63 소자실시예 43Device Embodiment 43 화합물 43Compound 43 5.25.2 3232 0.31, 0.620.31, 0.62 소자실시예 44Element Embodiment 44 화합물 44Compound 44 4.54.5 4040 0.32, 0.620.32, 0.62 소자실시예 45Device Example 45 화합물 45Compound 45 5.15.1 3131 0.34, 0.630.34, 0.63 소자실시예 46 Device Embodiment 46 화합물 46Compound 46 5.15.1 3030 0.33, 0.630.33, 0.63 소자실시예 47Device Embodiment 47 화합물 47Compound 47 5.45.4 2828 0.31, 0.640.31, 0.64 소자실시예 48Device Example 48 화합물 48Compound 48 5.75.7 2929 0.30, 0.630.30, 0.63 소자실시예 49Device Example 49 화합물 49Compound 49 4.64.6 4545 0.32, 0.610.32, 0.61 소자실시예 50Device Example 50 화합물 50Compound 50 5.55.5 3131 0.33, 0.610.33, 0.61 소자실시예 51Device Embodiment 51 화합물 57Compound 57 5.15.1 3131 0.33, 0.640.33, 0.64 소자실시예 52Device Example 52 화합물 58Compound 58 5.55.5 3131 0.32, 0.640.32, 0.64 소자실시예 53Element Embodiment 53 화합물 59Compound 59 5.25.2 3232 0.31, 0.630.31, 0.63 소자실시예 54Device Example 54 화합물 60Compound 60 5.15.1 3232 0.33, 0.630.33, 0.63 소자실시예 55Device Example 55 화합물 51Compound 51 5.35.3 3333 0.33, 0.620.33, 0.62 소자실시예 56Device Example 56 화합물 52Compound 52 5.55.5 2929 0.31, 0.620.31, 0.62 소자실시예 57Device Example 57 화합물 54Compound 54 5.45.4 2828 0.31, 0.620.31, 0.62 소자실시예 58 Element Embodiment 58 화합물 55Compound 55 5.55.5 2929 0.34, 0.630.34, 0.63 소자실시예 59Device Example 59 화합물 56Compound 56 5.55.5 3131 0.31, 0.630.31, 0.63 소자실시예 60Device Example 60 화합물 53Compound 53 5.65.6 3333 0.33, 0.610.33, 0.61 소자실시예 61Element Embodiment 61 화합물 61Compound 61 6.06.0 2727 0.33, 0.630.33, 0.63 소자실시예 62Device Embodiment 62 화합물 62Compound 62 6.16.1 2626 0.31, 0.640.31, 0.64 소자실시예 63Device Example 63 화합물 63Compound 63 5.95.9 2828 0.32, 0.620.32, 0.62 소자실시예 64Device Example 64 화합물 64Compound 64 5.65.6 2929 0.32, 0.630.32, 0.63 소자실시예 65Device Example 65 화합물 68Compound 68 5.75.7 2626 0.31, 0.610.31, 0.61 소자실시예 66Element Embodiment 66 화합물 69Compound 69 5.95.9 2626 0.32, 0.620.32, 0.62 소자비교예 1Device Comparative Example 1 CBPCBP 6.56.5 1919 0.30, 0.630.30, 0.63

구동전압 및 발광효율 측정Measurement of driving voltage and luminous efficiency

위에서 만든 유기발광소자(기판크기: 25*25mm2/증착면적: 2*2mm2)를 IVL 측정셋트(CS-2000+지그+IVL프로그램)에 고정 한 후 전류를 1mA/m2씩 상승시키며 증착면의 발광 휘도(cd/m2), 구동전압(V), 전류밀도(A/m2), 발광효율(cd/A)을 측정하여 휘도가 1000cd/m2 일 때 구동전압과 발광효율을 상기 표 1에 나타내었다.The organic light emitting element made from above (substrate size: 25 * 25mm 2 / deposition area: 2 * 2mm 2) an IVL measuring set (CS-2000 + fixture + IVL program) by the current deposition raises by 1mA / m 2 and then fixed to the the brightness of light emitted by the surface (cd / m 2), a driving voltage (V), current density (a / m 2), luminous efficiency (cd / a) drive voltage when measured brightness is 1000cd / m 2 days and luminous efficiency Shown in Table 1 above.

표 1에 따르면, 본 발명에 따른 유기전계발광소자용 화합물이 유기전계발광소자의 발광층의 호스트 물질로 사용될 때 종래의 CBP를 발광재료로 사용할 때보다 구동전압은 상당히 떨어지고, 발광효율은 상당히 향상된 것을 알 수 있다.According to Table 1, when the compound for an organic electroluminescence device according to the present invention is used as a host material of a light emitting layer of an organic electroluminescence device, the driving voltage is considerably lower than that of the conventional CBP as a light emitting material and the luminous efficiency is considerably improved Able to know.

Claims (14)

하기 구조식 1로 표시되는 유기전계발광소자용 화합물.
[구조식 1]
Figure pat00211

상기 구조식 1에서,
X1은 산소원자, 황원자,
Figure pat00212
,
Figure pat00213
,
Figure pat00214
, 또는
Figure pat00215
이고,
Ar1은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R7 내지 R11은 서로 같거나 다를 수 있고, R7 내지 R11은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
Y1 및 Y2는 서로 같거나 다를 수 있고, Y1 및 Y2는 각각 독립적으로 질소원자, 또는
Figure pat00216
이고,
R12는 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R1 내지 R6은 서로 같거나 다를 수 있고, R1 내지 R6은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이다.
A compound for an organic electroluminescence device represented by Structural Formula (1) below.
[Structural formula 1]
Figure pat00211

In the above formula 1,
X 1 represents an oxygen atom, a sulfur atom,
Figure pat00212
,
Figure pat00213
,
Figure pat00214
, or
Figure pat00215
ego,
Ar 1 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
R 7 to R 11 may be the same or different from each other, and R 7 to R 11 each independently represent a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
Y 1 And Y 2 may be the same or different from each other, and Y 1 And Y < 2 > are each independently a nitrogen atom, or
Figure pat00216
ego,
R 12 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 1 to R 6 may be the same or different from each other and each of R 1 to R 6 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제1항에 있어서,
상기 유기전계발광소자용 화합물은 하기 구조식 2 내지 4 중 어느 하나로 표시되고,
Figure pat00217

상기 구조식 2 내지 4에서,
Ar1은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
Y1 및 Y2는 서로 같거나 다를 수 있고, Y1 및 Y2는 각각 독립적으로 질소원자, 또는
Figure pat00218
이고,
R12는 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R1 내지 R6은 서로 같거나 다를 수 있고, R1 내지 R6은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
The method according to claim 1,
The organic electroluminescent device compound is represented by any one of the following structural formulas 2 to 4,
Figure pat00217

In the above Structural Formulas 2 to 4,
Ar 1 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
Y 1 And Y 2 may be the same or different from each other, and Y 1 And Y < 2 > are each independently a nitrogen atom, or
Figure pat00218
ego,
R 12 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 1 to R 6 may be the same or different from each other and each of R 1 to R 6 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제2항에 있어서,
R1 내지 R4, 및 R12는 서로 같거나 다를 수 있고, R1 내지 R4, 및 R12는 각각 독립적으로 수소원자,
Figure pat00219
,
Figure pat00220
,
Figure pat00221
,
Figure pat00222
,
Figure pat00223
,
Figure pat00224
,
Figure pat00225
,
Figure pat00226
,
Figure pat00227
,
Figure pat00228
,
Figure pat00229
,
Figure pat00230
,
Figure pat00231
,
Figure pat00232
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,
X2 내지 X9는 서로 같거나 다를 수 있고, X2 내지 X9는 각각 독립적으로 산소원자, 황원자,
Figure pat00233
, 또는
Figure pat00234
이고,
Ar2는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R57 및 R58은 서로 같거나 다를 수 있고, R57 및 R58은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
Y3 내지 Y16은 서로 같거나 다를 수 있고, Y3 내지 Y16은 각각 독립적으로 질소원자, 또는
Figure pat00235
이고,
R59는 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R13 내지 R56은 서로 같거나 다를 수 있고, R13 내지 R56은 각각 독립적으로 수소원자, 실릴기, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
3. The method of claim 2,
R 1 to R 4 , and R 12 may be the same or different from each other, and R 1 to R 4 and R 12 are each independently a hydrogen atom,
Figure pat00219
,
Figure pat00220
,
Figure pat00221
,
Figure pat00222
,
Figure pat00223
,
Figure pat00224
,
Figure pat00225
,
Figure pat00226
,
Figure pat00227
,
Figure pat00228
,
Figure pat00229
,
Figure pat00230
,
Figure pat00231
,
Figure pat00232
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,
X 2 to X 9 may be the same or different from each other, and each of X 2 to X 9 independently represents an oxygen atom, a sulfur atom,
Figure pat00233
, or
Figure pat00234
ego,
Ar 2 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
R 57 and R 58 may be the same or different from each other, and R 57 and R 58 are each independently a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
Y 3 To Y 16 may be the same or different from each other, and Y 3 To Y 16 each independently represents a nitrogen atom, or
Figure pat00235
ego,
R 59 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 13 to R 56 may be the same or different from each other, and each of R 13 to R 56 independently represents a hydrogen atom, a silyl group, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, Or an unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제3항에 있어서,
R13 내지 R56은 서로 같거나 다를 수 있고, R13 내지 R56은 각각 독립적으로 수소원자,
Figure pat00236
,
Figure pat00237
,
Figure pat00238
,
Figure pat00239
,
Figure pat00240
,
Figure pat00241
,
Figure pat00242
,
Figure pat00243
,
Figure pat00244
,
Figure pat00245
,
Figure pat00246
,
Figure pat00247
,
Figure pat00248
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,
Ar3은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
X10 내지 X14는 서로 같거나 다를 수 있고, X10 내지 X14는 각각 독립적으로 산소원자, 황원자,
Figure pat00249
, 또는
Figure pat00250
이고,
Ar4는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R105 및 R106은 서로 같거나 다를 수 있고, R105 및 R106은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
Y17 및 Y18은 서로 같거나 다를 수 있고, Y17 및 Y18은 각각 독립적으로 탄소원자, 또는 규소원자이고,
Y19 내지 Y23은 서로 같거나 다를 수 있고, Y19 내지 Y23은 각각 독립적으로 질소원자, 또는
Figure pat00251
이고,
R107은 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R60 내지 R104는 서로 같거나 다를 수 있고, R60 내지 R104는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
The method of claim 3,
R 13 to R 56 may be the same or different from each other, and R 13 to R 56 each independently represent a hydrogen atom,
Figure pat00236
,
Figure pat00237
,
Figure pat00238
,
Figure pat00239
,
Figure pat00240
,
Figure pat00241
,
Figure pat00242
,
Figure pat00243
,
Figure pat00244
,
Figure pat00245
,
Figure pat00246
,
Figure pat00247
,
Figure pat00248
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,
Ar 3 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
X 10 to X 14 may be the same or different from each other, and X 10 to X 14 each independently represent an oxygen atom, a sulfur atom,
Figure pat00249
, or
Figure pat00250
ego,
Ar 4 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
R 105 and R 106 may be the same or different from each other, and each of R 105 and R 106 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
Y 17 And Y 18 may be the same or different from each other, and Y 17 And Y 18 are each independently a carbon atom or a silicon atom,
Y 19 to Y 23 may be the same or different from each other, Y 19 to Y 23 each independently represent a nitrogen atom, or
Figure pat00251
ego,
R 107 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 60 to R 104 may be the same or different from each other, and each of R 60 to R 104 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제2항에 있어서,
Ar1
Figure pat00252
,
Figure pat00253
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,
X15는 산소원자, 황원자,
Figure pat00254
, 또는
Figure pat00255
이고,
Ar5는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R113 및 R114는 서로 같거나 다를 수 있고, R113 및 R114는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R108 내지 R112는 서로 같거나 다를 수 있고, R108 내지 R112는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
3. The method of claim 2,
Ar 1 is
Figure pat00252
,
Figure pat00253
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,
X 15 represents an oxygen atom, a sulfur atom,
Figure pat00254
, or
Figure pat00255
ego,
Ar 5 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
R 113 and R 114 may be the same or different from each other, and each of R 113 and R 114 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 108 to R 112 may be the same or different from each other, and each of R 108 to R 112 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제2항에 있어서,
R5 및 R6은 서로 같거나 다를 수 있고, R5 및 R6은 각각 독립적으로 수소원자,
Figure pat00256
,
Figure pat00257
,
Figure pat00258
,
Figure pat00259
,
Figure pat00260
,
Figure pat00261
,
Figure pat00262
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,
Ar6 및 Ar7은 서로 같거나 다를 수 있고, Ar6 및 Ar7은 각각 독립적으로 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
X16은 산소원자, 황원자,
Figure pat00263
, 또는
Figure pat00264
이고,
Ar8은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R141 및 R142는 서로 같거나 다를 수 있고, R141 및 R142는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R115 내지 R140은 서로 같거나 다를 수 있고, R115 내지 R140은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
3. The method of claim 2,
R 5 and R 6 may be the same or different from each other, and R 5 and R 6 are each independently a hydrogen atom,
Figure pat00256
,
Figure pat00257
,
Figure pat00258
,
Figure pat00259
,
Figure pat00260
,
Figure pat00261
,
Figure pat00262
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,
Ar 6 and Ar 7 may be the same or different from each other, Ar 6 and Ar 7 each independently represent a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
X 16 represents an oxygen atom, a sulfur atom,
Figure pat00263
, or
Figure pat00264
ego,
Ar 8 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
R 141 and R 142 may be the same or different from each other, and R 141 and R 142 are each independently a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 115 to R 140 may be the same or different from each other, and each of R 115 to R 140 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제6항에 있어서,
Ar6 및 Ar7은 서로 같거나 다를 수 있고, Ar6 및 Ar7은 각각 독립적으로
Figure pat00265
,
Figure pat00266
,
Figure pat00267
,
Figure pat00268
,
Figure pat00269
,
Figure pat00270
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,
Ar9는 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
X17 및 X18은 서로 같거나 다를 수 있고, X17 및 X18은 각각 독립적으로 산소원자, 황원자,
Figure pat00271
, 또는
Figure pat00272
이고,
Ar10은 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R161 및 R162는 서로 같거나 다를 수 있고, R161 및 R162는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
Y24 내지 Y26은 서로 같거나 다를 수 있고, Y24 내지 Y26은 각각 독립적으로 질소원자, 또는
Figure pat00273
이고,
R163은 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R143 내지 R160은 서로 같거나 다를 수 있고, R143 내지 R160은 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
The method according to claim 6,
Ar 6 and Ar 7 may be the same or different from each other, Ar 6 and Ar 7 are each independently
Figure pat00265
,
Figure pat00266
,
Figure pat00267
,
Figure pat00268
,
Figure pat00269
,
Figure pat00270
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,
Ar 9 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
X 17 and X 18 may be the same or different from each other, and X 17 and X 18 are each independently an oxygen atom, a sulfur atom,
Figure pat00271
, or
Figure pat00272
ego,
Ar 10 represents a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, An unsubstituted C1 to C30 heteroaryl group,
R 161 and R 162 may be the same or different from each other, and R 161 and R 162 are each independently a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group,
Y 24 To Y 26 may be the same or different from each other, and Y 24 To Y < 26 > each independently represent a nitrogen atom, or
Figure pat00273
ego,
R 163 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 143 to R 160 may be the same or different from each other, and each of R 143 to R 160 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제6항에 있어서,
R115 내지 R140은 서로 같거나 다를 수 있고, R115 내지 R140은 각각 독립적으로 수소원자,
Figure pat00274
,
Figure pat00275
,
Figure pat00276
, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기이고,
Y27 내지 Y29는 서로 같거나 다를 수 있고, Y27 내지 Y29는 각각 독립적으로 질소원자, 또는
Figure pat00277
이고,
R173은 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기이고,
R164 내지 R172는 서로 같거나 다를 수 있고, R164 내지 R172는 각각 독립적으로 수소원자, 치환 또는 비치환된 C1 내지 C30 알킬기, 치환 또는 비치환된 C3 내지 C30 시클로알킬기, 치환 또는 비치환된 C1 내지 C30 헤테로시클로알킬기, 치환 또는 비치환된 C6 내지 C30 아릴기, 또는 치환 또는 비치환된 C1 내지 C30 헤테로아릴기인 것을 특징으로 하는 유기전계발광소자용 화합물.
The method according to claim 6,
R 115 to R 140 may be the same or different from each other, and R 115 to R 140 each independently represent a hydrogen atom,
Figure pat00274
,
Figure pat00275
,
Figure pat00276
, A substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, or a substituted or unsubstituted C1 to C30 heterocycloalkyl group,
Y 27 To Y 29 may be the same or different from each other, and Y 27 To Y 29 each independently represent a nitrogen atom, or
Figure pat00277
ego,
R 173 represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, Or a substituted or unsubstituted C1 to C30 heteroaryl group,
R 164 to R 172 may be the same or different from each other and each of R 164 to R 172 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, A substituted or unsubstituted C1 to C30 heterocycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C1 to C30 heteroaryl group.
제1항에 있어서,
상기 유기전계발광소자용 화합물은 하기 화학식으로 표시되는 화합물 1 내지 441 중에서 선택된 어느 하나인 것을 특징으로 하는 유기전계발광소자용 화합물.
Figure pat00278

Figure pat00279

Figure pat00280

Figure pat00281

Figure pat00282

Figure pat00283

Figure pat00284

Figure pat00285

Figure pat00286

Figure pat00287

Figure pat00288

Figure pat00289

Figure pat00290

Figure pat00291

Figure pat00292

Figure pat00293

Figure pat00294

Figure pat00295

Figure pat00296

Figure pat00297

Figure pat00298

Figure pat00299

Figure pat00300

Figure pat00301

Figure pat00302

Figure pat00303

Figure pat00304

Figure pat00305

Figure pat00306

Figure pat00307

Figure pat00308

Figure pat00309

Figure pat00310

Figure pat00311

Figure pat00312

Figure pat00313

Figure pat00314

Figure pat00315

Figure pat00316

Figure pat00317
The method according to claim 1,
Wherein the compound for an organic electroluminescence device is any one selected from compounds 1 to 441 represented by the following formulas.
Figure pat00278

Figure pat00279

Figure pat00280

Figure pat00281

Figure pat00282

Figure pat00283

Figure pat00284

Figure pat00285

Figure pat00286

Figure pat00287

Figure pat00288

Figure pat00289

Figure pat00290

Figure pat00291

Figure pat00292

Figure pat00293

Figure pat00294

Figure pat00295

Figure pat00296

Figure pat00297

Figure pat00298

Figure pat00299

Figure pat00300

Figure pat00301

Figure pat00302

Figure pat00303

Figure pat00304

Figure pat00305

Figure pat00306

Figure pat00307

Figure pat00308

Figure pat00309

Figure pat00310

Figure pat00311

Figure pat00312

Figure pat00313

Figure pat00314

Figure pat00315

Figure pat00316

Figure pat00317
제1항 내지 제9항 중 어느 하나의 항에 따른 유기전계발광소자용 화합물을 포함하는 유기전계발광소자.An organic electroluminescent device comprising the compound for an organic electroluminescent device according to any one of claims 1 to 9. 제1전극, 제2전극 및 상기 제1전극과 제2전극 사이에 단수 또는 복수의 유기물층을 포함하는 유기전계발광소자에 있어서,
상기 단수 또는 복수의 유기물층 중에서 선택된 1종 이상의 유기물층은 제1항 내지 제9항 중 어느 하나의 항에 따른 유기전계발광소자용 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
1. An organic electroluminescent device comprising a first electrode, a second electrode, and a single or a plurality of organic layers between the first electrode and the second electrode,
Wherein at least one organic layer selected from the single or plural organic layers includes the organic electroluminescence compound according to any one of claims 1 to 9.
제11항에 있어서,
상기 단수 또는 복수의 유기물층은 발광층을 포함하는 것을 특징으로 하는 유기전계발광소자.
12. The method of claim 11,
Wherein the single or plural organic layers include a light emitting layer.
제11항에 있어서,
상기 복수의 유기물층은 발광층을 포함하고, 상기 복수의 유기물층은 전자주입층, 전자수송층, 정공차단층, 전자차단층, 정공수송층 및 정공주입층 중에서 선택된 1종 이상을 추가로 포함하는 것을 특징으로 하는 유기전계발광소자.
12. The method of claim 11,
Wherein the plurality of organic layers include a light emitting layer and the plurality of organic layers further include at least one selected from an electron injecting layer, an electron transporting layer, a hole blocking layer, an electron blocking layer, a hole transporting layer and a hole injecting layer Organic electroluminescent device.
제12항에 있어서,
상기 발광층은 호스트와 도펀트를 포함하는 것을 특징으로 하는 유기전계발광소자.
13. The method of claim 12,
Wherein the light emitting layer comprises a host and a dopant.
KR1020140003500A 2013-01-11 2014-01-10 Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same KR20140091487A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130003504 2013-01-11
KR20130003504 2013-01-11

Publications (1)

Publication Number Publication Date
KR20140091487A true KR20140091487A (en) 2014-07-21

Family

ID=51738643

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140003500A KR20140091487A (en) 2013-01-11 2014-01-10 Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same

Country Status (1)

Country Link
KR (1) KR20140091487A (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140143633A (en) * 2013-06-07 2014-12-17 삼성디스플레이 주식회사 Heterocyclic compound and organic light emitting device comprising same
KR20140144064A (en) * 2013-06-10 2014-12-18 삼성디스플레이 주식회사 Heterocyclic compound and organic light emitting device comprising same
KR20150008299A (en) * 2013-07-12 2015-01-22 삼성디스플레이 주식회사 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC LiGHT EMITTING DIODE INCLUDING THE SAME AND DISPLAY INCLUDING THE ORGANIC LiGHT EMITTING DIODE
WO2015037675A1 (en) * 2013-09-11 2015-03-19 東ソー株式会社 Benzothienopyrimidine compound, method for producing same and organic electroluminescent element containing same
KR20150066956A (en) * 2013-12-09 2015-06-17 삼성디스플레이 주식회사 Compound and organic light emitting device comprising same
KR20150107442A (en) * 2014-03-14 2015-09-23 (주)피엔에이치테크 Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20160021424A (en) * 2014-08-04 2016-02-25 주식회사 동진쎄미켐 Novel compound and organic electroluminescent device comprising same
EP3056498A1 (en) * 2015-02-13 2016-08-17 Samsung SDI Co., Ltd. Diazadibenzofurane and diazadibenzothiophene derivatives and their use in organic optoelectronic devices
WO2016021923A3 (en) * 2014-08-04 2016-09-15 주식회사 동진쎄미켐 Novel compound and orgarnic light emitting device containing same
EP3075731A1 (en) * 2015-03-30 2016-10-05 Samsung Display Co., Ltd. Phenanthro[4,5-bca]furan compound and organic light-emitting device including the same
CN106848072A (en) * 2015-11-24 2017-06-13 东进世美肯株式会社 Organic illuminating element
JP2017183727A (en) * 2016-03-30 2017-10-05 三星ディスプレイ株式會社Samsung Display Co.,Ltd. Organic electroluminescent element
WO2018181054A1 (en) * 2017-03-31 2018-10-04 富士フイルム株式会社 Organic semiconductor element, organic semiconductor composition, organic semiconductor film production method, organic semiconductor film, and compound and polymer used therefor
WO2018181056A1 (en) * 2017-03-31 2018-10-04 富士フイルム株式会社 Organic semiconductor element, organic semiconductor composition, organic semiconductor film production method, organic semiconductor film, and compound and polymer used therefor
WO2018182145A1 (en) * 2017-03-30 2018-10-04 주식회사 엘지화학 Organic light emitting element
CN108807697A (en) * 2017-04-26 2018-11-13 固安鼎材科技有限公司 Organic electroluminescence device and phenanthrene derivative
CN109671851A (en) * 2017-10-16 2019-04-23 北京鼎材科技有限公司 A kind of organic electroluminescence device
WO2019083216A1 (en) * 2017-10-23 2019-05-02 주식회사 두산 Organic compound and organic electroluminescent device comprising same
JP2019515877A (en) * 2016-03-28 2019-06-13 エルジー・ケム・リミテッド Compound and organic electronic device containing the same
CN110294663A (en) * 2018-03-23 2019-10-01 江苏三月光电科技有限公司 It is a kind of using anthracene as the compound of core and its application on organic electroluminescence device
CN112079824A (en) * 2019-06-12 2020-12-15 三星Sdi株式会社 Compound for organic photoelectric device, organic photoelectric device and display device
CN113354624A (en) * 2021-07-10 2021-09-07 浙江华显光电科技有限公司 Organic compound and organic light-emitting device using same
WO2021215742A1 (en) * 2020-04-21 2021-10-28 엘티소재주식회사 Heterocyclic compound, organic light-emitting device comprising same, manufacturing method therefor, and composition for organic layer
CN113801109A (en) * 2021-08-17 2021-12-17 南京高光半导体材料有限公司 Compound containing biscarbazole structure and organic electroluminescent device
WO2022230574A1 (en) * 2021-04-26 2022-11-03 株式会社Kyulux Charge transport material, composition, and organic luminescent element
EP4332096A1 (en) 2022-08-29 2024-03-06 Canon Kabushiki Kaisha Organic compound and organic light-emitting element

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140143633A (en) * 2013-06-07 2014-12-17 삼성디스플레이 주식회사 Heterocyclic compound and organic light emitting device comprising same
KR20140144064A (en) * 2013-06-10 2014-12-18 삼성디스플레이 주식회사 Heterocyclic compound and organic light emitting device comprising same
KR20150008299A (en) * 2013-07-12 2015-01-22 삼성디스플레이 주식회사 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC LiGHT EMITTING DIODE INCLUDING THE SAME AND DISPLAY INCLUDING THE ORGANIC LiGHT EMITTING DIODE
WO2015037675A1 (en) * 2013-09-11 2015-03-19 東ソー株式会社 Benzothienopyrimidine compound, method for producing same and organic electroluminescent element containing same
US9806267B2 (en) 2013-12-09 2017-10-31 Samsung Display Co., Ltd. Compound and organic light-emitting device comprising the compound
KR20150066956A (en) * 2013-12-09 2015-06-17 삼성디스플레이 주식회사 Compound and organic light emitting device comprising same
KR20150107442A (en) * 2014-03-14 2015-09-23 (주)피엔에이치테크 Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20160021424A (en) * 2014-08-04 2016-02-25 주식회사 동진쎄미켐 Novel compound and organic electroluminescent device comprising same
CN106573905A (en) * 2014-08-04 2017-04-19 东进世美肯株式会社 Novel compound and orgarnic light emitting device containing same
WO2016021923A3 (en) * 2014-08-04 2016-09-15 주식회사 동진쎄미켐 Novel compound and orgarnic light emitting device containing same
CN105884803A (en) * 2015-02-13 2016-08-24 三星Sdi株式会社 Compound For Organic Optoelectronic Device And Application Thereof
EP3056498A1 (en) * 2015-02-13 2016-08-17 Samsung SDI Co., Ltd. Diazadibenzofurane and diazadibenzothiophene derivatives and their use in organic optoelectronic devices
JP2016147851A (en) * 2015-02-13 2016-08-18 三星エスディアイ株式会社Samsung SDI Co., Ltd. Compound for organic optoelectronic device, organic optoelectronic device and display apparatus
EP3075731A1 (en) * 2015-03-30 2016-10-05 Samsung Display Co., Ltd. Phenanthro[4,5-bca]furan compound and organic light-emitting device including the same
CN106008420A (en) * 2015-03-30 2016-10-12 三星显示有限公司 Compound and organic light-emitting device including the same
KR20160117701A (en) * 2015-03-30 2016-10-11 삼성디스플레이 주식회사 Compound and Organic light emitting device comprising same
TWI686388B (en) * 2015-03-30 2020-03-01 南韓商三星顯示器有限公司 Compound, organic light-emitting device including the same, and display apparatus including the organic light-emitting device
US10043980B2 (en) 2015-03-30 2018-08-07 Samsung Display Co., Ltd. Compound and organic light-emitting device including the same
CN106008420B (en) * 2015-03-30 2021-04-16 三星显示有限公司 Compound and organic light emitting device including the same
CN106848072A (en) * 2015-11-24 2017-06-13 东进世美肯株式会社 Organic illuminating element
JP2019515877A (en) * 2016-03-28 2019-06-13 エルジー・ケム・リミテッド Compound and organic electronic device containing the same
JP2017183727A (en) * 2016-03-30 2017-10-05 三星ディスプレイ株式會社Samsung Display Co.,Ltd. Organic electroluminescent element
US11145819B2 (en) 2016-03-30 2021-10-12 Samsung Display Co., Ltd. Organic light emitting device
US11925111B2 (en) 2016-03-30 2024-03-05 Samsung Display Co., Ltd. Organic light emitting device
KR20170113975A (en) * 2016-03-30 2017-10-13 삼성디스플레이 주식회사 Organic light emitting device
WO2018182145A1 (en) * 2017-03-30 2018-10-04 주식회사 엘지화학 Organic light emitting element
US10454056B1 (en) 2017-03-30 2019-10-22 Lg Chem, Ltd. Organic light emitting device
JP2019525463A (en) * 2017-03-30 2019-09-05 エルジー・ケム・リミテッド Organic light emitting device
TWI752207B (en) * 2017-03-31 2022-01-11 日商富士軟片股份有限公司 Organic semiconductor element, organic semiconductor composition, method for producing organic semiconductor film, organic semiconductor film, and compounds and polymers used for these
JPWO2018181054A1 (en) * 2017-03-31 2019-11-07 富士フイルム株式会社 Organic semiconductor device, organic semiconductor composition, organic semiconductor film manufacturing method, organic semiconductor film, and compounds and polymers used in these
JPWO2018181056A1 (en) * 2017-03-31 2019-11-07 富士フイルム株式会社 Organic semiconductor device, organic semiconductor composition, organic semiconductor film manufacturing method, organic semiconductor film, and compounds and polymers used in these
WO2018181054A1 (en) * 2017-03-31 2018-10-04 富士フイルム株式会社 Organic semiconductor element, organic semiconductor composition, organic semiconductor film production method, organic semiconductor film, and compound and polymer used therefor
US11081651B2 (en) 2017-03-31 2021-08-03 Fujifilm Corporation Organic semiconductor element, organic semiconductor composition, method of manufacturing organic semiconductor film, organic semiconductor film, and compound and polymer using the same
WO2018181056A1 (en) * 2017-03-31 2018-10-04 富士フイルム株式会社 Organic semiconductor element, organic semiconductor composition, organic semiconductor film production method, organic semiconductor film, and compound and polymer used therefor
CN108807697A (en) * 2017-04-26 2018-11-13 固安鼎材科技有限公司 Organic electroluminescence device and phenanthrene derivative
CN108807697B (en) * 2017-04-26 2022-02-22 固安鼎材科技有限公司 Organic electroluminescent device and phenanthrene derivative
CN109671851B (en) * 2017-10-16 2021-10-22 北京鼎材科技有限公司 Organic electroluminescent device
CN109671851A (en) * 2017-10-16 2019-04-23 北京鼎材科技有限公司 A kind of organic electroluminescence device
WO2019083216A1 (en) * 2017-10-23 2019-05-02 주식회사 두산 Organic compound and organic electroluminescent device comprising same
CN110294663A (en) * 2018-03-23 2019-10-01 江苏三月光电科技有限公司 It is a kind of using anthracene as the compound of core and its application on organic electroluminescence device
CN112079824A (en) * 2019-06-12 2020-12-15 三星Sdi株式会社 Compound for organic photoelectric device, organic photoelectric device and display device
WO2021215742A1 (en) * 2020-04-21 2021-10-28 엘티소재주식회사 Heterocyclic compound, organic light-emitting device comprising same, manufacturing method therefor, and composition for organic layer
WO2022230574A1 (en) * 2021-04-26 2022-11-03 株式会社Kyulux Charge transport material, composition, and organic luminescent element
CN113354624A (en) * 2021-07-10 2021-09-07 浙江华显光电科技有限公司 Organic compound and organic light-emitting device using same
CN113801109A (en) * 2021-08-17 2021-12-17 南京高光半导体材料有限公司 Compound containing biscarbazole structure and organic electroluminescent device
EP4332096A1 (en) 2022-08-29 2024-03-06 Canon Kabushiki Kaisha Organic compound and organic light-emitting element

Similar Documents

Publication Publication Date Title
KR101521790B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101593465B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101447961B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101447959B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20140091487A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101527181B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101499102B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101550429B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101638072B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101584753B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101626523B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101401631B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101468493B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20150012974A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101401633B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20150022615A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20160040826A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20150059680A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20140004549A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20160041223A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20130069431A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101562883B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20150037133A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20150025379A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR101562882B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application